The effect of lipids from mycobacterium bovis on bovine nnate and acquired immune responses by Pirson, Chris
 The Effects of Lipids from Mycobacterium 
bovis on Bovine Innate and Acquired 
Immune Responses 
 
 
By 
 
 
Christopher Pirson 
 
 
A thesis submitted to the University of Birmingham 
for the Degree of Doctor of Philosophy 
 
 
 
Bovine Tuberculosis Research Team 
Animal Health & Veterinary Laboratories Agency 
& 
School of Biosciences 
University of Birmingham 
 
September 2014 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Declaration 
 
The work presented in this thesis was carried out in the Bovine TB Research Team at the 
Animal Health and Veterinary Laboratories Agency KT15 3NB, during the period 
September 2009 to September 2014.  The work in this thesis is original except where 
acknowledged by references. 
 
No portion of the work is being, or has been submitted for a degree, diploma or any other 
qualification at any other University. 
  
ii 
Published Work Declaration 
 
This thesis contains work which has been accepted to and / or published in peer - 
reviewed journals.  Any publications arising from the work presented in this thesis were 
written and prepared by Christopher Pirson who is listed as the publications primary 
author and the contributions of other authors to the text in this thesis are not substantial. 
 
Thesis content which is similar to that contained in associated peer - reviewed 
publications is listed below: 
 
Pirson et al., (2012) “Differential effects of Mycobacterium bovis - derived polar and 
apolar lipid fractions on bovine innate immune cells” Veterinary Research 43:54 
 
• Chapter One: pages 6, 10 and 31 
• Chapter Two sections: 
o Preparation of Bacterial Isolates for Lipid Extraction 
o Extraction of Crude Free Mycobacterial Lipids 
o Analysis of Lipid Fractions by 2D Thin Layer Chromatography 
o Preparation of Lipid Antigen Suspensions 
o Uninfected Cattle 
o Isolation of Bovine PBMC from Whole Blood 
o Isolation of CD14+ Monocytes from Bovine PBMC 
o Generation of Bovine Cultured Monocytes and MDDC 
o Multiplex Measurement of Cytokine Production 
o Innate Cell Labelling & Analysis by Flow Cytometry 
o Mixed Lymphocyte Reaction 
• Chapter Three, Discussion: page 70 
• Chapter Four sections: 
o Results 
o Discussion 
 
 
 
 
 
iii 
Pirson et al., (2015) “Highly purified mycobacterial phosphatidylinositol mannosides 
drive cell mediated responses and activate NKT cells in cattle” Clinical and Vaccine 
Immunology 22:2 
 
• Chapter Two sections: 
o  Preparation of Lipid Antigen Suspensions 
o M. bovis Infected Cattle 
o Isolation of Bovine PBMC from Whole Blood 
o Measurement of IFNγ by BovigamTM ELISA 
o Lymphocyte Transformation Assay 
o Lymphocyte Labelling & Analysis by Flow Cytometry 
• Chapter Six: pages 130, 131 and 137 - 138 
 
Signed: 
 
 
C. Pirson 
 
 
 
H. M. Vordermeier 
  
iv 
Abstract 
 
The interaction between the host and the pathogen is critical in defining the 
outcome of an infection.  For cattle with bovine tuberculosis (BTB), this interaction is 
likely to occur between antigen presenting cells in the lung and the lipid rich surface of 
the causative agent Mycobacterium bovis (M. bovis).  It is well documented that lipid 
molecules from mycobacteria are capable of modulating immune responses however 
previous work has made use of model animal systems or lipids from avirulent bacteria.  
The aim of this study was to extract lipids from virulent M. bovis and assess any 
immunomodulatory ability of these molecules in cattle with a view to aiding in the 
development of control measures for BTB. 
 
To this end, lipids were extracted from M. bovis AF 2122/97 and AN5 and the fractions 
characterised.  Upon thin layer chromatography analysis, polar and apolar fractions from 
both bacterial strains were found to be broadly similar in their lipid constitution although 
quantitative differences were noted.  Lipopeptide was also identified in both polar 
fractions.  Stimulation of bovine antigen presenting cells with the lipid fractions showed 
polar lipids mediated increases in IL - 10 and IL - 12 production and reductions in cell 
surface expression of MHCII and CD1b.  Further investigation of the polar lipid fraction 
was performed by subfractionation but no individual lipid could be found responsible for 
the responses of antigen presenting cells to these subfractions. 
 
The ability of the polar and apolar lipid fractions to be recognised by cells of the adaptive 
immune system was assessed and the polar fraction was found to drive production of 
IFNγ and strong proliferation of bovine lymphocytes.  The role of lipopeptide in the polar 
fraction was evaluated by enzymatic degradation with Proteinase K and blockade of 
either MHCII or CD1.  While lipopeptide was found to play a role in the generation of 
lymphocyte responses, these treatments did not abrogate the effects completely 
suggesting a lipid mediated component as well.  Screening of highly purified individual 
lipid molecules led to the selection of one molecule (AcPIM6), which was found to be 
capable of driving antigen specific proliferation of NKT cells.  
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Chapter One  Introduction Chapter One 
Introduction 
 
 
The Mycobacteria 
 
Mycobacteria are members of the Actinomycete branch of the Gram - positive 
bacteria.  Other Actinomycete genera include the Nocardia, Corynebacterium and 
Streptomyces(1).  The name Mycobacterium stems from the mould-like appearance of 
strains when grown as pellicles on nutrient broth.  There are now at least 49 recognised 
species of mycobacteria(1), however most of the energies associated with research into 
mycobacteria are devoted to perhaps the best known members of the genus: 
Mycobacterium tuberculosis (M. tuberculosis), the causative agent of tuberculosis (TB) in 
humans; Mycobacterium bovis (M. bovis), the causative agent of tuberculosis in cattle 
(and a range of mammalian species, including humans) and Mycobacterium leprae, the 
agent responsible for the disease of leprosy.  The mycobacteria have a genome of 
approximately 4.5 million base pairs which contains a high G+C content (65.6%) and 
around 4,000 genes, many of which encode enzymes involved in lipogenesis, lipolysis and 
lipid transport(2).  In fact, lipids may be responsible for one of the most characteristic 
properties of the mycobacteria; that of acid - fastness(3).  The ability to resist acid 
mediated decolourisation after red fuchsin is not a property unique to mycobacteria but 
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was critical in the first identification of the bacilli(4, 5).  Originally using Bismarck brown 
and methylene blue, Robert Koch noted that “Under the microscope all the constituents 
of animal tissue, that is, the cell nuclei and their products of disintegration appear brown, 
while the tubercle bacilli, on the other hand, stain a beautiful blue”(4, 5).  This technique 
was modified by Ehrlich(6) who used red fuchsin and a mineral acid but was further 
refined by the eponymous Ziehl (who optimised the acid decolourisation)(7) and Neelsen 
(who combined Ehrlich’s red stain with Ziehl’s acid)(8). 
 
The Mycobacterium tuberculosis Complex 
 
 The isolation of the tubercle bacillus in 1882 by Robert Koch(4, 5) was one of the 
single most significant points in the history of microbiology, as it was also the first 
isolation of any micro - organism in pure culture.  However, it soon became apparent that 
there were characteristic differences between the strains isolated from man, cattle and 
birds.  During the allocation of species in the 1890s, the mammalian tubercle bacillus was 
named M. tuberculosis specifically to reflect its significance within the genus(9).  Around 
the same time it was noted that there were distinct morphological and cultural 
differences between human and bovine isolates and that the bovine strains were more 
virulent in rabbits(10). 
 
In 1946, a further mammalian derivative of the tubercle bacillus was isolated from 
voles(11) and became known as Mycobacterium microti(12).  M. microti is primarily 
pathogenic for rodents and demonstrates little or no pathogenicity in man or domestic 
animals. 
2 
Chapter One  Introduction 
Further reclassification of the genus occurred in the 1960’s, when it was discovered that 
strains initially thought to be M. tuberculosis isolated from patients in tropical Africa 
resembled a heterogeneous group of isolates.  These strains were phenotypically 
different from M. tuberculosis and M. bovis and were named Mycobacterium 
africanum(13). 
 
Due to this close relationship, M. tuberculosis, M. africanum, M. bovis and M. microti are 
known as the M. tuberculosis complex.  A recent addition to the complex was a strain 
isolated from human TB patients in Africa which proved to have a distinct phenotype, 
different from the other members of the complex.  This strain has been named 
Mycobacterium canetti(14).  Other members of the complex include M. caprae, M. 
pinnipedii, M. suricattae, and M. mung. 
 
Mycobacterium tuberculosis 
 
Tuberculosis (TB) has been referred to as “one of a few severe communicable 
diseases that may be described as true pestilences of mankind”(15).  Often described as an 
ancient disease, M. tuberculosis has been detected in the remains of Bison dating from 
18,000 years ago(16) as well as in Neolithic human remains(17) and as Potts disease in the 
spines of Egyptian mummies(18). 
 
Today the tubercle bacillus continues to claim more lives than any other single infectious 
agent with an estimated 8.7 million new cases of TB and 1.4 million deaths in 2011 
alone(19).  In recent years, the incidence of TB has risen drastically in both industrialised 
3 
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and developing countries.  Until 60 years ago, there were no anti - TB drugs, as was the 
case for virtually all infectious diseases, yet in a recent survey by the World Health 
Organisation (WHO), strains of M. tuberculosis resistant to at least a single anti - 
tuberculous agent were documented in every country surveyed(20).  This is compounded 
by the emergence of strains resistant to both primary anti - TB drugs (isoniazid and 
rifampicin), known as multi drug resistant TB (MDR - TB). 
 
M. tuberculosis displays many characteristic features such as its slow growth, dormancy, 
intracellular lifecycle and pathogenesis, and a complex cell envelope.  With its generation 
time of approximately 24 hours in synthetic medium or infected animals it is a difficult 
organism to study and its long doubling time also contributes to the chronic nature of the 
disease.  This slow growth may also provide a selective advantage; where other 
organisms outgrow their intracellular environment and kill their habitat, mycobacteria 
slow their growth and convert into a so called “dormant” phase, thereby further limiting 
their chances of destroying their hosts(21, 22). 
 
M. tuberculosis is spread predominantly by the aerosol route, where droplet nuclei 
containing 3 to 5 bacilli in a particle of <5 μm are inhaled and gain access to the alveoli(23-
25).  Once inside the alveoli, the bacilli are engulfed by alveolar macrophages which 
attempt to kill the organism via the respiratory burst and phagolysosome fusion(26, 27).  
Virulent mycobacteria remain within phagosomes which fail to fuse with lysosomes, even 
though mycobacterial phagosomes are almost identical to other early phagosomes(28), 
and thereby avoid lysosomal degradation.  This ability is dependent on viable bacilli, as 
killed cells are rapidly destroyed(29, 30).  By remaining in so - called “mycobacterial 
4 
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phagosomes” the bacilli avoid destruction and also hinder the induction of adaptive 
immune responses(31, 32). 
 
Mycobacterium bovis 
 
In his speech upon receiving the Nobel Prize in 1901, Emil von Behring stated “as 
you know, tuberculosis in cattle is one of the most damaging infectious diseases to affect 
agriculture”(33).  Bovine tuberculosis (BTB) caused by M. bovis is a zoonotic disease that 
has posed major animal health problems for the farming industry in England and Wales 
since the 1930s(34) and affects cattle and other mammals worldwide. 
 
M. bovis causes a disease in man which is clinically indistinguishable from M. tuberculosis 
infection and it was thought previously that tuberculosis in domestic animals appeared 
prior to its recognition in humans(35) and that M. tuberculosis was derived from M. 
bovis(36).  However, thanks to the completion of the genomes of M. tuberculosis(2) and M. 
bovis(37), it has been shown that the pattern of deletions amongst members of the M. 
tuberculosis complex suggests a derivation from a common ancestral organism(38, 39). 
 
Many studies were performed comparing human and bovine strains, fuelled by the 
incorrect statement “the human subject is immune against infection with bovine bacilli or 
is so slightly susceptible that it is not necessary to take any steps to counteract risk of 
infection” made by Koch to the British Congress on Tuberculosis in 1901(40).  This 
supposition was arrived at due to the relatively non - pathogenic nature of human 
tubercle isolates in cattle and Koch assumed the strains were species - specific.  The most 
5 
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fervent voice of dissent came from the veterinary profession and the British Royal 
Commission was appointed to study the issue.  Research was funded by the Commission 
between 1901 and 1911 and provided irrefutable proof that humans could be infected by 
the bovine tubercle bacillus(41).  The bovine bacilli became known as M. bovis; although 
this name only became recognised in the literature considerably more recently(42). 
 
The zoonotic importance of M. bovis cannot be underestimated.  As far back as 1810, it 
was reported that the incidence of tuberculous cervical lymphadenitis (also known as 
scrofula) was higher in those children who were fed cow’s milk rather than breast milk(43).  
The importance of M. bovis infection in humans was further highlighted in 1927 when a 
study of 906 pulmonary and 202 extra - pulmonary cases of tuberculosis revealed that 
67% of extra - pulmonary tuberculosis was caused by M. bovis(44).  This zoonotic potential 
is still of great concern today.  Consumption of raw or unpasteurised animal products, or 
direct contact with infected animals in slaughterhouses, plays a large role in zoonotic M. 
bovis infection of humans in Africa and South America(45-47).  Yet this is not just a problem 
associated with less developed countries; recently Rodwell et al. have shown that as 
much as 45% of all culture positive TB in children from Hispanic populations in San Diego 
was caused by M. bovis(48). 
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Control of BTB In Great Britain 
 
The control programme for BTB in Great Britain (GB) is a test and slaughter policy 
which relies on the ability to identify M. bovis infected animals and their subsequent 
removal and slaughter.  This policy is in accordance with European Law which specifies 
the requirements for testing and diagnosis of BTB(49).  Previously, regular testing of cattle 
occurred at intervals based on the prevalence of BTB in their geographical location 
(parish testing intervals) which were determined each year based on the level of BTB in 
the parish in the previous 6 years.  However, on the 1st of January 2013, a new system 
was introduced which replaced the use of parishes with county borders and split the 
country into high and low risk areas based on disease prevalence.  Animals within the 
high risk area are tested annually whilst those in the low risk area are tested every four 
years.  Dividing the high and low risk areas is the ‘edge’ area, where BTB is not endemic 
but animals are tested annually to enable any early detection of spread from the high risk 
area.  The high risk, low risk and edge areas are shown in figure 1:1. 
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Figure 1:1 - BTB testing areas shown for the year 2014 
Available from http://ahvla.defra.gov.uk/documents/bovine-tb/pti-map.pdf. 
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Infection is identified using the single intradermal comparative tuberculin test (SICTT) 
which enables the veterinarian to measure the delayed type hypersensitivity (DTH) 
response to an intradermal injection of a crude preparation of mycobacterial antigens 
known as purified protein derivative (PPD) or tuberculin. 
 
In the early 1890’s, Bernhard Bang introduced the intradermal test as a diagnostic tool in 
the control of BTB in Denmark.  The ‘Bang method’ of testing consisted of repetitive six-
monthly use of the intradermal assay combined with physical separation of test - positive 
and test - negative cows, and only culling cattle with “tuberculosis of the udder”(50).  Bang 
also introduced the pasteurisation of milk, buttermilk, and whey, to prevent transmission 
of BTB via milk and milk products to calves long before pasteurisation of these products 
for human consumption became standard(50).  Following reports on the achievements of 
the Bang method, it was accepted worldwide as the major tool in the control of BTB and 
is still the basis of all control programs for BTB today. 
 
It was Koch who developed what is now known as ‘old’ tuberculin, the reagent used as 
the stimulating antigen in the early intradermal tests.  While attempting to isolate the 
“active principle of tuberculin”(51) for use as a treatment for human TB infection, Koch 
subcutaneously injected heat killed samples of cultures into guinea pigs and noted the 
presence of a characteristic skin reaction 24 - 48 hours later(52, 53).  Despite not 
recognising the importance of this reaction as a diagnostic tool, he introduced this 
method to assess the potency of tuberculin preparations. 
In the 1930’s a major improvement in the quality of the tuberculins, replacing Koch’s Old 
Tuberculin, was achieved by the work of Florence Seibert.  The use of a synthetic medium 
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and precipitation methods, facilitated a more reproducible and a large scale production 
leading to the PPD reagents used today(54).  
 
The advent of a compulsory skin test, after the voluntary Attested Herd Scheme of the 
1950’s and 1960’s, coupled with compulsory slaughter of all test positive animals, 
resulted in a significant drop in the levels of BTB in GB from an estimated 40% of all cattle 
infected in 1934(34) to 0.41% in 1996(55).  However, the original skin testing regimen was 
not without its flaws. 
 
The use of M. tuberculosis to produce tuberculin for use in cattle lead to a high 
proportion of test - positive cattle which displayed no clinical evidence of disease when 
examined post mortem.  The introduction of the comparative test, using a tuberculin 
derived from the avian mycobacterial species (M. avium), was based on pioneering 
studies performed in the late 1930’s(56, 57).  The use of avian tuberculin (PPD - A) adds a 
significant degree of specificity to the skin test by allowing an assessment of any immune 
priming caused by exposure to environmental mycobacteria.  The skin test has remained 
unchanged since with the exception of a switch from mammalian tuberculin, which was 
produced using the M. tuberculosis strains DT, C and PN(58), to bovine tuberculin (PPD - B) 
produced from an M. bovis strain isolated in England in 1948(59).  It was found that the 
tuberculin generated from the M. bovis AN5 strain was both more potent when used in 
cattle and more specific(58). 
 
The incidence of BTB in cattle in GB has shown a steady and continual increase since 1996 
(figure 1:2), despite the unremitting implementation of control measures, possibly due to 
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the presence of a wildlife reservoir consisting primarily of the badger(55) (Meles meles).  
Large scale trials have been performed to study the effect of culling badgers on the 
incidence of BTB(55) which suggest that, while culling can reduce disease incidence in 
cattle in the area of the cull, perturbation of the badger population leads to an increase in 
disease occurrence in the surrounding areas(60).  Within GB, BTB has spread drastically 
since the Foot & Mouth disease outbreak in 2001 with the annual number of animals 
slaughtered rising from a mean of 5,646 animals between 1996 and 2001 to an annual 
mean of 29,504 between 2002 and 2012 inclusive(61). 
 
 
Figure 1:2 - Incidence of BTB in GB since 1996 
Bars represent number cattle subjected to SICTT; line shows number of cattle slaughtered.  Available from: 
http://www.defra.gov.uk/animal-diseases/a-z/bovine-tb/. 
 
 
New Strategies for BTB Control 
 
In 1996 Douglas Hogg MP, the then Minister of Agriculture, Fisheries and Food 
commissioned an independent scientific review into Government policy on BTB.  Chaired 
by the Chief Executive of the Natural Environment Research Council, Professor John 
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Krebs, the review’s final report contained many recommendations, the first of which was 
the development of a cattle vaccine; a strategy which was considered to be the best long 
term option to control BTB(55). 
 
The only licensed vaccine for use against TB (in any host species) is the attenuated M. 
bovis strain bacille Calmette - Guérin (BCG).  BCG is the most widely used vaccine in the 
world today with more than 3 billion individuals immunised(62).  The development of BCG 
was the result of pathogenesis experiments at the Pasteur Institute in France where 
Albert Calmette and Camille Guérin discovered that for successful infection of guinea pigs 
the bovine tubercle bacilli needed to be emulsified(63). 
 
While BCG is the only available vaccine for use against TB infection, reports of its 
usefulness have varied.  Overall, it is widely accepted that BCG vaccination significantly 
reduces the risk of TB in humans by 50 %(64).  However BCG daughter strains are not 
identical(65, 66) and, across a variety of populations, the protective efficacy of BCG has 
been reported anywhere between 0 % and 80 %, and usually in children and 
adolescents(67).  More recently it has been reported that BCG - induced protection may 
last for up to 60 years in certain human populations(68) but other reports have shown that 
2 doses of BCG are required to confer protection to children in Turkey(69) and a large 
study performed in India involving patients covering a wide age range showed no 
protective effect of 2 different BCG vaccines when compared with a placebo(70).  The 
reasons for this variable efficacy are not understood although many theories have been 
proposed, such as interference of the immune response to BCG due to exposure to 
environmental mycobacteria; differences between the BCG daughter strains used for 
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vaccination; the loss of protective antigens from BCG during passage and potential failure 
in stimulating adequately balanced CD4+ and CD8+ T cell responses(64, 71).  Other potential 
confounders include variability in dose, route of administration, age of patients, genetic 
variance between vaccinees and storage methods of the vaccine such as lyophilisation(64, 
71).  Clearly a better defined and tailored approach is needed to develop more efficacious 
and promising vaccines. 
 
A variety of strategies have been adopted in an effort to improve the efficacy of BCG 
vaccination.  One major route of investigation is the modification of BCG at the genomic 
level such that it overexpresses known tuberculoid antigens such as 85B (Ag85B).  For 
example, the vaccine candidate rBCG30, which overexpresses Ag85B, has been shown to 
be more protective than it’s parental strain in animal challenge studies(72, 73). 
 
A second improvement strategy has been to enhance priming of CD8+ T cells, rather than 
primarily targeting CD4+ T cells.  An elegant strategy developed by Kaufmann has been to 
enhance the ability of BCG to escape from phagocytic endosomes, thus allowing 
endogenous antigen processing and presentation in the context of the major 
histocompatibility complex (MHC) I.  Inclusion of a cytolysin gene (hly) from Listeria 
monocytogenes into the BCG genome, along with deletion of the BCG urease gene ureC 
enables the vaccine to puncture the membrane of the early endosome and escape into 
the cytoplasm(74).  Not only does this enable greater endogenous antigen processing and 
MHCI mediated presentation, but bacterial escape from the endosome can lead to 
apoptosis in the infected cell and hence allow cross presentation of exogenous antigen to 
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naïve CD8+ T cells(75).  This approach has led to enhanced protection over the parental 
strain and was also safer in immunocompromised SCID mice(76). 
 
Other potential improvements to BCG include the addition of superoxide dismutase to 
the genome to enhance BCG survival and granuloma formation(77) and the reintroduction 
of genes that were lost from BCG during its attenuation such as the RD1 locus(78).  This 
latter approach is not without criticism, for fears that it may increase the virulence of 
BCG(79).  Alternatives to modification or enhancement of BCG itself are also being 
assessed.  Generation of a live attenuated M. tuberculosis vaccine is a possibility, 
although there is concern over the potential for these strains to revert to a virulent 
phenotype(80). 
 
The use of antigens which activate T cells in previously infected subjects may also provide 
novel vaccines.  The search for antigens has identified a raft of potential vaccine 
candidates, some of which have been formulated into recombinant fusion proteins.  The 
vaccine candidate Hybrid-I, consisting of Ag85B and the immunodominant Early Secreted 
Antigenic Target 6 kDa (ESAT - 6), has been shown to be as protective as BCG when 
formulated with an adjuvant(81, 82).  The use of ESAT - 6 as an immunising antigen is 
controversial as it is also the primary basis of the new generation of diagnostic tests, 
which may be compromised by its use(83). 
 
Antigenic proteins such as Hybrid-I are promising vaccine candidates but there is little 
improvement in protection over traditional BCG vaccination.  However, these candidates 
may be of significant use in a highly productive area of research - the heterologous prime 
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- boost strategy.  Using an initial priming vaccine and boosting with a more defined 
subunit has the advantage that the boost preferentially expands TB - specific memory T 
cells generated by the initial priming immunisation.  Using BCG as a primary vaccine 
allows the potential to boost with any of the subunit candidates currently under research, 
such as Hybrid-I, however these boosting antigens may not stimulate sufficient CD8+ T 
cell responses. 
 
A popular trial strategy used a recombinant, non - replicating virus presenting antigenic 
subunits on its surface as the boost to the BCG prime.  The use of the poxvirus Modified 
Vaccinia Ankara (MVA) which expresses Ag85A, known as MVA85A, as a boosting agent, 
after priming with BCG, has been shown to induce greater levels of antigen specific CD4+ 
and CD8+ T cells as well as greater protection against challenge when compared to either 
BCG or the MVA85A alone(84).  Similar responses have been seen in human trials with this 
regimen where immunisation with one of the vaccines generated only short - lived 
antigen specific immune responses but the prime - boost strategy generated longer lived, 
stronger responses(85).  However in a phase 2B clinical trial where 2,797 BCG vaccinated 
South African infants were boosted with MVA85A, only 2 % of participants were 
protected against M. tuberculosis infection(86).  The authors note that the levels of antigen 
specific CD4+ T cells in the study participants was as much as 90 % lower than in previous 
studies performed with adults(87, 88) and suggest that understanding the mechanisms 
behind expanding the appropriate T cell populations may be critical to the development 
of an efficacious human vaccine. 
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As reported in humans(67), estimates of protective efficacy of BCG in cattle have ranged 
between 0 % and 70 %(89-94) and heterologous prime - boost strategies also show promise 
in cattle(95, 96).  Similar to work in humans, a variety of alternative strategies have been 
tried in cattle.  DNA vaccines expressing mycobacterial antigens (including MPB70, 
MPB83, Hsp60 and Hsp70) have been developed and trialled with generally inadequate 
results(97, 98).  However, one study reported significant protection using a DNA vaccine 
which encoded ESAT - 6 as well as the co - stimulatory molecules CD80 and CD86, usually 
found on dendritic cells (DC)(99).  DNA vaccines have proven more successful when 
applied in a heterologous prime - boost strategy based upon a BCG prime(97).  
Interestingly, a subsequent follow up study from the same authors demonstrated no 
difference in protection if the DNA vaccine was used to prime and BCG used as the 
boosting antigen(100).  Vital work performed by Vordermeier et al. compared several 
vaccination strategies in cattle using BCG and boosting with either MVA85A or a 
recombinant adenovirus also expressing Ag85A (Ad85A) and demonstrated greater 
protective efficacy with the heterologous prime - boost strategies(96).  Critically, this was 
the first time any enhanced protective effect was shown in a natural host of 
mycobacteria.   
 
Another potential method for successful vaccination of cattle is administration of BCG via 
the oral route.  Studies performed in New Zealand demonstrated that this method 
conveyed similar protection to experimental challenge as subcutaneous immunisation, 
however the dose had to be increased and the vaccine had to be administered in a lipid 
formulation(101).  Unfortunately, reducing the dose of BCG used in these experiments 
renders this system unprotective(102) and the protective efficacy cannot be increased by 
16 
Chapter One  Introduction 
co - administration of mycobacterial proteins as heterologous prime - boost antigens(103).  
Interestingly, all oral vaccines trialled have required formulation in a lipid matrix to confer 
protection(104-107).  Not only do these lipid formulations enhance BCG survival in the gut, 
but they can play a role in enhancing the host immune response(108).  Several commercial 
lipid adjuvants exist which have been shown to enhance Th1 responses or vaccine 
efficacy(109-111) and the addition of mycobacterial lipids into these adjuvant formulations 
has been further shown to enhance the protective activity of vaccines.  The most studied 
mycobacterial adjuvants have been the cord factors.  Trehalose dimycolate (TDM) has 
been shown to enhance long term protection of mice when administered as an adjuvant 
for the boost in a heterologous prime - boost strategy(112) and use of the synthetic 
analogue trehalose dibehenate (TDB) as an adjuvant has been shown to activate Th1 and 
Th17 responses via the macrophage inducible Ca2+ - dependant C - type lectin 
(Mincle)(113).  The polar lipid mono - mycolyl glycerol (MMG) has also been formulated 
into an adjuvant which has been shown to be capable of activating DC and driving Th1 
responses(114, 115).  These advances clearly highlight the role of lipids in modulating 
immune responses and their potential applications as adjuvants or vaccine candidates. 
 
Mycobacterial Lipids 
 
Biologically, the mycobacteria are considered to be Gram positive as they possess 
a single peptidoglycan cell wall.  What is unusual about the mycobacterial cell wall is that, 
rather than proteins and carbohydrates found in many other bacteria, most of the 
molecules attached to it are lipids(116).  In fact, it has been estimated that as much as 60% 
of the dry weight of mycobacteria is cell wall associated lipid(117) and these lipids are 
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widely believed to be important in directing the interactions between the pathogen and 
its host(118, 119).  Fractionation of the mycobacterial cell envelope is difficult as the 
envelope is physically strong and fractions tend to adhere to one another(120), however 
pioneering work by Brodie et al., using rapid growing mycobacterial species, lead to the 
ability to isolate the plasma membrane and fractionate the cell wall(121). 
 
While the plasma membrane appears essentially the same as found in other Gram 
positive bacteria, there are some distinct membrane bound components not found in 
other bacterial genera, primarily lipomannan, lipoarabinomannan (LAM) and 
phosphatidylinositol mannosides (PIMs)(120).  Freeze fracture studies of the mycobacterial 
plasma membrane show a typical fracture plane between the membrane surfaces, with 
integral membrane proteins embedded in these layers(122), and no evidence of a second 
outer membrane, such as those found in Gram negative bacteria.  However a second 
plane of fracture has been identified which is associated with carbohydrate molecules(123) 
that may include LAM and PIMs(120). 
 
Much time and effort has been invested in developing a comprehensive model of the 
mycobacterial cell envelope.  Thin - section transmission electron microscopy of 
mycobacteria reveals a plasma membrane surrounded by a thick electron - transparent 
periplasmic space.  External to this is an electron - dense layer which, unlike the 
peptidoglycan found in most Gram positive bacteria, is believed to be composed of a 
peptidoglycan and arabinogalactan complex.  Attached to this is another electron - 
transparent layer of mycolic acids(124).  A final electron - dense outer layer composed of 
carbohydrates and protein surrounds the bacterium and may also contain lipids(125-127).  
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This lipid - rich envelope is unusual in that it forms a permeability barrier and may be a 
bilayer in composition, similar to the outer membrane seen in Gram negative 
bacteria(128). 
 
The outer membrane, and the arrangement of the lipids therein, has been the study of 
enormous research and many models have been proposed(128-132).  It is believed that 
mycolic acids are covalently bound to the external arabinogalactan portion of the cell wall 
and an outer membrane of various lipids surrounds this.  Lipids found in this outer 
membrane may be glycolipids, such as trehalose monomycolate (TMM) and TDM, 
phospholipids, phthiocerol dimycocerosates and other species - specific lipids(128-132).  The 
model is illustrated in figure 1:3 and the structures of some of the outer lipids are shown 
in figure 1:4. 
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Figure 1:3 - Model of the mycobacterial cell wall. 
Symbols do not denote specific molecules.  PI: phosphatidylinositol. 
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Figure 1:4 - Structures of some common outer envelope lipids found in virulent mycobacteria 
(A) Phosphatidylinositol dimannoside (PIM2); (B) Diacylated phosphatidylinositol hexamannoside (Ac2PIM6); (C) 
Phthiocerol dimycocerosate (PDIM); (D) Trehalose-6-6’-dimycolate (TDM); (E) Phosphatidylinositol (PI); (F) 
Phosphatidylethanolamine (PE). 
 
The structure of the cell wall and its outer envelope are critical to the stability of the cell.  
It is well documented that mutations affecting either the length of mycolic acids(133) or 
their modification(134-136) can alter the phenotype of the bacterial cell leading to altered 
colony morphology and persistence in host cells(137) or alter the permeability and lability 
of the outer membrane(138).  In fact, genetic removal of mycolic acids from 
Corynebacterium glutamicum caused complete removal of the outer membrane(127, 139) 
and even renders the mutant bacteria more permeable to drug entry(140). 
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Immune Recognition of Lipids 
 
Dendritic cells (DC) are a group of bone marrow derived leucocytes, found in 
many tissues which serve several functions but, perhaps most importantly, initiate 
adaptive immune responses(141).  Originally identified in 1973 by Steinman & Cohn(142), DC 
are highly specialised for antigen uptake, processing and presentation to T cells and are 
considered to be the only antigen presenting cells (APC) capable of presenting antigen to, 
and activating, naïve T cells(143).  These cells are considered to epitomise the so called 
“professional” APCs(142).  Their dendritic membrane extensions maximise the surface area 
of the cell and the membrane is replete with MHC, adhesion and costimulatory 
molecules(141, 142).  Tissue localisation and different routes of derivation from the bone 
marrow mean that there are several types of highly specialised DC(144). 
 
So - called immature DCs, primarily resident in peripheral tissues, are highly efficient 
phagocytes capable of engulfment and presentation of a huge variety of antigens(145).  
Activation of these “sentinel” cells is driven via a signal, which may consist of physical 
tissue insult (and the consequent release of TNFα and IL - 1), antigen uptake or contact 
with molecules containing pathogen - associated molecular patterns (PAMPs)(142, 146, 147).  
Activated DCs exit tissue via the draining lymphatic system and migrate to the draining 
lymph nodes.  Migration is mediated by chemotactic gradients and this migratory stage is 
often characterised by increased expression of the chemokine receptor CCR7(148-150).  The 
chemokines CCL19 (MIP - 3β) and CCL21 (6Ckine) are ligands for CCR7 and their 
production by lymph node resident stromal cells is known to be important in directing 
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naïve T cells and migratory DCs to the lymph node(151).  However, whether expression of 
both of these chemokines is essential for DC migration remains unclear(152-154). 
 
Upon arrival at the lymph node, DCs are capable of stimulating and modulating the T cell 
response, a process believed to be driven by the innate interaction between DCs and 
pathogen and the subsequent production of IFNα and IL - 12(155-157).  These DCs are 
primarily characterised by their increase in expression of MHCII molecules on the cell 
surface(158), as well as other co - stimulatory molecules such as CD40, CD80 and CD86(141, 
159). 
 
Lipid Modulation of Innate Immune Responses 
 
The role of macrophages in protection against tuberculous infection was 
discovered over 60 years ago(160-162).  Much work was performed in the 1980s which lead 
to a greater understanding of the interaction between the macrophage and other host 
immune components including a method of macrophage mediated bacterial killing using 
hydrogen peroxide(163) and the critical role of IFNγ in the activation and enhancement of 
macrophages and their killing(164, 165).  Since then the interaction between mycobacterial 
species, usually M. tuberculosis or BCG, and APCs has been heavily studied.  Both DCs and 
macrophages can interact with mycobacteria using an array of receptors such as 
complement receptors (CR) 1, 3 and 4; and pattern recognition receptors (PRRs) including 
the scavenger receptor, the Toll - like receptors (TLRs), nucleotide binding oligomerisation 
domain containing (NOD) - like receptors and surface bound lectins such as the mannose 
receptor (MR) and the DC-specific intercellular adhesion molecule - 3 grabbing 
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nonintegrin (DC - SIGN)(166).  Ligation of different receptors drives different effector 
functions, some specifically promoting phagocytosis (e.g. scavenger receptors) and others 
triggering non - phagocytic maturation or activation (such as the TLRs).  It is the selective 
and multiple ligation of these receptors which dictates the effector function of the 
APC(167, 168). 
 
Of course, a successful pathogen is one which is capable of, in part at least, avoiding or 
subverting the host immune response.  It was originally hypothesised in the 1970s that 
M. tuberculosis had the ability to avoid killing by the macrophage(29, 169).  In fact it has 
been suggested that the typical immunopathology associated with pathogenic 
mycobacterial infection (the granuloma) may be beneficial to the bacilli(170).  
Nevertheless, the interface between the bacilli and their host is pivotal in defining the 
progress of infection, and those cells which interact with the pathogen both initiate and 
shape the response.  Immune recognition of M. bovis (as well as M. tuberculosis) is 
mediated by receptor : ligand interaction and lipids, being so abundant in the 
mycobacterial cell envelope, are likely to be central in this contact. 
 
Interaction between mycobacteria and a variety of mammalian PRRs has been well 
documented(171-174).  Both macrophages and DC have been shown to recognise a variety 
of lipid antigens via TLR2 including AraLAM(175), lipomannan (from both M. tuberculosis 
and BCG)(176), PIM2(175) and PIM6(177).  Other PRRs, especially C - type lectins such as the 
mannose receptor (CD207), DC - SIGN (CD209) and Dectin - 1, have also been 
documented as playing important roles in sensing tuberculous infection. 
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Macrophage phagocytosis of M. tuberculosis is primarily mediated through the mannose 
receptor and usually leads to an anti - inflammatory response(178, 179).  M. tuberculosis 
derived  mannosylated LAM (ManLAM) has been shown to bind to the mannose receptor 
and is capable of inhibiting IL - 12 production(180) and this interaction is also a key step in 
blocking phagosome - lysosome fusion(181). 
DC - SIGN is usually found on the surface of DC and is known to bind a range of 
mycobacterial lipids including ManLAM and lipomannans(182, 183).  This has been shown in 
vivo and it has been suggested that interaction with DC - SIGN may allow mycobacterial 
entry into a DC, where it remains during DC migration to the lymph nodes(182).  More 
recently, Doz et al.(171) have shown that diacylated lipomannans are capable of inhibiting 
both cytokine and nitric oxide production in LPS - activated macrophages and this 
property was assigned to interaction with either DC - SIGN or the mannose receptor(171). 
Although Dectin - 1 is more commonly associated with pattern recognition during fungal 
infection, recent studies have suggested a role in TNFα production in M. avium - infected 
macrophages(184).  In another study, Dectin - 1 dependant signalling was been shown to 
be involved in the production of IL - 12p40 and IL - 12p70 by splenic DC in response to M. 
tuberculosis(185).  Despite these studies no specific mycobacterial lipid ligands for Dectin - 
1 have been found. 
 
Innate recognition of mycobacterial antigens may not be limited to the cell surface.  NOD 
like receptor (NLR) 2 has been shown to synergise with TLR2 to increase nitric oxide and 
TNFα production(186) whilst removal of NOD2 from murine macrophages and DC impairs 
cytokine and nitric oxide production in response to live M. tuberculosis(187).  This study 
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also showed that the arabinogalactan - peptidoglycan cell wall core of M. tuberculosis 
induced TNFα and IL - 12p40 production via NOD2 in murine macrophages (187). 
 
Lipid Recognition by Adaptive Immunity 
 
Lipids have been shown to mediate a range of effects on lymphocytes.  Molecules 
such as LAM are known to be chemotactic for T cells when purified from either virulent or 
attenuated M. tuberculosis(188).  Interestingly, supernatants from macrophage cultures 
only retain this chemotactic activity when infected with virulent M. tuberculosis 
suggesting differences between the strains in their ability to export LAM(188).  ManLAM 
has also been shown to supress T cell proliferation when added to T cell clones specific 
for other antigens(189) and also to supress T cell activation as measured by reduced mRNA 
expression of IL - 2, IL - 3, GM - CSF and the IL - 2 receptor α chain(190).  The discovery that 
T cells could recognise lipids if the antigen is presented in the context of CD1 was a 
significant breakthrough(191).  It is now known that, within the human genome at least, 
there are 5 CD1 molecules: CD1a - e.  These are split into 3 groups based on their 
sequence homology; group 1 consists of CD1a, b and c, group 2 just CD1d and group 3 
contains CD1e. 
 
CD1a is found on DC and differs from other group 1 CD1 molecules in that it is 
constitutively expressed at high levels on human Langerhans cells(192) and has been 
shown to be able to present some mycobacterial lipids to CD8+ αβ T cells(193).  CD1a has 
also been found to present the mycobacterial lipopeptide didehydroxymycobactin(194) 
and is capable of activating CD8+ αβ T cells(195).  As the precursor to mycobactin, an iron 
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chelating agent critical for survival within the macrophage, levels of 
didehydroxymycobactin increase during intracellular growth(196) and this may be an 
important mechanism for recognition of infected cells. 
 
The second group 1 molecule CD1b is expressed by activated monocytes and DC and 
presents most of the identified mycobacterial lipid antigens(197) and is unique amongst 
CD1 molecules in that the structure of the binding cleft allows for binding of lipids of a 
large range of sizes(198-200).  The first CD1b restricted mycobacterial antigen identified was 
mycolic acid, which was shown to stimulate T cells(191), and all subsequent mycolic acid 
based lipid antigens are presented through CD1b thanks to its ability to accept long acyl 
chains into the binding pockets. 
In fact, the mycolic acid structure may be responsible for the immunstimulatory activity 
of other lipids as many are based on the same backbone.  For example, GMM consists of 
a glucose residue attached to a mycolic acid and is capable of stimulating specific T 
cells(201).  GMM loaded CD1b tetramers have been shown to label T cells from M. 
tuberculosis infected patients(202) suggesting an expansion of lipid responsive T cells in 
response to infection.  These tetramer labelled cells were found to be CD4+ and express 
limited diversity in their TCR repertoire and further analysis demonstrated expansion of 
these cells in patients latently infected with M. tuberculosis(203).  Interestingly, the authors 
also identified that the restricted TCR repertoire was associated with high levels of 
tetramer labelling and found that tetramer - intermediate labelled cells expressed a more 
diverse TCR repertoire suggesting the presence of other CD1b restricted mycobacterial 
lipids(203). 
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GroMM is another example and consists of a glycerol moiety attached to a mycolic acid 
structure and has been shown to drive T cell proliferation and IL - 2 production(204). 
Another family of CD1b presented lipids are those containing PI such as PIM and LAM(205).  
Both LAM and LM, which lacks the arabinose molecules, are capable of stimulating 
specific T cells through CD1b although some discrimination is made between molecules 
from different bacteria(205).  Despite the large binding pockets of CD1b, lipoglycans 
require internalising and processing before they are bound(206).  For example, the 
hexamannsoylated PIM6 is known to stimulate T cells in the context of CD1b but only 
after partial digestion involving CD1e(207).  It has since been shown that CD1e selectively 
assists an α - mannosidase based on the degree of acylation of the PIM molecule(208). 
Sulphoglycolipids are also presented by CD1b(209) but these molecules are not present in 
M. bovis (210, 211). 
 
The final group 1 CD1 molecule is CD1c which is unique in that the binding cleft allows the 
hydrophilic component of a bound antigen to protrude and it is thought that this may 
interact with the T cell receptor(212).  While CD1c cycles through deep endosomal 
compartments where lipid binding proteins are present in a similar fashion to CD1b and 
CD1d, it also cycles through early endosomal compartments where the pH is higher and 
no lipid chaperone proteins are present(197) and it is thought that the partially open 
structure of CD1c may allow for antigen binding to happen in this environment(197). 
CD1c has been shown to present a variety of lipids of a range of structures(213-215) and the 
role of CD1c in mycobacterial infection has been well characterised.  Experiments with T 
cell lines meant that it was initially thought that CD1c presented branched chain 
phospholipids such as mannosylated phosphomycoketide(213) however use of the DN6 T 
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cell line showed responses to unglycosylated molecules revealing the specificity of the 
cell line to be naked phosphmycoketide(216).  Further, CD1c tetramer analysis showed only 
unglycosylated molecules were recognised despite the ability of cells to respond to 
glycosylated molecules when presented by APC suggesting that antigen processing must 
be removing the glycosyl residues(216). 
 
Unusually, CD1 molecules are also known to be ligands for both αβ and γδ T cells.  Initially 
γδ T cells were found to be CD1c responsive(217) but studies with duodenal cells have 
since shown this population to be responsive to all group 1 and group 2 CD1 
molecules(218) despite a limited TCR repertoire.  The use of CD1d tetramers has identified 
a sulphatide responsive γδ population in peripheral blood which express the same limited 
TCR repertoire(219).  While little is known about γδ T cell ligands, CD1d has been shown to 
be expressed in locations where this restricted γδ T cell population exists(220-222) and 
activated cells have a Th1 effector phenotype and produce granulysin(217) hence CD1d 
may constitute a legitimate γδ T cell ligand. 
 
Found on the surface of most haematopoietic cells, CD1d is the only group 2 molecule 
and one of the best studied of the CD1 family.  Crystal structure analysis performed using 
antigen - loaded CD1d bound to a TCR has shown that the molecule binds lipids with acyl 
chains of specific lengths(223).  Levels of CD1d are highly variable and alter in response to a 
range of microorganisms, the receptors ligated and the presence of different soluble 
factors.  M. tuberculosis infection or exposure to mycobacterial lipids has been shown to 
upregulate CD1d expression on bone marrow - derived macrophages(224) whilst infection 
of monocytes prevents the upregulation of CD1d in cells that differentiate into DC(225). 
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CD1d restricted T cells are classified into 2 groups; the invariant NKT cells and the non - 
invariant CD1d restricted T cells.  Invariant NKT cells in mice and humans express only a 
single TCR α chain and only a small selection of β chains and are characterised by their 
high affinity recognition of α galactosylceramide (αGalCer)(226) but these cells are highly 
conserved in other species(197).  CD1d restricted invariant NKT cells are known to 
recognise certain non - microbial lipids including PI and PE, albeit with low affinity in 
comparison to αGalCer(227), and one study has suggested that these cells are also capable 
of recognising mycobacterial PIM4 extracted from BCG(228). 
The non - invariant CD1d restricted T cells resemble other, more traditional T cells and 
are involved in classical adaptive responses(197).  These cells have been shown to 
recognise DPG and PI from M. tuberculosis(229). 
 
Group 3 CD1 molecules consist solely of CD1e which remains within the cytosol of DC and 
is not externalised(230).  CD1e acts as a lipid binding protein and mediates the transfer of 
lipids to CD1b(231) and also in the degradation of some large lipid molecules, such as PIM6, 
as discussed above(207, 208). 
 
The Aims of this Study 
 
Acquired cellular immune responses are utterly dependent on the initial 
interaction between the pathogen and the host’s innate immune system and this first 
point of contact for M. bovis is likely to be an interaction with either alveolar 
macrophages or dendritic cells in the host lung.  It is widely accepted that the interaction 
between the phagocyte and the external molecules of the bacilli play a significant role in 
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the establishment of infection and, hence, the outcome of disease(118, 143, 159, 166, 232-238).  
Cell - mediated immunity is essential in developing both protective and pathological 
immunity to tuberculosis, as pulmonary macrophages alone are insufficient to control 
infection.  Rather, they act as a refuge for the bacilli which are capable of inhibiting 
phagosome - lysosome fusion and thereby avoiding destruction(239, 240).  In humans, 
granuloma formation usually contains the infection(241) leading to a state of so - called 
dormancy, or latency, although infection is rarely eliminated.  However, in cattle there is 
considerable debate about the presence of latent infection(242). 
 
As previously discussed, the production of IL - 12 by DCs and the subsequent Th1 
polarisation of the cell - mediated response is essential for IFNγ production and 
macrophage activation(243) and the bacilli : antigen presenting cell interaction is perhaps 
the most important event that occurs during the infection process(170).  Given the high 
levels of lipid found on the mycobacterial cell wall, it is highly likely that these lipids will 
play an important role in immune recognition of the pathogen.  In fact, many lipids have 
already been shown to stimulate potent immune responses(115), some have even been 
associated with immune suppression and hypervirulence(244) and immunostimulatory 
lipids have even been used to develop Th1 polarising adjuvants(114). 
 
Yet there is a distinct lack of published information regarding the interaction of the 
virulent pathogen and it’s hosts APCs.  A search of PubMed using the relevant terms 
returns very few results and none of them discuss pathogen derived lipid in host - derived 
APCs.  For example, Andersen et al.(115) demonstrated upregulation of CD40, CD86 and 
HLA - DR and the production of IL - 6 and TNFα by MDDC derived from human 
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macrophages but either extracted lipids from M. bovis BCG rather than the virulent 
human pathogen M. tuberculosis or used chemically synthesised MMG.  Bovine specific 
work performed by Hope et al. made use of bovine monocytes in the generation of 
MDDC but these cells were stimulated with a synthetic lipopeptide(233) rather than a 
pathogen - derived lipid antigen.  In the study performed by Reed et al.(244), the authors 
showed that blockage of synthesis of the phenolic glycolipid (PGL) correlated with 
increased secretion of TNFα, IL - 6 and IL - 12 by the host, and removed the “hyperlethal” 
phenotype displayed by the bacilli, however this was shown only in the murine model. 
 
Immunologically active bacterial lipids play a major role in the outcome of tuberculous 
infection and have a range of potential practical uses.  The use of specific lipids from BCG 
and M. tuberculosis to enhance protective efficacy or duration of immunity of vaccines 
has been demonstrated in a variety of model systems(112-115). 
Further, given the ability of lipids to traffic more freely than proteins between 
macrophage intracellular compartments(245) and the ability of lipids to enter directly into 
the membranes of APC(246), it is possible that lipid molecules themselves could confer 
protective immunity.  A potential advantage of this approach to vaccine development is 
that CD1 molecules are highly non - polymorphic and CD1 - presented lipids are not 
subject to large structural changes(247) as well as the fact that CD1 - restricted T cells are 
known to exhibit anti - microbial activity(213, 248).  These data suggest that specific lipid 
molecules could be used as adjuvants or as vaccine candidates for cattle however more 
needs to be known about how lipids interact with bovine immune cells. 
Lipids such as mycolic acids and LAM have also been investigated as highly specific 
diagnostic reagents in humans(249-251) and similar methods could be applied to cattle. 
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Therefore, this study addresses the hypothesis that lipids from M. bovis constitute a 
source of molecules that could be developed into tools which could contribute to the 
development of control measures for BTB.  These may include subunit vaccine candidates 
acting as antigens, or biological adjuvants, immunostimulators and specific diagnostic 
reagents.  As a first step towards these goals, this thesis aims to identify and 
immunologically characterise M. bovis - derived lipid preparations and compounds by 
pursuing the following objectives: 
 
• Develop methods to isolate and characterise lipid moieties from M. bovis, 
• Assess the effect of M bovis lipids on bovine APC to identify potential 
immunomodulatory activity which could be exploited in the development of novel 
adjuvants, 
• Identify the lipid targets of the bovine adaptive immune response which could be 
used as innovative vaccine candidates. 
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 Chapter Two 
Materials & Methods 
 
 
Preparation of Bacterial Isolates for Lipid Extraction 
 
Mycobacterum bovis strain AF 2122/97 was grown in Middlebrooks 7H9 medium, 
prepared using 4.7 g 7H9, 2 ml glycerol and 0.5 g Tween 80 in 800 ml of reverse osmosis 
purified water (roH20).  This mixture was stirred until homogeneous and autoclaved at 
121 oC for 30 minutes.  After cooling, 100 ml of a sterile 10x sodium pyruvate stock was 
added along with 100 ml of sterile Middlebrooks albumin / dextrose / catalyse (ADC) 
enrichment broth. 
 
Initial starting cultures were performed in 10ml volumes in static flasks at 37 oC within an 
ACDP Containment Level 3 (CL3) facility.  Large quantities of bacterial cells were grown in 
100 ml rolling culture flasks inoculated with 1ml of starting culture and incubated until 
mid - log phase, defined as an optical density (at 600 nm wavelength) of 0.6 - 0.8. 
 
To harvest cells, mid - log phase cultures were decanted into sterile 50 ml Falcon tubes 
and spun at 2,500 g for 5 minutes.  Supernatants were decanted and cell pellets were 
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washed twice in sterile milliQ purified water.  Pellets were suspended in 5ml sterile milliQ 
water and stored at -80 oC until being killed and removed from the CL3 facility.  Cell 
pellets were thawed before killing and heat killed in a water bath at 80 oC to 90 oC for 
between 1 and 2 hours.  Finally, heat killed cell pellets were freeze dried prior to 
extraction of lipids.  
 
M. bovis AN5 was sourced from the Tuberculin Production Unit at AHVLA Weybridge.  
Bacterial cells were grown in an ACDP CL3 laboratory as a surface pellicle on glycerol rich 
Bureau of Animal Industry (BAI) medium containing 14 g of L - asparagine, 1.5 g of 
dipotassium hydrogen phosphate, 0.74 g of sodium citrate, 1.5 g of magnesium sulphate, 
0.3 g of ferric sulphate, 0.08 g of zinc sulphate, 0.008 g of manganese chloride, 0.00138 g 
of cobaltous chloride, 10 g of glucose and 100 g of glycerol litre-1. 
The pellicle was autoclaved at 134 oC for 1 hour before being freeze dried prior to 
extraction of lipids. 
 
Extraction of Crude Free Mycobacterial Lipid 
 
The extraction method used in this thesis has been previously described(252).  
Freeze dried bacterial cells were added to a mixture of 400 ml CH3OH and 40 ml 0.3 % 
aqueous NaCl.  A further 440 ml of petroleum ether was added, the top of the vessel 
covered and mixed for 12 to 16 hours.  The mixture was decanted into centrifuge bottles 
and spun at 4000 g for 10 minutes to pellet the bacterial cells.  The upper, non - aqueous 
phase was removed by pipetting and stored.  To the lower, aqueous phase a further 440 
ml of petroleum ether was added and the mixture stirred for 2 hours before being spun 
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again, the non - aqueous layer removed and pooled with the first.  The petroleum ether 
was removed from these extracts using a rotary evaporator with cold finger condenser 
and the lipid transferred to a pre - weighed glass tube in 4 : 1 CHCl3 : CH3OH.  The CHCl3 : 
CH3OH mixture was evaporated using a heating block and a stream of N2 gas leaving dried 
lipid in the pre - weighed tube which was subsequently weighed again to determine the 
mass of apolar lipids extracted. 
 
Extraction of the polar lipids was performed by adding 212 ml CHCl3, 236 ml CH3OH and 
72 ml 0.3 % aqueous NaCl (520 ml of 9 : 10 : 3 mixture of CHCl3 : CH3OH : NaCl).  This 
mixture was stirred for 12 to 16 hours before being passed through double Whatman 91 
240 mm filters papers to collect the cells.  Once dried on the filter, the cells were re - 
extracted twice using 170 ml of a 5 : 10 : 4 mixture of CHCl3 : CH3OH : NaCl.  After a final 
filtration to remove cells and cell debris from the polar phase, 290 ml of both CHCl3 and 
NaCl were added to polar phase which was mixed for one hour and allowed to split in a 
separating funnel.  The lower, aqueous, phase was removed and dried in a rotary 
evaporator.  Final polar lipid mass was ascertained as described for the apolar petroleum 
ether extracted lipid fraction.  The process is illustrated in figure 2:1. 
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Figure 2:1 - Schematic representation of the extraction of free mycobacterial lipids. 
 
 
Analysis of Lipid Fractions by 2D Thin Layer Chromatography 
 
Aluminium backed silica gel 60 F254 TLC plates were cut into approximately 6 cm 
squares and 100 μg of lipid extract was spotted onto the plates using glass micro - 
capillary pipettes.  Plates were dried at 80 oC in an oven for 10 minutes before running. 
 
Appropriate solvent mixtures were prepared in 100 ml volumes as previously 
described(252) and TLC tanks were equilibrated using blotting paper before plates were 
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run.  The solvent systems used in all 5 TLC systems are shown in table 2:1 and plates were 
run as indicated. 
 
TLC plates were dried for 10 minutes at 80 oC between each run and before staining to 
ensure that all residual solvent was removed. 
 
Staining was performed using either a 5 % solution of molybdophosphoric acid (MPA) in 
100 ml of 95 % v/v ethanol in water (MPA) or a 1.5 % w/v solution of ninhydrin dissolved 
in 100 ml n - butanol to which 3 ml glacial acetic acid was added.  Stains were sprayed 
onto TLC plates which were subsequently charred using a hot air gun before being 
photographed or scanned.   
 
Table 2:1 - Solvent systems for TLC analysis of mycobacterial lipids (adapted from Dobson et al.(252)) 
 
Solvent 
System 
Run 
Direction Components Runs 
Fractions 
Analysed 
Lipids 
Resolved 
A 1 petroleum ether : ethyl acetate (98 : 2) 3 
Apolar PDIM, TAG, MQ  2 petroleum ether : acetone (98 : 2) 1 
B 1 petroleum ether : acetone (92 : 8) 3 
Apolar ATs, PGL, MMG  2 toluene : acetone (95 : 5) 1 
C 1 chloroform : methanol (96 : 4) 1 
Apolar PGL, MMG  2 toluene : acetone (80 : 20) 1 
D 1 chloroform : methanol : water (100 : 14 : 0.8) 1 Apolar 
& Polar 
CF, SL, 
GMM  2 chloroform : acetone : methanol : water (50 : 60: 2.5 : 3) 1 
E 1 chloroform : methanol : water (60 : 30 : 6) 1 
Polar DPG, PE PI, PIM  2 chloroform : acetic acid : methanol : water (40 : 25 : 3 : 6) 1 
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Thin Layer Chromatography Densitometrical Analysis 
 
High resolution uncompressed TIFF images were loaded into Quantity One 
analysis software and the gradient tool used to select individual lipid spots.  Automatic 
and manual separation of the spots from the background colour was found to be optimal 
when the TLC images were false coloured using the “spectrum” option.  A block selection 
of the entire plate was also made to include all lipids, including those present either at 
the origin or solvent front (figure 3:5).  Calculation of the volume of each spot was 
performed by multiplying the intensity of the spot by its area in mm2.   The intensity of 
each spot was calculated as a percentage of the total plate. 
 
Preparation of Lipid Antigen Suspensions 
 
Suspensions of all lipid antigens were prepared in an aqueous phase for use in cell 
culture experiments after first removing any CHCl3 : CH3OH by evaporation using an N2 
gas stream.  Complete RPMI was added to the dried lipid and the mixture was then 
heated to 80 oC for 5 minutes followed by sonication for 5 minutes.  This heating and 
sonicating cycle was repeated twice.  A visual check was made of lipid preparations; were 
any lipid visible to the naked eye either on the glass or in solution, another round of heat 
and sonication was performed.  Apolar and polar lipids were used at 20 µg ml -1 for 12 - 
16 hours. 
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Lipid Purification by 1D Thin Layer Chromatography 
 
 Thirty milligrams of crude free mycobacterial lipid was streaked onto the long side 
of 10 cm x 20 cm plastic backed silica gel 60 F254 TLC plate.  Plates were run in an 
equilibrated 14 : 6 : 0.8 mixture of CHCl3 : CH3OH : H2O and dried with warm air before 
being sprayed with a solution of 0.01 %  1, 6 - diphenyl - 1, 3, 5 - hexatriene (DPH) in a 9 : 
1 mixture of petroleum ether : acetone.  Staining was visualised under long wavelength 
ultra - violet light (366 nm; UV - A) and visible bands were marked with pencil.  A 
representative plate is shown in figure 2:2. 
 
Once bands had been marked, plates were washed in toluene to remove DPH and 
confirmation of removal was made by visualising the plate under 366 nm UV light.  Bands 
were then scraped from the plate and collected into individual glass tubes containing 5 ml 
of a 2 : 1 mixture of CHCl3 : CH3OH and mixed on a rotor for 10 minutes.  After pelleting 
the samples at 2000 g for 5 minutes, the supernatants were removed and filtered 
through glass wool.  The silica pellet re - extracted a further 2 times before being dried 
under a stream of N2. 
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Figure 2:2 - Representative 1D TLC of crude free polar mycobacterial lipids 
Plate was run in 14 : 6 : 0.8 CHCl3 : CH3OH : H2O, stained with 0.01 % 1, 6 - diphenyl - 1, 3, 5 - hexatriene in 9 : 1 
petroleum ether : acetone.  Plate visualised under long wavelength (366 nm) UV light. 
 
Finely suspended and colloidal silica was removed from the samples by dissolving in 6 ml 
of a 10 : 10 : 3 mixture of CHCl3 : CH3OH : H2O.  Samples were mixed on a rotor for 30 
minutes before the addition of 2.625 ml of CHCl3 and 1.125ml of H2O for a further 10 
minutes.  Separation of the phases was performed by centrifugation at 2000 g for 5 
minutes and the upper, aqueous, phase and silica interface was removed.  The remaining 
lower organic phase was treated with 3 ml of a 3 : 47 : 48 mixture of CHCl3 : CH3OH : H2O 
and mixed on a rotor for a further 10 minutes before centrifugation and removal of the 
silica interface and upper layer.  This process was repeated a further 3 times. 
 
Finally, the silica free lower phase was dried under a stream of N2, resuspended in 5 ml of 
a 2 : 1 mixture of CHCl3 : CH3OH and transferred to a clean, pre - weighed tube for 
weighing and suspension. 
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Uninfected Cattle 
 
Cattle between the ages of 6 and 36 months were obtained from herds within 4 - 
yearly testing parishes with no history of a BTB breakdown in the past 4 years as 
previously described(253).  These animals were purchased when around 6 months old and 
transported to AHVLA.  Whilst at AHVLA they tested negative in both Bovigam IFNγ assay 
and the SICCT.  Further, they were also tested in the IFNγ test with the specific antigens 
ESAT - 6 and culture filtrate protein - 10 kDa (CFP - 10) used as a combined peptide 
cocktail and results confirmed the animals as negative. 
 
M. bovis Infected Cattle 
 
Cattle between the ages of 6 and 36 months were obtained from herds within 1 - 
yearly testing parishes with a confirmed BTB breakdown within the past year as 
previously described(253).  These animals were purchased at the disclosing skin test and 
transported to AHVLA.  Whilst at AHVLA they regularly tested positive in both Bovigam 
IFNγ assay and the SICCT.  Further, they were also tested in the IFNγ test with the specific 
antigens ESAT - 6 and CFP - 10 used as a combined peptide cocktail and results confirmed 
the animals as M. bovis infected. 
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Isolation of Bovine PBMC from Whole Blood 
 
The isolation of PBMC has been previously described(253).  Briefly, whole blood was 
mixed in equal amounts with sterile HBSS containing 10 U ml -1 heparin.  This mixture was 
overlaid onto Histopaque 1077 (Sigma) and centrifuged at 800 g for 40 minutes.  The 
PBMC interface was removed using a pastette and washed twice in HBSS containing 
heparin.  Cells were identified via trypan blue exclusion and enumerated using a 
haemocytometer. 
 
Isolation of CD14+ Monocytes from Bovine PBMC 
 
Isolation of CD14+ cells was performed according to the manufacturer’s 
instructions.  PBMC were counted and suspended in 80 µl of MACS rinsing buffer (sterile 
PBS containing 2mM EDTA and 035 % BSA or FCS) per 107 cells before the addition of 10 
µl of MACS anti - CD14 MicroBeads (Miltenyi) per 107 cells.  After a 15 minute incubation 
at +4 oC on a rotator, cells were pelleted and resuspended in 500 µl per 108 cells and 
passed through MACS LS columns as per the manufacturer’s instructions.  The CD14+ 
fraction was counted and cells diluted to 1.5 x106 ml -1 in complete RPMI 1640. 
 
Generation of Bovine Cultured Monocytes and MDDC 
 
CD14+ monocytes were plated in 1 ml volumes of complete RPMI 1640 at 1.5 x106 
ml-1 in 24 well plates (Nunc Nunclon) before adding either 1000 U ml -1 equine GM - CSF 
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(Kingfisher Biotech; RP0022E - 005) (cultured monocytes - CM) or 1000 U ml -1 equine GM 
- CSF and 4 ng ml -1 bovine IL - 4 (AbD Serotec; PBP006) (monocyte derived DC - MDDC).  
Cells were incubated at 37 oC + 5 % CO2 for 3 days. 
 
After 3 days cells were harvested using a cell scraper and enumerated before being 
plated out at 1.5 x106 ml -1 in fresh complete RPMI and lipid solution was added to the 
wells.  Cells were incubated for a further 12 - 16 hours before supernatants were 
collected and cells harvested for subsequent flow cytometric analysis. 
 
Measurement of IFNγ by BovigamTM ELISA 
 
Levels of IFNγ were determined using the BovigamTM ELISA kit (Prionics AG, 
Switzerland) in accordance with the manufacturer’s instructions.  For the assessment of 
adaptive immune responses to individual PIM molecules (see Chapter Six) responses 
were considered positive if the OD450 exceeded the mean + 2 times the standard 
deviation of OD450 for nil antigen stimulated cultures from all 10 animals. 
 
Multiplex Measurement of Cytokine Production 
 
Fresh and cultured monocytes and MDDC were derived as described above.  After 
3 days in culture, cells were stimulated with 20 µg ml -1 of either the polar or apolar lipid 
fraction dissolved in RPMI as previously described.  After 12 - 16 hours of stimulation, 
supernatants were harvested and assayed for cytokine levels using the MSD multiplex 
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platform (MSD Systems, Washington) as described previously(254, 255).  Briefly, 
supernatants generated were analysed using a custom multiplex 
electrochemiluminescent system which allows simultaneous detection of IL - 1β, IL - 6, IL - 
10, IL - 12, MIP - 1β and TNFα (Meso Scale Discovery, Maryland, USA).  Multiplex 96 well 
plates were supplied with target capture antibodies spotted onto 6 separate carbon 
electrodes in each well (commercially available antibodies: TNFα (Endogen, Rockford, IL, 
USA); IL - 10 and IL - 12 (AbD-Serotec); IL - 1β, IL - 6 and human cross-reactive MIP - 1β 
(MSD)). 
 
Plates were blocked with MSD assay buffer for 30 minutes at room temperature before 
the addition of samples or standards for 1 hour at room temperature.  Standards were 
prepared by serial dilution. 
 
After incubation, plates were washed and combined biotinylated secondary detector 
antibodies were added for a further hour.  Finally, plates were washed, loaded with MSD 
read buffer T and analysed using an MSD Sector Imager 6000. 
 
Innate Cell Labelling & Analysis by Flow Cytometry 
 
Cells were harvested from the well and labelled with the live / dead indicator 
ViViD (Invitrogen) in PBS.  Cells were then plated at approximately 50,000 stain-1 and 
washed using 150 µl MACS rinse buffer before being stained for 15 minutes using either 
anti - bovine CD14 (ccG33; Institute for Animal Health; 1 : 50), anti - equine MHCII 
(MCA1085; AbD Serotec; 1 : 50), anti - bovine CD40 (IL - A156; cell supernatant, AHVLA; 1 
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: 10), anti - bovine CD80 (IL - A159; cell supernatant, AHVLA; 1 : 10), anti - bovine CD86 (IL 
- A190; cell supernatant, AHVLA; 1 : 10),  anti - bovine CD1b (CC14; AbD Serotec 
MCA831G; 1 : 10) or an IgG1 isotype control (Av20; Institute for Animal Health; 1 : 50). 
 
Labelled cells were washed using 150 µl MACS rinse buffer and secondary labelling was 
performed using a 1 : 400 dilution of anti - IgG1 conjugated to R - Phycoerythrin (R - PE) 
(Invitrogen; P21129) in 50 µl volumes for 10 minutes.  After incubation, cells were 
washed by the addition of 150µl PBS, pelleted and resuspended in 100 µl of 2 % 
paraformaldehyde (Cytofix; BD Biosciences) for at least 30 minutes at 4 oC before analysis 
on a CyAn ADP analyser. 
For capture and analysis, initial gating was on the ViViDlo (live) cells into a subsequent 
small cell / lymphocyte exclusion gate.  An example of the gating strategy is shown in 
figure 2:3.  Normalisation of the median fluorescence intensity (MFI) was performed by 
subtraction of the MFI of the Av20 isotype control from the MFI of the specific antibody 
labelling (Δ MFI). 
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Figure 2:3 - Example of gating strategy for analysis of monocytes, MDM and MDDC 
A singlet gate (FSC lin v FSC area) removes debris and clusters of cells; ViViD staining allows isolation of live / viable 
cells; a FSC vs SSC plot previously reverse gated on PBMC acts as a lymphocyte exclusion gate.  Typical CD1b labelled 
MDDC are shown with their concurrent isotypte labelling. 
 
 
Mixed Lymphocyte Reaction 
 
Bovine MDDC and cultured monocytes were prepared as described above.  
Following 3 days in culture, cells were pulsed with lipid antigen overnight before being 
enumerated, washed to remove any cytokines and lipid from the media and incubated at 
107 cells ml-1 in the presence of Mitomycin C at 100 μg ml-1 for 30 minutes at 37 oC + 5 % 
CO2.  Lipid pulsed, Mitomycin C treated MDDC or cultured monocytes were cultured in 1 
ml at 37 oC + 5 % CO2 at 2 x105 with 1 x105 PBMC isolated from a second, allogeneic 
animal.  After 5 days, cells were pulsed overnight with 1 µCi well-1 of 3H-thymidine before 
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being harvested using a Harvester 96 Mach III (TomTec Inc, Hamden, CT, USA) as 
described previously(256).  Lymphocyte proliferation was assessed by the increased cellular 
incorporation of 3H-thymidine which was measured using a MicroBeta2 2450 (Perkin 
Elmer, Waltham, MA, USA). 
 
Lymphocyte Transformation Assay 
 
PBMC were isolated from heparinised whole blood using Histopaque 1077 (Sigma) 
gradient centrifugation (as described above) and 2 x105 cells well -1 plated out in triplicate 
wells after resuspension in complete RPMI 1640.  Cells were mixed with lipid antigen, 
complete RPMI as a negative control, pokeweed mitogen (PWM) at 10 µg ml -1 as a 
positive control, or a 1 : 100 dilution of PPD - B. 
 
Measurement of proliferation by the incorporation of 3H - Thy has been previously 
described(256).  Briefly, after 4 days of incubation at 37 oC + 5% CO2, 30 µl of supernatant 
was harvested for cytokine analysis and cells were pulsed with 1 µCi 3H - Thy well -1 in 30 
µl to replace the removed supernatant.  After a further 16 - 24 hours incubation the cells 
were washed and harvested using a semi - automated harvester (Tomtec) and 
incorporation of 3H - Thy was read using MicroBeta2 (Perkin Elmer). 
 
For the assessment of adaptive immune responses to individual PIM molecules (see 
Chapter Six) responses were considered positive if the counts per minute (CPM) exceeded 
the mean + 2 times the standard deviation of the CPM for nil antigen stimulated cultures 
from all 10 animals. 
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Lymphocyte Labelling & Analysis by Flow Cytometry 
 
Bovine PBMC were isolated as described above and labelled with CellTrace Violet 
(Invitrogen Molecular Probes, Paisley, UK) in accordance with the manufacturer’s 
instructions.  Briefly, PBMC were suspended at 1 x107 ml-1 in pre - warmed PBS and 5 mM 
CellTrace Violet was added to a final working concentration of 1 μM.  Cells were 
incubated at 37 oC for 20 minutes before unbound dye was quenched with 5 times the 
labelling volume of complete cell culture medium at 37 oC for 5 minutes.  Finally, cells 
were pelleted and washed in pre - warmed complete cell culture medium, plated at 2 
x105 cells well-1 and incubated at 37 oC + 5 % CO2 for 5 days in the presence of antigen. 
Cultured cells were harvested and resuspended in flow cytometry buffer (PBS containing 
2 % FCS and 0.05 % NaN3) and labelled for 15 mins with near infrared live / dead viability 
dye (NIRViD, Invitrogen Life Technologies, Paisley, UK) and mouse anti - bovine CD335 
(AKS1, AbD Serotec, Oxfordshire, UK).  Cells were washed in flow cytometry buffer and 
secondary labelling of anti - CD335 was performed using a 1 : 400 dilution of rat anti - 
mouse IgG2a conjugated to allophycocyanin for a further 15 minutes.  After a subsequent 
wash, cells were further labelled with combinations of R - PE Zenon labelled (Invitrogen 
Life Technologies, Paisley, UK) mouse anti - bovine CD3 (MM1A; WSU Monoclonal 
Antibody Centre, Pullman, Washington, USA), mouse anti - bovine CD4 conjugated to 
alexafluor 647 (CC30, AbD Serotec, Oxfordshire, UK), mouse anti - bovine CD8 conjugated 
to alexafluor 647 (CC63, AbD Serotec, Oxfordshire, UK) and alexafluor 488 Zenon labelled 
(Invitrogen Life Technologies, Paisley, UK) mouse anti - bovine γδ TCR1 (GB21a; WSU 
Monoclonal Antibody Centre, Pullman, Washington, USA).    Finally, labelled cells were 
washed in flow cytometry buffer and resuspended in 150 μL of 2 % paraformaldehyde 
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(Cytofix; BD Biosciences, Oxfordshire, UK) for at least 30 min at 4 °C before analysis on a 
CyAn ADP analyser.  For capture and analysis, initial gating was on single, NIRViDlo (live) 
cells into a subsequent lymphocyte gate before gating on CellTrace Violetlo cells and 
assessing surface phenotype (figure 2:4). 
 
 
Figure 2:4 - Example of gating strategy for analysis of proliferative cells 
Flow cytometric gating strategy: single, live CD3+ CD335+ lymphocytes are assessed for CellTrace Violet labelling and 
CellTracelo cells gated for phenotyping.  Numbers represent the percentage of proliferating cells in response to each 
antigen. 
 
 
Monoclonal Antibody Blocking of MHCII and CD1 
 
 Bovine PBMC were isolated as described above and incubated for 2 hours in the 
presence of either anti - equine MHCII (MCA1085; AbD Serotec), anti - ovine CD1 
(MCA2212; AbD Serotec), anti - galline Bu - 1a/b as an isotype control (MCA5764; AbD 
Serotec) or no monoclonal antibody.  All antibodies were sterile and contained no 
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preservatives.  After 2 hours, antigens were added and proliferation measured as 
described for the Lymphocyte Transformation Assay 
 
Removal of Lipopeptide by Proteinase Treatment  
 
 The use of Proteinase K to remove lipopeptide has been previously described(257).  
For treatment, 20 µg of lipid was combined with 5 µg of Proteinase K from Tritirachium 
album (Sigma Alrdich; P6556) in PBS in a PCR plate.  Using a thermocycler, the mixture 
was incubated at 50 oC for 30 minutes and the Proteinase subsequently inactivated by 
increasing the temperature to 80 oC for a further 30 minutes.  After inactivation, the 
samples were chilled to 4 oC.  Mock treatment was performed by incubating the 5 µg of 
Proteinase K at 80 oC for 30 minutes before adding 20 µg of lipids and continuing the 
treatment as above.  Proteinase K treated and mock treated lipid antigens were 
suspended as described above and used to stimulate PBMC as described for the 
Lymphocyte Transformation Assay. 
 
Data & Statistical Analysis 
 
All data representation and statistical analysis was performed using GraphPad 
Prism version 5 and GraphPad InStat version 3.  Densitometry analysis of TLCs was 
performed using the gradient selection tools in Quantity One version 4.6.9.  All flow 
cytometric data was captured using a 9 colour Beckman Coulter CyAn ADP analyser and 
data was captured and analysed using Summit v4.3. 
51 
Chapter Three  Preparation & Characterisation of Crude Lipid Extracts Chapter Three 
Preparation & Characterisation of Crude Lipid Extracts 
 
 
Background 
 
 To enable analysis of specific M. bovis - derived lipids, and subsequently the host 
response to them, lipids first need to be extracted from bacterial cells.  Furthermore, the 
content of these extracts must be analysed to show the presence of lipids and allow for 
basic identification of specific lipid moieties. 
 
The extraction of bacterial lipids was first described in 1959 by Bligh and Dyer(258) and was 
further  pioneered by Minnikin(128, 259, 260).  Extraction of free lipids essentially removes the 
outer - membrane or leaflet of the mycobacterial cell wall, leaving the long chain 
molecules, such as the mycolic acids, intact in the defatted cells(259, 260).  The process 
(illustrated in figure 2:1) involves treatment of freeze dried bacterial cells with a mixture 
of methanol, saline and petroleum ether.  From this mixture, the cells and aqueous phase 
are removed using chloroform and methanol leaving the extractable free apolar lipids.  
Further treatment of the secondary extract with chloroform and saline yields the 
remaining polar lipids. 
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Primary analysis of these lipid extracts is usually performed using 5 specially developed 
thin - layer chromatography (TLC) systems (as detailed in table 2:1).  Four of these 
systems (A - D) are used to analyse the apolar lipids, while the polar fraction was analysed 
with using System D and E.   
These systems cover the polarity range of the extracted lipids; system A is used to detect 
triacyl glycerols (TAG), menaquinones (MQ) and the phthiocerol family of mycocerosic 
acids (phthiocerol dimycocerosates; PDIMs)(261).  Identification of unesterified fatty acids 
and acyltrehaloses is performed using system B, the second least polar system(252).  The 
third, slightly more polar, system C enables detection of more fatty acids and some 
glycosides, which are structurally related to the PDIMs.  System D, the most polar system 
used in the analysis of the non - aqueous petroleum ether extracts, resolves the trehalose 
based mycolates (such as trehalose dimycolate [TDM] or cord factor), the acylated 
trehaloses such as diacyl trehalose (DAT) and the sulpholipids (such as SL - 1). 
 
As well as the petroleum ether extracts, system D is also used to analyse the least polar 
entities in the chloroform : methanol extracts and enables identification of the 
glycopeptidolipids and small amounts of sulpholipids.  The most polar TLC  system is only 
useful in the analysis of the chloroform : methanol extracts and was introduced to the 
standard array of systems in 1966(262).  The system primarily resolves glycolipids and 
phosphatide based lipids such as diphosphatidylglycerol (DPG), 
phosphatidylethanolamine (PE) and phosphatidylinositol (PI) and its mannosides (PIMs). 
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TLC plates may be stained to further aid identification of individual lipid classes and 
functional residues.  Treatment with MPA, usually dissolved in ethanol or another polar 
solvent, stains phenolics, hydrocarbon based waxes and alkaloids.  Used as a general 
stain, it allows identification of any lipid molecules which appear brown after staining and 
subsequent heating.  Upon charring, reduction of MPA (Mo6+) to Mo5+ and Mo4+ 
compounds by organic compounds causes the production of dark spots against a light 
green background.  Alternatively, plates may be sprayed with a solution of ninhydrin 
dissolved in n - butanol.  Originally discovered accidentally by Siegfried Ruhemann in 
1910(263) who observed the ability of the compound to react with amine residues forming 
a purple coloured product(264), ninhydrin was originally used to detect trace amounts of 
amino acids in biological samples(265, 266) and has been used to detect amino acids in TLC 
since the 1950s(267) and has been used in the detection of fingerprints since 1959(268).  The 
formation of either Ruhemann’s Purple upon reaction of ninhydrin with a primary amine 
or a light yellow compound upon reaction with a secondary amine allows for the 
identification of lipopeptides co - extracted with the lipid fractions. 
 
While initial experiments were performed using AF 2122/97 - derived lipids (see Chapter 
Four), biosafety concerns over the high cell mass required for large scale lipid extraction 
meant that an alternative source of high volume mycobacterial culture was required.  To 
this end, pellicle grown M. bovis AN5 was sourced and used for subfractionation work 
(see Chapter Five).  This chapter documents the extraction of lipids from both the 
reference strain of M. bovis, AF 2122/97 and the PPD - B production strain, AN5 and the 
identification of the individual lipid components by 2D TLC. 
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This chapter addresses the hypothesis that lipids from the virulent M. bovis strains AF 
2122/97 and AN5 could be extracted based on their solubility in aqueous and non - 
aqueous solvents.  These fractions could be subsequently characterised, quantified and 
their main components identified using previously published analysis of mycobacterial 
lipids(252).  
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Results 
 
Extraction & Analysis of Lipids from M. bovis AF 2122/97 
 
Lipids were extracted from the reference strain of M. bovis (AF 2122/97) using the 
methods described above and were stained using both MPA and ninhydrin.  AF 2122/97 - 
derived lipids are shown in figure 3:1 (MPA stained) and figure 3:2 (ninhydrin stained). 
 
Analysis of the petroleum ether extract (containing the apolar fraction) with the least 
polar solvent system (figure 3:1 A) enabled the identification of TAG, MQ and the PDIMs.  
System B (figure 3:1 B) resolved pentacyl trehalose (PAT) and the co - located 
monomycolyl glycerol (MMG) and phenolic glycolipid (PGL), a lipid unique to M. bovis.  
The use of solvent system C (figure 3:1 C) allowed further discrimination of MMG and PGL 
whilst the most polar constituents of the petroleum ether extract, the cord factors TDM 
and TMM and glucose monomycolate (GMM) were seen using system D (figure 3:1 D). 
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Figure 3:1 - 2D TLC analysis of crude, free lipids extracted from M. bovis AF 2122/97 and stained with MPA 
(A - D): Apolar fraction analysed with TLC systems A, B, C and D.  (E and F): Polar fraction analysed with systems D and E. 
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Analysis of the chloroform : methanol extract (which contains the polar lipid fraction) 
with system D (figure 3:1 E) resolved TDM and TMM.  More individual lipids were seen 
using the most polar system (figure 3:1 F) which mainly resolved a variety of PIMs and 
miscellaneous phospholipids. 
 
Staining of plates with ninhydrin allows for the discrimination of amines and amino acids 
and is commonly used to assess the presence of lipopeptide in lipid preparations.  As can 
be seen in figure 3:2 A - D, no ninhydrin staining can been seen in the petroleum ether 
fraction. 
 
Analysis of the polar, chloroform : methanol extract, stained with ninhydrin showed no 
lipopeptide present in TLC system D (figure 3:2 E).  In contrast, lipopeptide was resolved 
using system E (figure 3:2 F).  A primary amine containing molecule was found co - 
located with the dimannoslylated PIMs (figure 3:2 F, red arrow) and an unknown 
secondary amine containing molecule was seen to have migrated near to the PE spot 
(figure 3:2 F, yellow arrow). 
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Figure 3:2 - 2D TLC analysis of crude, free lipids extracted from M. bovis AF 2122/97 and stained with ninhydrin 
(A - D): Apolar fraction analysed with TLC systems A, B, C and D.  (E and F): Polar fraction analysed with systems D and E. 
Red arrows indicate primary amines; yellow arrows indicate secondary amines; black arrows indicate charred lipid for 
reference.  Identifiable spots are named. 
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Extraction & Analysis of Lipids from M. bovis AN5 
 
 To perform larger scale lipid extraction for subsequent subfractionation, a far 
greater bacterial cell mass was required than had been used thus far (see Chapter Five).  
From a biosafety perspective, culturing such large volumes of M. bovis AF 2122/97 was 
considered unreasonable as high yield, pellicle grown M. bovis AN5 was already available 
for use.  M. bovis AN5 - derived crude lipid extracts were analysed using the same solvent 
systems (table 2:1) and stained with the same reagents (MPA and ninhydrin) as shown for 
AF 2122/97 lipids. 
 
As was seen for AF 2122/97 - derived lipids, the apolar fraction, resolved using system A, 
contained TAG, MQ and the PDIMs (figure 3:3 A).  PAT, MMG and PGL were identified 
using system B (figure 3:3 B) and MMG and PGL further separated with the use of system 
C (figure 3:3 C).  TMM, TDM and GMM were again resolved using system D (figure 3:3 D). 
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Figure 3:3 - 2D TLC analysis of crude, free lipids extracted from M. bovis AN5 and stained with MPA 
(A - D): Apolar fraction analysed with TLC systems A, B, C and D.  (E and F): Polar fraction analysed with systems D and E. 
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Similarly, the polar fraction from M. bovis AN5 contained TMM and TDM (figure 3:3 E) 
and the same array of PIMs, phospholipids, PE and PI (figure 3:3 F) as the M. bovis AF 
2122/97 - derived lipids (figure 3:1 E - F). 
 
As was seen with AF 2122/97 - derived lipids, ninhydrin staining of the M. bovis AN5 - 
derived lipid fractions showed no lipopeptide present in the apolar fraction (figure 3:4 A - 
D) and no ninhydrin staining was seen in the polar fraction separated with system D 
(figure 3:4 E). 
Finally, ninhydrin staining of system E revealed amine containing molecules co- locating 
with the dimannoside PIMs (figure 3:4 F, red arrow) and an unknown secondary amine 
located close to the PE spot (figure 3:4 F, yellow arrow). 
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Figure 3:4 - 2D TLC analysis of crude, free lipids extracted from M. bovis AN5 and stained with ninhydrin 
(A - D): Apolar fraction analysed with TLC systems A, B, C and D.  (E and F): Polar fraction analysed with systems D and E.  
Red arrows indicate primary amines; yellow arrows indicate secondary amines; black arrows indicate charred lipid for 
reference.  Identifiable spots are named. 
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Abundance Analysis of the Crude Lipid Fractions 
 
 The use of densitometry analytical techniques allows for the quantification of 
individual lipids on the TLC plates and thus enables calculation of the relative abundance 
of each lipid.  As the same quantity of each crude lipid fraction (100 µg) was loaded onto 
each TLC plate, it is possible to directly compare all of the plates containing lipids from 
either the polar or apolar fractions.  Of note, differences in the separation of the spots 
made the selection of individual spots challenging which introduced a degree of 
variability into the quantification. 
 
Using false coloured TLC images of the AF 2122/97 - derived polar fraction (figure 3:5 A - 
D) the abundance of the individual lipids is shown in table 3:1. 
In total, around 16 % of the apolar lipid fraction can be identified by this method.  The 
largest proportion of identifiable lipid is made up of TAG (4.77 % of the apolar fraction) 
followed by the PDIMs (3.81 %).  In system B (figure 3:5 B) PGL and MMG co - locate on 
the plate and cannot be resolved individually, however in system C (figure 3:5 C) they can 
be resolved separately.  MMG makes up the larger proportion of these lipids (2.15 % of 
the total apolar fraction) while PGL accounts for 1.2 % of the total lipid preparation.  
GMM, visible in system D (figure 3:5 D) makes up 1.62 % of the total fraction and the 
remaining lipids all account for less than 1 % of the fraction each (MQ: 0.89 %, PAT: 0.79 
%, TDM: 0.72 % and TMM: 0.60 %). 
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Figure 3:5 - False coloured densitometry analysis of lipids extracted from M. bovis AF 2122/97 and analysed by 2D TLC 
(A - D): Apolar fraction analysed with TLC systems A, B, C and D.  (E and F): Polar fraction analysed with systems D and E. 
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As shown in table 3:2, within the AF 2122/97 - derived polar lipid fraction visible in 
systems D and E (figure 3:5 E and F) TDM is the most abundant identifiable lipid species 
(4.04 %) with TMM second comprising 1.22 % of the fraction.  The lipids resolved by 
system E (figure 3:5 F) make up less than 1 % of the total polar fraction each, however in 
total these 8 lipid moieties account for 4.09 % of the fraction. 
 
Analysis of the AN5 - derived polar fraction (figure 3:6 A - D) was also performed and the 
abundance of the individual lipids is shown in table 3:1. 
In total, around 9 % of the apolar lipid fraction can be identified by this method.  The 
largest proportion of identifiable lipid is made up of the PDIMs (3.36 % of the apolar 
fraction) followed by MMG (1.36 %), TAG (1.1 %) and MQ (0.94 %).  The remaining 2 % of 
identifiable lipids consisted of PAT (0.58 %), PGL (0.5 %), TDM (0.43 %), GMM (0.37 %) 
and TMM (0.15 %). 
 
In total, only 4.5 % of the AN5 - derived polar fraction could be identified (figure 3:6 E and 
F; table 3:2).  The largest component was Ac1PIM6 (1.59 %) followed by TDM (0.93 %).  
Ac2PIM6 and DPG were present in similar quantities (0.46 %) and the remaining 1 % was 
accounted for by P (0.28 %), Ac2PIM2 (0.26 %),TMM (0.21 %), PE (0.16 %), Ac1PIM2 (0.08 
%) and PI (0.07 %). 
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Figure 3:6 - False coloured densitometry analysis of lipids extracted from M. bovis AN5 and analysed by 2D TLC 
(A - D): Apolar fraction analysed with TLC systems A, B, C and D.  (E and F): Polar fraction analysed with systems D and E. 
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Table 3:1 - Densitometry of the apolar lipid fractions. 
Volumes (intensity x area) are used to calculate to amount of total identifiable lipid within the apolar fractions. 
*Lipids are co - located and inseparable in this system and have not been used as part of the total calculation. 
 
Solvent 
System 
Identified 
lipids 
% Total lipid 
AF 2122/97 
% total lipid 
AN5 
A TAG 
MQ 
PDIMs 
4.77 
0.89 
3.81 
1.10 
0.94 
3.36 
B PGL / MMG 
PAT 
3.44* 
0.79 
0.93* 
0.58 
C MMG 
PGL 
2.15 
1.20 
1.36 
0.50 
D TMM 
TDM 
GMM 
0.60 
0.72 
1.62 
0.15 
0.43 
0.37 
Total identifiable lipids 16.54 % 8.79 % 
 
 
 
Table 3:2 - Densitometry of the polar lipid fractions. 
Volumes (intensity x area) are used to calculate to amount of total identifiable lipid within the polar fractions. 
 
Solvent 
System 
Identified 
lipids 
% Total lipid 
AF 2122/97 
% total lipid 
AN5 
D TMM 
TDM 
1.22 
4.04 
0.21 
0.93 
E Ac1PIM6 
Ac2PIM6 
Ac1PIM2 
Ac2PIM2 
PI 
P 
DPG 
PE 
0.28 
0.53 
0.62 
0.43 
0.69 
0.37 
0.52 
0.66 
1.59 
0.46 
0.08 
0.26 
0.07 
0.28 
0.46 
0.16 
Total identifiable lipids 9.35 % 4.50 % 
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Using these methods it was possible to identify approximately 25 % of the total lipids 
extracted from M. bovis AF 2122/97 and approximately 13 % of those from M. bovis AN5.  
Whilst identical compounds could be identified qualitatively in the lipid profiles of both 
strains, there were obvious quantitative differences.  Thse will be discussed in the 
following section. 
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Discussion 
 
Extraction of mycobacterial lipids and their subsequent analysis by 2D TLC has 
been previously described for M. tuberculosis (269), but little data exists on total lipid 
profiling of M. bovis.  Previous work by Dandapat et al.(270) attempted to characterise M. 
bovis AN5 based on the expression of PGL and PDIMs, but only as a tool for identification 
of the organism.  Further, the use of M. bovis AN5 may not have been representative of 
the AF 2122/97 reference strain.  Presented here is the first biphasic extraction and 
complete analysis of the lipids of M. bovis AF 2122/97. 
 
In figure 3:1, the use of MPA staining allowed the identification of a broad range of 
characteristic mycobacterial lipids including PDIMS (figure 3:1 A), the M. bovis 
characteristic PGL(271) (figure 3:1 B and C), TDM (figure 3:1 D and E) and PIMs (figure 3:1 
F).  As expected, no sulphoglycolipid was found (figure 3:1 D)(210, 211).  Interestingly, TDM 
was found in both the polar and apolar extracts (figure 3:1 D and E).  This may be related 
to its particularly amphipathic nature(272) and variable acylation states which are known 
to alter its hydrophobicity(273, 274) and may cause the molecule to split differentially across 
the biphase interface during lipid extraction. 
 
No systematic lipopeptide profiles have been published for any mycobacterial species, 
despite the fact that lipopeptides from a variety of mycobacterial species have been 
shown to modulate immune responses(275-277) and that some responses attributed to 
lipids may be driven by lipopeptide instead(257).  
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Analysis of the AF 2122/97 - derived lipid fractions by ninhydrin indicated no lipopeptide 
presence in the apolar fraction (figure 3:2 A - D) but both primary and secondary amine 
containing molecules in the polar lipid fraction (figure 3:2 F).  Interestingly, one primary 
lipopeptide co - locates precisely with PI suggesting that the amine containing molecule 
may be physically associated with the lipid.  A secondary amine was seen which located 
near the PE spot (figure 3:2 F).  The identity of both these molecules is unknown, as is the 
reason for their co - location with the lipid molecules although it may be that any 
lipopeptide present is chemically bonded with the lipids. 
 
Analysis of the M. bovis AN5 - derived lipids with the standard TLC systems and stained 
with MPA (figure 3:3) allowed for a comparison between the 2 bacterial strains.  Overall, 
the same lipid molecules were present in the apolar (figure 3:3 A - D) and polar (figure 3:3 
E - F) lipid fractions.  However, it is clear that the lipids derived from M. bovis AN5 do not 
separate in exactly the same manner as those from AF 2122/97 and form spots of 
different shapes.  From the analysis performed here it is not possible to tell if these 
differences are due to the synthesis of inherently different forms of these lipids in the 2 
strains, or if the differing conditions of bacterial culture have affected lipid synthesis; a 
factor known to play a role in the lipid production of mycobacteria(278, 279). 
Lipids from M. bovis AN5 were also stained with ninhydrin (figure 3:4).  Although not as 
clear as for AF 2122/97 - derived lipids, the primary amine staining co - located with PI is 
present in AN5 - derived lipids, as is the secondary amine seen located near the PE spot 
(figure 3:4 F). 
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It is worth noting that the lipids from M. bovis AN5 separated less cleanly than those from 
AF 2122/97.  This is most clearly demonstrated in the most polar solvent systems used to 
analyse the apolar lipids (figure 3:3 C - D) where lipids dissolved in the mobile phase have 
left streaks or smears in both directions of the TLC.  Such smearing or streaking is often 
due to overloading of the analyte on the TLC plates, however this is unlikely in this 
instance. Each plate shown in figure 3:1, figure 3:2 and figure 3:4 has 100 µg of lipid 
loaded at the origin and spots are consistently located and well defined.  Perhaps more 
likely is that damage was caused to some of the AN5 - derived lipid molecules by 
autoclaving at 134 oC for 1 hour.  For technical reasons, it was not possible to heat kill the 
pellicle grown M. bovis AN5 by the same method as the AF 2122/97, which was heated to 
between 80 oC and 90 oC for 1 - 2 hours, and this extra heat may have denatured some of 
the lipid structures causing them to dissolve into or precipitate out of the mobile phase 
less efficiently. 
 
The effect of growth as a pellicle upon lipid composition is not well understood, despite 
the fact that growth at the interface between medium and air plays an important role in 
many other bacterial genera.  Vibrio cholerae, some streptococci and staphylococci are 
known to form biofilms which have been implicated in their virulence(280-283).  It has been 
suggested that M. tuberculosis is capable of forming biofilms and some evidence has 
been found that biofilm - like structures form in guinea pig lung lesions which enhance 
antimicrobial resistance and virulence of the bacteria(284).  However little information 
exists on changes in lipid profile, synthesis or metabolism when mycobacteria are 
cultured in their planktonic form.  It has been shown that the use of carbon limiting 
chemostats to replicate bacterial growth rates of active infection and a slower dormant 
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phenotype led to significant changes in total lipid composition of BCG(285).  However, this 
study used a single lipid extraction and subsequent elemental analysis by combustion to 
ascertain the authors’ findings.  Other work has demonstrated an alteration of the 
transcriptional response which led to the identification of a novel wax ester when M. 
tuberculosis was grown in iron limited conditions(278).  It is also known that keto - mycolic 
acids are essential for pellicle formation by M. tuberculosis(286) and that pellicle formation 
can allow drug resistant bacteria to replicate(287). 
 
Overall, the lipid profiles obtained by extraction of the apolar and polar fractions from 
both AF 2122/97 and AN5 are remarkably similar.  All lipids migrated to the same 
locations upon 2D TLC analysis and all lipids of known identities were present in both 
strains. 
 
In an attempt to further characterise the lipid fractions, densitometry analysis was 
performed to allow relative quantification of the lipids present in the polar and apolar 
subfractions.  This technique is more commonly used for imaging gels analysed using a gel 
documentation system, however it was possible to load in high resolution images of the 
TLC plates, false colour them and select individual spots for analysis (figure 3:5 and figure 
3:6). 
 
Using the images of the AF 2122/97 - derived lipids, each spot of a known identity was 
selected, along with the entire plate.  As the plates shown in figure 3:5 A - D all contain 
100 µg of the apolar lipid fraction it is possible to collate the information for the total 
lipid on each plate and calculate the volume of each individual spot.  In total, the 
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identifiable apolar lipids from AF 2122/97 constitute just over 16 % of the total, MPA 
stained lipid in the fraction (table 3:1).  Similarly, just over 9 % of the polar lipids could be 
identified (table 3:2). 
 
Interestingly, a smaller proportion of the AN5 - derived lipid fractions could be quantified 
despite the presence of the same lipid molecules.  As discussed above, growth conditions 
could have played a significant role in the different relative abundances of the lipid 
molecules.  It is also likely that autoclave treatment of the AN5 pellicle, and the 
subsequent damage to the lipid molecules, affected the ability to perform the 
densitometry analysis.  More spreading and smearing of lipid was present in the AN5 - 
derived lipids upon TLC analysis which compromised the ability of the analysis software 
to select the edges of the spots.  Therefore it is possible that more identifiable lipid is 
present than can be reported here. 
 
These data demonstrate that considerably more lipid is present in these fractions than 
can be identified with these TLC systems.  Further evidence of this can be seen in the 
solvent front and origins of the TLC plates.  The least polar solvent system used (system 
A) allows only the least polar lipids to dissolve into the mobile phase and migrate over the 
plate.  However, some extremely apolar lipid material is contained within the solvent 
front and can be seen in the apolar lipids from both AF 2122/97 (figure 3:1 A) and AN5 
(figure 3:3 A). 
 
Similarly, system E is the most polar solvent system currently in use and allows the most 
polar lipids to dissolve.  However MPA stained lipid material is still present at the origin 
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(figure 3:1 F and figure 3:3 F) suggesting that lipid, or lipid containing, material of greater 
polarity is present in the fraction which requires further analysis in more polar solvents. 
 
In conclusion, this chapter demonstrates the ability to chemically extract aqueous and 
non - aqueous lipid fractions from virulent strains of M. bovis.  Further, it was possible to 
characterise these fractions by MPA stained 2D TLC and identify the main lipid families 
contained within the fractions of both strains of M. bovis.  Ninhydrin staining of these 
TLCs also enabled the discovery of lipopeptides present in the polar fraction from both 
strains.  Finally, the application of densitometrical analysis allowed the quantification of 
the lipid species within the fractions.  Having generated and characterised these 
fractions, both qualitatively and quantitatively, they could then be used to stimulate 
bovine innate immune responses. 
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Chapter Summary 
 
 
• Objective 
The extraction of polar and apolar lipid fractions from M. bovis strains AF 
2122/97 and AN5 and their subsequent characterisation by 2D TLC and 
densitometry 
• Results 
Polar and apolar lipid fractions were successfully extracted from both M. bovis 
strains.  A broad range of lipids was identified in both polar and apolar 
fractions and qualitative TLC analysis showed that AF 2122/97 and AN5 
fractions consist of similar lipid species.  Lipopeptide was identified in the polar 
fractions from both strains and these were qualitatively similar. 
Densitometrical analysis showed that identifiable lipids composed 
approximately 25 % of the AF 2122/97 - derived fractions.  The AN5 - derived 
fractions were composed of 13 % identified lipids. 
• Conclusions 
Polar and apolar lipid fractions can be chemically extracted from virulent M. 
bovis and have been characterised and quantified here for the first time.  
Further, the polar fraction has been shown to contain lipopeptides.  Much of 
the content of the fractions is unknown and requires the development of new 
analytical techniques as the current TLC systems will not resolve these 
molecules. 
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Effects of Crude Lipids on Bovine Innate Immune Cells 
 
 
Background 
 
It is widely accepted that the interaction between host and pathogen is critical in 
establishing an appropriate and effective immune response which controls the invading 
pathogen and protects the host from the effects of infection.  The role of macrophages in 
protection against tuberculous infection was discovered over 60 years ago(160-162).  Much 
work was performed in the 1980s which lead to a greater understanding of the 
interaction between the macrophage and other host immune components including a 
method of macrophage mediated bacterial killing using hydrogen peroxide(163) and the 
critical role of IFNγ in the activation and enhancement of macrophages and their 
killing(164, 165).  Since then the interaction between mycobacterial species, usually M. 
tuberculosis or BCG, and APCs has been heavily studied. 
 
Ligation of different receptors drives different effector functions, some specifically 
promoting phagocytosis (e.g. scavenger receptors) and others triggering non - phagocytic 
maturation or activation (such as the TLRs).  It is the selective and multiple ligation of 
these receptors which dictates the effector function of the APC(167, 168).  Further, it has 
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been reported that M. tuberculosis interaction with TLR2 mediates TNFα release(174).  
Genetic removal of TLR2 in murine models leads to impaired immune responses to M. 
avium(172) and recent work has shown impaired anti - mycobacterial activity of 
macrophages and reduced TNFα production in TLR2 deficient mice(173).  It has also been 
shown that triacylated lipomannans bound to the TLR2 - TLR1 heterodimer induced the 
production of IL - 12p40 and nitric oxide and that tetra - acylated lipomannans exerted 
the same effect but through TLR4(171).  In contrast, mannose receptor mediated 
phagocytosis of M. tuberculosis has been shown to generate Th2 T cell responses 
characterised by production of IL - 10, CCL22 and CCL17(178, 179) and ligation of the MR by 
mannosylated LAM (ManLAM) inhibits IL - 12 production(180). 
 
The ability to derive DCs and macrophages from blood monocytes in vitro and harness 
their antigen presenting ability was first described by Sallusto & Lanzavecchia(288).  
Previous to this, in vitro derivation of DCs required either cord blood or bone marrow 
precursor cells and was performed using GM - CSF and TNFα(289).  In their ground breaking 
work, Sallusto & Lanzavecchia demonstrated not only the ability to culture DC from 
peripheral blood monocytes, but that TNFα inhibits DC development and that IL - 4 
enhanced it.  This has since proven to be a major advancement, thanks to the simplicity 
of their method, and has led to a huge increase in the study of DCs. 
 
It is clear that innate recognition of mycobacteria is critical in generating an appropriate 
immune response and that the mammalian immune system has many ways of sensing 
mycobacteria.  This chapter addresses the hypothesis that the lipid fractions generated 
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and characterised in Chapter Three would be capable of driving functional and 
phenotypic responses in bovine antigen presenting cells.   
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Results 
 
Characterisation of Cultured Monocytes and Monocyte Derived DC 
 
CD14+ monocytes were isolated from uninfected cattle and cultured for 3 days in 
the presence of either GM - CSF (cultured monocytes) or GM - CSF and IL - 4 (MDDC).  
Cultured monocytes displayed little morphological change from the freshly isolated cells 
(figure 4:1 A).  However, after 3 days of culture in the presence of GM - CSF and IL - 4, the 
cells displayed characteristic DC - like morphology primarily characterised by flattening 
and the extension of dendritic processes (figure 4:1 B). 
 
CD14+ cells were also cultured for 3 days without the addition of cytokines to the 
medium.  These cells did not display any flattening or process extension and appeared 
almost morphologically indistinguishable to those cultured with GM - CSF (not shown).  
The majority of the untreated cells did not survive 3 days of culture and, upon 
enumeration using trypan blue to discriminate live cells, yields were typically very low 
with only 10 - 15 % the cells viable.  Further, upon subsequent flow cytometric analysis, 
up to 95 % of these trypan blue counted cells were considered dead after staining with 
ViViD, therefore these cells were not used in any further studies. 
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Figure 4:1 - CD14+ cells after culture for 3 days in the presence of either GM - CSF or GM - CSF and IL - 4. 
(A) bovine GM - CSF; (B) bovine GM - CSF and IL - 4.  Arrow (i) indicates flattening and enlarging of cells.  Arrow (ii) 
indicates a dendritic cellular processes.  Magnification 400x using phase contrast microscopy. 
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Having shown morphologic differences between the culture conditions, the cells were 
further characterised using flow cytometry to assess the expression of several key 
molecules to define their individual phenotypes. 
 
Figure 4:2 summarises the normalised expression of the surface molecules MHCII (A), 
CD86 (B), CD40 (C), CD80 (D), and CD1b (E) on freshly isolated monocytes, GM - CSF 
treated cells (regarded as cultured monocytes [CM]) and GM - CSF and IL - 4 treated cells 
(regarded as MDDC).  When comparing monocytes with CM, a trend was evident for 
lower expression of MHCII on cultured monocytes (figure 4:2 A).  This small reduction in 
MHCII expression was accompanied by a similar trend for a reduction in CD86 expression.  
No difference was seen in the levels of CD40 expressed by either monocytes or CM 
(figure 4:2 C).  CM expressed significantly more CD80 than monocytes expression when 
compared to monocytes (figure 4:2 D).  Finally, neither monocytes nor CM expressed any 
CD1b (figure 4:2 E). 
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Figure 4:2 - Phenotype of fresh CD14+ monocytes, cultured monocytes (CM) and cultured DC (MDDC) 
Median fluorescence intensity of (A) MHCII, (B) CD86, (C) CD40, (D) CD80, (E) CD1b.  Points represent individual 
animals; bar represents mean Δ MFI. * p < 0.05, ** p < 0.01 using repeated measures ANOVA with Bonferroni multiple 
comparisons test. 
 
Comparison of MDDC with monocytes showed that there was a trend for increased levels 
of MHCII expression on MDDC (figure 4:2 A).  No difference was seen in the levels of 
CD86 expressed by either MDDC or monocytes (figure 4:2 B) or CD80 (figure 4:2 D).  
However, MDDC were found to express significantly higher levels of CD40 than 
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monocytes (figure 4:2 C) and, perhaps most strikingly, MDDC were the only cells to 
express the lipid - specific antigen presentation molecule CD1b (figure 4:2 E). 
 
Finally, comparison of CM with MDDC showed a strong trend for higher levels of MHCII 
expression on MDDC (figure 4:2 A) and similar levels of CD86 expression on both cell 
types (figure 4:2 B).  MDDC expression of CD40 was significantly higher than that seen on 
CM (figure 4:2 C) while CM expression of CD80 was significantly higher than that by 
MDDC (figure 4:2 D).  As was seen with monocytes, MDDC expressed significantly 
increased levels of CD1b in comparison to CM, which expressed no CD1b (figure 4:2 E). 
 
Overall, clear differences were apparent between bovine monocytes, cultured monocytes 
and MDDC.  Cultured monocytes were characterised by their decreased expression of 
MHCII (Δ MFI = 114 compared to Δ MFI = 172 on monocytes) and CD86 (Δ MFI = 35 
compared to Δ MFI = 50 on monocytes) combined with the subsequent significant 
increase in CD80 expression (Δ MFI = 23 compared to Δ MFI = 10 on monocytes; p < 
0.0005). 
 
MDDC were defined by their significantly higher levels of CD40 (Δ MFI = 126 compared to 
Δ MFI = 41 on monocytes; p < 0.001) and the presence of CD1b (Δ MFI = 30 compared to 
Δ MFI = 0 on monocytes and MDM).  Furthermore, MDDC displayed a characteristic 
flattened morphology and the extension of long cellular process. 
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Cytokine Responses to Crude Mycobacterial Lipids 
 
In order to assess the effect of M. bovis - derived lipids on these bovine innate 
cells, cytokine production was measured after overnight stimulation with the lipid 
fractions (figure 4:3). 
 
Significantly increased IL - 10 secretion was seen from all 3 cell types following 
stimulation with the polar lipid fraction (figure 4:3 A).  Strong IL - 10 responses were seen 
for 3 animals, while only modest increases were noted for the remaining cattle (figure 4:3 
A).  In contrast, little or no significant increase in IL - 10 production was seen following 
stimulation with the apolar lipid fraction, although apolar lipids induced some IL - 10 
production by cultured monocytes and MDDC from 3 animals.  All responses to apolar 
lipids were by far lower than those induced by the polar lipid fraction 
 
IL - 12 levels in the culture supernatants were measured simultaneously and the results 
are shown in figure 4:3 B.  Stimulation with the polar lipid fraction induced a large 
increase in IL - 12 production by MDDC, while lower responses were also observed from 
monocyte and cultured monocyte populations.  In contrast to the polar lipids, stimulation 
with the apolar lipid fraction resulted in minimal increases in IL - 12 production by 
monocytes, cultured monocytes or MDDC. 
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Figure 4:3 - Effect of stimulation with the polar and apolar lipid fractions on cytokine production by bovine innate 
immune cells. 
(A) IL - 10, (B) IL - 12, (C) MIP - 1β, (D) TNFα & (E) IL - 6.  Points represent mean responses from duplicate wells for each 
of 7 animals tested.  Lines indicate that cells were derived from the same animal; * 0 < 0.05; ** p < 0.01; *** p < 0.001 
using Friedman repeated measures ANOVA with Dunn’s multiple comparisons test. 
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Levels of MIP - 1β were also found to be significantly increased after exposure to the 
polar lipid fraction with no significant increase seen after apolar lipid stimulation (figure 
4:3 C).  Both cultured monocytes and MDDC produced noticeably more MIP - 1β than 
fresh monocytes, with MDDC from 6, and cultured monocytes from 3, of the 7 animals 
responding strongly (figure 4:3 C). 
 
Significant increases in TNFα production were also seen, again in response to the polar 
lipid fraction (figure 4:3 D).  While polar lipid treated cultured monocytes from all 7 cattle 
produced significant levels of TNFα, considerably more TNFα was produced by MDDC 
(figure 4:3 D).  Further, the level of TNFα production was similar between fresh and 
cultured monocytes (figure 4:3 D). 
 
The production of IL - 6 (figure 4:3 E) followed a broadly similar pattern to that of TNFα 
(figure 4:3 D) although statistical significance was not achieved.  Fresh monocytes from 2 
cattle produced more IL-6 after exposure to the polar lipids, which also drove increased 
IL-6 production in cultured monocytes from 6 cattle (figure 4:3 E).  Polar lipid driven IL - 6 
production by MDDC was noted in 5 of the 7 animals screened, with one of these animals 
producing more IL - 6 to the apolar lipid fraction than the polar.  While statistical 
significance was not achieved, the levels of IL - 6 produced by MDDC are notably higher 
than from fresh or cultured monocytes (figure 4:3 E). 
 
These data clearly demonstrate that the polar lipid fraction drives the production of 
significant amounts of IL - 10, IL - 12, MIP - 1β and TNFα from all cell types.  Furthermore, 
it is clear that MDDC produced more IL - 12, TNFα and IL - 6 than fresh or cultured 
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monocytes and MIP -1β production is greater from both cultured monocytes and MDDC 
than in fresh monocytes. 
 
Phenotypic Responses to Crude Mycobacterial Lipids 
 
Exposure of bovine antigen presenting cells to the polar lipid fraction led to 
significant increases in the production of a variety of cytokines (figure 4:3 A - E), all of 
which can play important roles in directing the subsequent cell - mediated response.  In 
order to further assess the effect of M. bovis - derived lipids and the local cytokine milieu 
on these cells, analysis of the expression of key antigen presentation related molecules 
was assessed by flow cytometry (figure 4:4). 
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Figure 4:4 - Effect of stimulation with the polar and apolar lipid fractions on phenotype of bovine innate immune cells. 
(A) MHCII, (B) CD86, (C) CD1b and (D) CD40.  A single point represents the median fluorescence intensity of the specific 
stain after subtraction of an isotype control (ΔMFI) for each of 7 animals tested; ** p < 0.01; *** p < 0.001 using 
repeated measures ANOVA with Bonferroni multiple comparisons test. 
 
Stimulation with the polar lipid fraction resulted in a significant reduction in the cell 
surface expression of MHCII on all three cell types (figure 4:4 A).  Furthermore, MHCII 
expression was also lower on MDDC following stimulation with apolar lipids, although this 
did not achieve statistical significance (figure 4:4 A).  CD86 expression was also 
significantly reduced on all three cell types following stimulation with the polar lipid 
fraction (figure 4:4 B).  While there was a trend for lower CD86 expression on all three 
cell types following stimulation with the apolar lipid fraction, this again did not achieve 
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statistical significance (figure 4:4 B).  Similarly to unstimulated cells, monocytes and CM 
stimulated with either lipid fraction did not express CD1b (figure 4:4 C).  However, 
incubation of MDDC with the polar lipid fraction resulted in a significant reduction in 
CD1b surface expression (figure 4:4 C).  Not all cell surface molecules were down - 
regulated following treatment with lipids.  CD40 expression on both monocytes and 
cultured monocytes increased significantly following stimulation with the polar lipid 
fraction (figure 4:4 D), although no effect was seen on MDDC.  Finally, no significant 
difference was seen in CD80 levels following stimulation with either the polar or apolar 
lipid fractions (data not shown). 
 
In summary, these data demonstrate that M. bovis - derived lipids, and in particular the 
polar fraction, downregulate the expression of several key cell surface molecules involved 
in antigen presentation. 
 
Consequence of MDDC Exposure to M. bovis - Derived Lipids 
 
To identify and assess any functional consequence of the lipid induced reduction 
in molecules related to antigen presentation the ability of lipid treated innate cell types 
to stimulate an alloreactive response was assessed.  Co - culture of the responder PBMC 
population with either untreated MDDC or cultured monocytes resulted in a 5 - fold 
increase in their proliferation (figure 4:5).  No proliferation was noted for either MDDC or 
cultured monocytes in the absence of responder cells (data not shown).  Polar lipid 
treated MDDC retained their ability to induce proliferation in the responder population 
despite the downregulation of important costimulatory molecules.  In contrast, allo - 
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stimulation of the responder population by polar lipid treated cultured monocytes 
resulted in significantly reduced proliferative responses to levels comparable with the 
unstimulated responder control cells (figure 4:5). 
 
 
Figure 4:5 - Proliferative responses of PBMC stimulated with polar lipid treated allotypic cultured monocytes and MDDC 
Red bars - polar lipid treated allotypic cultured monocytes or MDDC; light grey bars - untreated allotypic cultured 
monocytes or MDDC.  Bars represent the mean of triplicate wells ± standard error of the mean; *** p < 0.001 using 
repeated measures ANOVA with Bonferroni multiple comparisons test. 
 
  
91 
Chapter Four  Effects of Crude Lipids on Bovine Innate Immune Cells 
Discussion 
 
To assess whether crude lipid fractions were capable of mediating the responses 
of bovine innate cells, stimulation experiments were performed and the level of a range 
of cytokines was analysed.  Cells were stimulated with either polar and apolar fractions, 
however it was only after stimulation with the polar fraction that significant increases in 
the production of various cytokines were detected.  Perhaps most striking is the 
significant increase in the production of both the Th - 1 polarising IL - 12 and the anti-
inflammatory cytokine IL - 10 (figure 4:3 A - B).  Initially this seems contradictory, but it is 
important to note that the fractions used are complex mixtures of a variety of lipids some 
of which, such as MMG(115), are known to induce potent immunostimulatory cytokine 
profiles while others, such as glycerol monomycolate (GroMM), are known Th2 
polarisers(290).  Further, many lipid molecules from M. tuberculosis have been shown to 
mediate a range of pleiotropic effects on innate cells in murine models(291, 292). 
 
There is little information in the published literature discussing cytokine production by 
lipid treated antigen presenting cells.  Instead, much work concentrates on assessing 
CD4+ and CD8+ T cells responses either after direct exposure of the lymphocytes to lipid 
antigens or by stimulating lymphocytes with infected or treated antigen presenting cells.  
For example, TDM, which is present in the polar and apolar fractions (figure 3:1 D - E), has 
been shown to induce both Th1 and Th2 cytokines.  The induction of IFNγ and IL - 12 and 
the depletion of IL - 4 producing NK cells has been attributed to TDM(293, 294) as well as a 
role, along with IL - 6 and TNFα, in stable granuloma formation(295).  Yet TDM is also 
implicated in the production of IL - 5 and IL - 10 in a CD1 - dependant manner(296).  
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Furthermore, GroMM has been implicated in the induction of Th2 polarising 
responses(290) whilst the closely related GMM has been shown to induce Th1 cytokine 
responses in T cells(297).  Similarly, anti - inflammatory effects have also attributed to PIM2 
and PIM6 where, upon lipid treatment of LPS activated macrophages, Doz et al. measured 
downregulation of TLR4, TNFα, IL - 12p40, IL - 6, KC and IL - 10 as well as MyD88 mediated 
NO release(298).  However, PIM2 has also been shown to activate MDDC, inducing 
significant increases in IL - 12 production(299, 300). 
 
Given the significant increase in IL - 10 production by all innate cell types assessed, and 
the important role these cells play in generating and directing the immune response, the 
expression of antigen presentation associated cell surface molecules after lipid exposure 
was analysed.  Lipid treatment of APCs lead to a significant decrease in the levels of 
costimulatory molecules associated with antigen presentation including MHCII and CD86 
on all cell types studied and CD1b on MDDC (figure 4:4 A - C).  Negative regulation of 
these molecules by a variety of lipid components has been noted previously, especially 
MHCII in human and murine systems.  Similar to the data presented here, the 19 - kDa 
lipoprotein is capable of downregulating MHCII expression on human THP - 1 
macrophages by inhibiting activation of the IFNγ - induced CIITA(301, 302).  Downregulation 
of MHCII, as well as TLR2 and TLR4, has also been reported on human MDDC after lipid 
exposure(303) and a further study also found impaired expression of CD1a, MHCII, CD80 
and CD83 on human MDDC(304). 
 
Downregulation of CD1 molecules has also been shown previously.  Gagliardi et al. 
demonstrated that MDDC generated in vitro from monocytes which had been treated 
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with BCG did not express CD1 and showed reduced MHCII, CD40 and CD80(305) and this 
has since been shown to be due to cell wall associated carbohydrate α - glucan(225) and 
mediated through the p38 MAPK pathway(306).  However these experiments have all been 
performed in human or murine systems and with specific lipids, often from avirulent 
bacterial isolates. 
 
Interestingly, treatment of fresh and cultured monocytes with the polar lipid fraction 
significantly increased the level of CD40 expression (figure 4:4 D) and this effect is not 
seen on MDDC.  This finding seems contradictory to the published literature(305, 307) 
however these studies used avirulent BCG or TDM alone, rather than the complex and 
more biologically representative lipid preparations derived from virulent mycobacteria 
used here, as well as being performed in human or murine macrophage models.  Bovine 
MDDC expression of CD40 does not alter after stimulation with either polar or apolar 
lipids which may be due to its constitutively higher levels of expression than on fresh or 
cultured monocytes. 
 
Finally, no difference was seen in the expression of CD80 after lipid treatment, although 
this has also been reported in other systems using virulent M. tuberculosis or avirulent 
BCG derived lipids(304, 305, 307). 
 
The significant reduction in the levels of MHCII, CD86 and CD1b is consistent with the 
phenotype of an impaired antigen presenting cell(308).  Given the effect of the polar lipids 
on the expression of these molecules and the concurrent increase in IL - 10 production, it 
was hypothesised that the polar lipid fraction, or one of its components, hampers the 
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ability of the cells to successfully present antigen to T cells and may be able to suppress 
the induction of a Th1 response during infection.  To assess any functional deficit in these 
cells, especially due to the loss in MHCII, lipid treated and untreated cells were used to 
drive allotypic proliferative responses. 
 
Cultured monocytes drove proliferation of allogeneic PBMC (figure 4:5) and treatment of 
cultured monocytes with the polar lipid fraction significantly abrogated these responses 
as suggested by the downregulation of MHCII and other costimulatory molecules.  
Proliferative responses were also seen when allogeneic PBMC were combined with 
untreated MDDC (figure 4:5) however no difference in proliferation was seen using lipid 
treated MDDC despite flow cytometric analysis revealing characteristic reduction in the 
level of MHCII on the MDDC (data not shown).  While these results seem at odds with 
each other, it is possible that the loss of MHCII may be overcome by the high level of 
CD40 expressed by MDDC (figure 4:4 D)  or the constitutively higher levels of IL - 12 
produced by these cells which further increases significantly after lipid stimulation (figure 
4:3 B).  Also, some evidence exists that the presence of CD80 is enough to stimulate 
allogeneic T cells in the absence of CD86 signalling(309).  Given the significant reduction in 
CD86 expression on MDDC, the maintenance of CD80 may play a role.  Finally, it is 
possible that, due to constitutively higher levels of MHCII and CD40 present on MDDC, as 
well as their expression of CD1b, the levels of MHCII and CD86 on these cells remains 
sufficient to drive an allotypic reaction. 
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These data demonstrate that M. bovis derived lipid fractions are capable of stimulating 
responses in bovine innate cells and that these different cell types respond in distinct 
ways. 
 
Interestingly, the alteration in cell surface phenotype of both cultured monocytes and 
MDDC seen after polar lipid stimulation is also evident after exposure to the apolar lipid 
fraction, albeit to a lesser, not statistically significant, extent.  This may be due to specific 
lipid components present in both the polar fraction and the apolar preparation, such as 
TDM.  However, it may also be due to the insolubility of less polar lipids in the aqueous 
environment an in vitro culture system which may limit lipid bioavailability. 
 
Despite the presence of individual compounds known to have Th1 inducing properties, 
the overall effect of these fractions appears to be down modulation of APC function.  This 
may be a strategy employed by the bacilli to delay protective immune responses.  The 
effects presented here confirm similar to observations seen in humans(302, 310-315).  In 
conclusion, this chapter demonstrates the ability of the lipid fractions to mediate effects 
on bovine innate cells.  These lipids, especially those contained within the polar fraction 
are capable of interacting with the host’s innate immune cells such that the cells ability to 
initiate an adequate T cell response may be compromised, although this effect could only 
be demonstrated for cultured monocytes and not MDDC.  The effects mediated by these 
lipids may play a pivotal role in the outcome of infection and subfractionation may help 
to differentiate down - modulatory compounds from those that may have adjuvant or 
Th1 stimulatory properties. 
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Chapter Summary 
 
• Objective 
To measure any effects mediated by the lipid fractions on bovine innate 
immune cells, characterise the innate cell cytokine and phenotypic responses 
and assess if the function of the cell was affected. 
• Results 
MDDC and CM were derived and characterised.  CM were found to express 
significantly increased levels of CD80 and no CD1b; MDDC were found to 
express high levels of CD1b and CD40. 
The polar fraction was found to drive significant increases in the levels of IL - 
10, IL - 12, MIP - 1β and TNFα from all cell types.  MDDC were seen to produce 
more IL - 10 than other cells.  Polar lipids were also shown to significantly 
decrease expression of MHCII and CD86 on all cell types as well as CD1b on 
MDDC.  Polar lipids also significantly increased CD40 expression by monocytes 
and CM. 
Polar lipid treated CM drove significantly less proliferation in allogeneic PBMC 
than untreated CM.  This effect was not seen with MDDC. 
• Conclusions 
The polar lipid fraction has been shown to modulate both the cytokine 
production and potential antigen presentation ability of bovine innate immune 
cells.  These lipids may play a critical role in defining the outcome of infection. 
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Effects of Lipid Subfractions on Bovine Innate Immune Cells 
 
 
Background 
 
 It is clear that the components in the polar lipid fraction are capable of interacting 
with bovine innate immune cells in a manner which may impair the cells effectiveness in 
modulating immune responses.  These effects could mean that the innate cells ability to 
initiate an adequate T cell response may be compromised.  However, the use of crude 
lipid fractions containing the total free extractable lipid from M. bovis does not allow for 
any discrimination of effects mediated within the antigen mixtures and the responses 
seen so far cannot be attributed to any specific lipid entities. 
 
Individual lipids have been shown to bind with a large array of innate cell receptors and 
mediate a broad range of effects.  Various mycobacterial lipids have been shown to be 
recognised directly by TLR2 including AraLAM(175), lipomannan(176), PIM2(175), and PIM6(177) 
or in association with TLR1 / 6, TLR4(316, 317) or other molecules. 
For example, Means et al. demonstrated the TLR2 mediated recognition of LAM but 
found that CD14 was required for signalling and effector function modulation(318) whilst 
Jones et al. showed that TLR2 mediated recognition of PIM2 generated increases in TNFα 
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as well as activation of the NF - κB and MAP kinases without the requirement for 
accessory molecules(175).  In another study, Means et al. also demonstrated CD14 
independent, TLR4 - mediated activation of both CHO cells and murine macrophages by a 
heat labile, protease resistant cell wall component able to induce TNFα production(319).  
Despite further research demonstrating that TNFα production can be blocked by a TLR4 
antangonist, this cell wall component remains unidentified(320) and most TLR - activating 
purified mycobacterial antigens tested so far signal through TLR2(317). 
 
Polar lipids such as PIMs are also known to mediate a range of effects based on 
differential receptor binding.  Although both PIMs and LM contain mannose and have 
been shown to regulate cytokine, NO and T cell responses(321-323), LM has been shown not 
to bind to the mannose receptor but to DC - SIGN and mediate a responses through 
TLR2(324).  Through this mechanism, LM induces apoptosis(325) and IL - 12 production by 
macrophages(326).  In contrast to LM, the higher PIMs (PIM5-6) have been shown to bind to 
the mannose receptor and can interfere with phagosome : lysosome fusion(183) whilst the 
lower mannosylated PIMs (PIM1-4) preferentially bind to complement receptor 3 (CR3) 
and facilitate phagosome fusion with the early endosomal compartment(327-329).  To 
further complicate the situation, more recent work has shown that the higher 
mannosylated PIMs are also bound by DC - SIGN(330). 
 
Unsurprisingly, lipid recognition and receptor interaction exhibits a degree of cellular 
specificity.  For example, human MDDC have been repeatedly shown to bind M. 
tuberculosis through DC - SIGN(182, 331, 332) whilst the major M. tuberculosis receptors on 
macrophages are CR3 and the mannose receptor(183, 327-329). 
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The huge complexity highlighted here demonstrates both the variety of potential 
antigenic structures on the bacterial surface as well as the broad array of host molecules 
which play a role in host - pathogen interaction.  The crude lipid extracts used previously 
are enormously complex and contain an array of lipid molecules shown here to mediate a 
broad range of effects on the host, as well as some lipopeptide and unidentified lipids. 
 
This chapter addresses the hypothesis that the polar lipid fraction could be separated into 
smaller and more defined subfractions which could be used to stimulate bovine MDDC to 
identify an individual or subset of lipids responsible for driving the responses seen in 
Chapter Four.  A variety of strategies were employed to separate this fraction into smaller 
fractions or individual components.  These subfractions were then used to stimulate 
bovine innate immune cells and subsequently assessing the cells for changes in cytokine 
production and surface phenotype. 
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Results 
 
The Effect of Crude Polar Lipids from M. bovis AN5 
 
 Due to the biosafety constraints of culturing large volumes of M. bovis AF 2122/97 
and the substantial length of time required to grow the large amount of cell mass 
required for subfractionation, an alternative source of material was used for these 
studies.  Given that M. bovis AN5 lipids appear qualitatively very similar to those from AF 
2122/97 (see Chapter Three), a pellicle of AN5 was obtained.  Used in the production of 
bovine PPD, M. bovis AN5 cultured in this way yields very high bacterial mass.  However, 
as M. bovis AN5 is genotypically distinct from AF 2122/97, and it is known that conditions 
of bacterial culture can affect the overall lipid profile of the cells(278, 333), the effects 
mediated by the polar lipid fraction isolated from M. bovis AF2122/97 on bovine MDDC 
was compared to the polar lipid fraction from M. bovis AN5. 
 
The polar lipids from AN5 were assessed to see if they generated similar phenotypic 
changes to those seen with AF 2122/97 - derived lipids (figure 5:1).  As was seen 
previously, treatment of bovine MDDC with AF 2122/97 - derived lipids lead to a 
significant reduction in the expression of both MHCII (figure 5:1 A) and CD1b (figure 5:1 
B).   Despite the quantitative differences in the lipid profiles of both strains, polar lipids 
extracted from M. bovis AN5 also generated a significant reduction in the expression of 
MHCII (figure 5:1 A) and CD1b (figure 5:1 B).  These data therefore suggested that the 
AN5 - derived lipid preparation contained the same immunologically active lipid species 
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as the AF 2122/97 - derived lipid fraction and could, therefore, serve as starting material 
for large scale subfractionation. 
 
 
Figure 5:1 - Effect of polar lipids from M. bovis AF 2122/97 and AN5 on phenotype of bovine MDDC. 
(A) MHCII, (B) CD1b.  Points represent mean responses from duplicate wells for each of 14 animals tested.  Lines 
indicate the sample median; * p < 0.05; *** p < 0.001 using Friedman repeated measures ANOVA with Dunn’s multiple 
comparisons test. 
 
 
Subfractionation of the Crude Polar Lipids from M. bovis AN5 
 
 Having shown that the polar lipids derived from M. bovis AN5 mediate 
comparable responses in bovine MDDC as those from AF 2122/97, AN5 - derived lipids 
were used for subfractionation experiments.  Several subfractionation methods were 
trialled.  Firstly, silica columns packed in CHCl3 with a mobile phase increasing in polarity 
by the addition of increasing levels of CH3OH yielded no separation of the polar fraction.  
As can be seen in figure 5:2 A, most lipid was eluted from the column with no polar 
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solvent added (0 % CH3OH) whilst the remaining lipid eluted as soon as any CH3OH was 
present (figure 5:2 B).  Further, the efficiency of this method was poor.  Columns were 
initially loaded with 50 mg of crude lipid fraction and less than 800 µg of total lipid was 
eluted, leading to an efficiency of only 1.6 %. 
 
 
Figure 5:2 - Subfractionation by glass column chromatography. 
Crude polar lipid was loaded onto a glass column packed with silica in CHCl3 before being eluted with a mobile phase 
consisting increasing levels of CH3OH.  TLCs run in solvent system E and stained with MPA. 
(A) 0 % v/v; (B) 2 % v/v; (C) 5 % v/v; (D) 10 % v/v; (E) 15 % v/v; (F) 20 % v/v; (G) 30 % v/v; (H) 50 % v/v. 
 
This method was refined with the use of syringe mounted solid phase extraction columns.  
Columns were loaded with 5 mg of AN5 - derived crude polar lipid and the same mobile 
phases applied.  Some lipid material was washed from the column even in the presence 
of no polar solvent (figure 5:3 A).  Once CH3OH was present, increasing the polarity of the 
mobile phase had little effect until the level of solvent reached 5 % where 
phosphatidylinositol and diphosphatidyl glycerol  began to elute off the column (figure 
5:3 C).  However, once the polarity of the mobile phase was increased to 15 % CH3OH 
(figure 5:3 E) all the components of the crude fraction were eluted from the column.  
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Increasing the levels of CH3OH beyond this point increased the elution of PIMs and the 
more polar components of the fraction (figure 5:3 F - H). 
 
 
Figure 5:3 - Subfractionation by solid phase extraction chromatography. 
Crude polar lipid was loaded onto a solid phase extraction column packed with silica in CHCl3 before being eluted with a 
mobile phase consisting increasing levels of CH3OH.  TLCs run in solvent system E and stained with MPA. 
(A) 0 % v/v; (B) 2 % v/v; (C) 5 % v/v; (D) 10 % v/v; (E) 15 % v/v; (F) 20 % v/v; (G) 30 % v/v; (H) 50 % v/v. 
 
Whilst this method allowed for some discrimination of the lipids within separate 
fractions, the carryover of lipids between subfractions was quite marked (figure 5:3).  The 
use of SPE columns was found to be more efficient that silica column chromatography.  
Of the 5 mg used for each experiment, around 0.5 mg of lipid was eluted in the combined 
subfraction.  This equates to an efficiency of around 10 %. 
 
To try to further separate the polar fraction, and decrease loss of the crude lipid fraction, 
the lipids were separated by 1 dimensional TLC, visualised under UV light after staining 
with 1, 6 - diphenyl - 1, 3, 5 - hexatriene (figure 2:2).  Individual bands were scraped from 
the plate and the lipid dissolved into a 2 : 1 mixture of CHCl3 : CH3OH.  Using this 
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approach, it was possible to isolate 6 individual subfractions as can be seen in figure 5:4.  
Each scraped band corresponds to a region of the polar lipid fraction and little carryover 
between subfractions is visible (figure 5:4). 
 
 
Figure 5:4 - One dimensional TLC of the polar lipid subfractions. 
Crude polar lipids were separated by TLC and 6 bands scraped off TLC plates and pooled into individual subfractions.  
Each individual band can be seen here run in the same 1D TLC system next to the polar fraction for comparison. 
 
Further analysis of these subfractions by 2D TLC was performed using 2D TLC system E 
(figure 5:5).  Band 1 was found to contain phospholipid, phosphatidylinositol, Ac1PIM2 
and Ac2PIM2 (figure 5:5 A).  P, PI and Ac2PIM2 were also found in band 2, as well as DPG 
(figure 5:5 B).  Band 3 contained Ac2PIM2, DPG and PE (figure 5:5 C) whilst bands 4 and 5 
both Ac2PIM2 and PE and DPG respectively (figure 5:5 D and E).  Band 6 was initially 
scraped from the solvent front of the 1D TLCs and contained no identifiable lipids (figure 
5:5 F). 
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Figure 5:5 - 2D TLC analysis of the 6 polar lipid subfractions stained with MPA 
(A) Band 1, (B) Band 2, (C) Band 3, (D) Band 4, (E) Band 5, (F) Band 6.  Each subfraction was run on 2D TLC system E. 
 
The subfractions generated by 1D TLC were demonstrably different in their lipid 
compositions and exhibited less carryover between subfractions than using either of the 
column based methods.  Furthermore, the efficiency of subfractionation was increased 
greatly.  Of the 30 mg loaded onto each 1D plate, the combined subfractions contained at 
least 6.5 mg which equates to an efficiency of approximately 21 %.  Given the greater 
separation between the subfractions and increase in efficiency, 1D TLC subfractionation 
was chosen as the method to generate subfractions for further biological analysis. 
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Cytokine & Phenotypic Responses to Lipid Subfractions 
 
Having successfully separated the polar lipid fraction, the 6 discrete subfractions 
were tested for their ability to modulate MDDC functions as seen with unfractionated 
polar lipids (see Chapter Four).  MDDC were generated from 3 uninfected cattle and 
stimulated with the AN5 - derived polar lipid fraction and each of the 6 subfractions at 20 
µg ml-1 and the levels of IL - 10 and IL - 12 were measured as described above. 
 
The AN5 - derived polar lipid fraction generated robust IL - 10 responses from the MDDC 
of all 3 animals tested with a median IL - 10 level of 66,404 RLU compared to a median Nil 
of 26,553 RLU (figure 5:6 A).  All 6 subfractions also drove increases in IL - 10 production 
with bands 3 and 4 generating the highest responses while bands 1 and 6 generating the 
lowest responses although this trend was not significant (figure 5:6 A).  Similarly, an 
increase in IL - 12 production was seen after lipid stimulation of the MDDC (figure 5:6 B).  
The AN5 - derived polar lipid fraction increased the median IL - 12 response and 
responses of a similar magnitude were seen after stimulation with bands 2, 3 and 4 while 
bands 1, 5 and 6 drove more modest increases in IL - 12.  Again, this trend was not 
statistically significant. 
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Figure 5:6 - Effect of polar lipids from M. bovis AN5 on cytokine production by bovine MDDC 
(A) IL - 10, (B) IL - 12.  Points represent mean responses from duplicate wells for each of 3 animals tested.  
Measurements in Relative Light Units (RLU).  Lines indicate the sample median;  ns = not significant using Friedman 
repeated measures ANOVA with Dunn’s multiple comparisons test. 
 
MDDC expression of MHCII and CD1b after stimulation with the lipid subfractions was 
also assessed (figure 5:7).  Stimulation of MDDC with AN5 - derived polar lipid fraction 
generated a notable loss of MHCII expression with the median Δ MFI decreasing from 
243.08 to 55.55 (figure 5:7 A).  Again, all the subfractions mediated a similar effect in 
reducing the level of MHCII expression to almost the same level with the median Δ MFI 
ranging from 59.71 for band 5 to 68.15 for band 6 (figure 5:7 A). 
 
MDDC expression of CD1b after stimulation with the lipid subfractions followed a similar 
pattern to that seen for MHCII.  Exposure of the cells to the polar lipids generated a 
noticeable loss of surface CD1b (figure 5:7 B) where the median Δ MFI of 16.03 for 
untreated cells dropped to 3.13.  Treatment of MDDC with any of the subfractions also 
caused a loss of CD1b expression with the median Δ MFI ranging from 4.89 for band 4 
down to 2.23 for band 5 (figure 5:7 B). 
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Figure 5:7 - Effect of lipid subfractions from M. bovis AN5 on phenotype of bovine MDDC 
(A) MHCII, (B) CD1b.  Points represent mean responses from duplicate wells for each of 3 animals tested.  Lines indicate 
the sample median; * p < 0.05; ns = not significant using Friedman repeated measures ANOVA with Dunn’s multiple 
comparisons test. 
 
As each subfraction contained fewer lipid moieties than the crude fraction, it was 
possible that their use at the same concentration as the crude fraction (20 µg ml-1) meant 
that individual lipids were present at higher concentrations in the subfractions than in the 
crude fraction, and this could have been one possible reason for the lack of 
discrimination between the subfractions.  To assess this, MDDC from 2 animals were 
exposed to the subfractions at a series of concentrations.  Again, exposure of bovine 
MDDC to the polar lipid fraction from AN5 generated elevated levels of IL - 10 (figure 5:8). 
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Figure 5:8 - Effect of serially diluted polar lipids from M. bovis AN5 on IL - 10 production by bovine MDDC 
Points represent mean responses from duplicate wells for each of 2 animals tested.  Solid lines indicate the sample 
mean; dashed lines indicate the Nil or AN5 Polar mean. 
 
Stimulation of bovine MDDC using bands 1 - 5 also drove dose dependant increase in IL - 
10 production (figure 5:8).  Band 6 did not increase in the level of IL - 10 produced 
regardless of the concentration at which it was used (figure 5:8).  Treatment of cells with 
band 1 - 5 at 20 µg ml-1 drove IL - 10 production but, in general, not to the same level as 
the AN5 - derived polar lipid fraction alone (figure 5:8).  Of the subfractions, band 4 drove 
the largest IL - 10 response (figure 5:8).  Overall no increases were seen when any of the 
subfractions were used at 1 µg ml-1 (figure 5:8). 
 
An increase in production of IL - 12 was also evident after stimulation with the crude AN5 
- derived polar fraction and bands 1, 2 and 4 (figure 5:9).  Again, the increase in IL - 12 
production in response to the lipid subfractions was dose dependant and the level of IL - 
12 detected when bands 1, 2 and 4 were used at 1 µg ml-1 had returned to the 
background level (figure 5:9).  Unlike IL - 10 production, those subfractions which 
stimulated IL - 12 production did so to at least a similar level as the complete AN5 - 
derived polar lipid fraction (figure 5:9).  In fact, the mean level of IL - 12 driven by band 4 
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was higher than that for the AN5 polar fraction (figure 5:9).  Bands 3, 5 and 6 induced 
limited increases in IL - 12 from bovine MDDC (figure 5:9). 
 
 
Figure 5:9 - Effect of serially diluted polar lipids from M. bovis AN5 on IL - 12 production by bovine MDDC 
Points represent mean responses from duplicate wells for each of 2 animals tested.  Solid lines indicate the sample 
mean; dashed lines indicate the Nil or AN5 Polar mean. 
 
As the decrease in MHCII expression had been a consistent indicator of lipid activity on 
cell phenotype, this was also assessed with the diluted lipid subfractions.  As expected, a 
large reduction in MHCII expression was seen after stimulation with the crude polar 
fraction from AN5 (figure 5:10).  Further, all of the lipid subfractions also caused a 
decrease in the levels of MHCII expressed, although this reduction was not of the same 
magnitude as the crude lipid fraction (figure 5:10).  The reduction of MHCII levels was 
also dose dependant, with the expression of MHCII increasing as the concentration of 
lipid subfraction decreased.  When the subfractions were used at 1 µg ml-1 the levels of 
MHCII were similar to that of unstimulated cells (figure 5:10). 
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Figure 5:10 - Effect of serially diluted polar lipids from M. bovis AN5 on MHCII expression by bovine MDDC 
Points represent mean responses from duplicate wells for each of 2 animals tested.  Solid lines indicate the sample 
mean; dashed lines indicate the Nil or AN5 Polar mean. 
 
Despite the differences in lipid composition of the subfractions, when used to stimulate 
MDDC, little difference was seen in their ability to drive cytokine responses or affect 
levels of MHCII expression.  Band 4 drove the highest mean levels of IL - 10 and IL - 12 
production and had the strongest effect on mean MHCII expression, however the 
responses generated by each subfraction were broadly similar.  As the biological activity 
of the subfractions was dose dependant the subfractions were assessed for the presence 
of other potentially stimulatory molecules. 
 
Assessment of Lipopeptide presence in Lipid Subfractions 
 
Subfractionation of the M. bovis AN5 - derived polar fraction generated 6 
subfractions which contained demonstrably different lipid compositions (figure 5:5).  
When bovine MDDC were treated with these subfractions, bands 1 - 5 were able to 
generate dose - dependent increases in the levels of IL - 10 (figure 5:8) and all bands 
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generated increased levels of IL - 12 (figure 5:9).  Further, all bands led to a dose 
dependant reduction in the expression of MHCII (figure 5:10).  However there was little 
difference between the responses to the different subfractions despite the differing lipid 
contents of the subfractions. 
 
To try to explain the lack of variation in biological responses to these subfractions, each 
was re - analysed by 2D TLC and stained with ninhydrin to assess the presence and 
distribution of any lipopeptide. 
 
 
Figure 5:11 - 2D TLC analysis of the 6 polar lipid subfractions stained with ninhydrin 
(A) Band 1, (B) Band 2, (C) Band 3, (D) Band 4, (E) Band 5, (F) Band 6.  Each subfraction was run on 2D TLC system E.  Red 
arrows indicate primary amines; yellow arrows indicate secondary amines; black arrows indicate charred lipid for 
reference.  Identifiable spots are named. 
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Amine residues were found throughout the subfractions.  As was seen in the crude lipid 
fractions (figure 3:2 and figure 3:4) a primary amine containing molecule was identified 
co - located with PI and was visible in bands 1, 2 and 4 (figure 5:11 A, B and D).  Band 1 
also contained 4 unidentified secondary amines (figure 5:11 A).  As well as the primary 
amine located at the PI spot, another primary amine of unknown identity and several 
unknown secondary amines were found (figure 5:11 B).  In band 3, a primary amine was 
identified located very close to the DPG spot along with 2 more unknown molecules 
(figure 5:11 C).  Band 4 contained the primary amine located at the PI spot and 4 
unidentified secondary amine residues (figure 5:11 D).  Band 5 also contained amine 
residues, 1 primary and 1 secondary, neither of which were co - located with lipid 
molecules (figure 5:11 E).  Finally, band 6 contained no clear amine resides, however a 
secondary amine residue was identified as a smudge (figure 5:11 F). 
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Discussion 
 
 In an attempt to identify individual lipid components responsible for the effects 
mediated by the polar fraction in bovine innate immune cells, the polar fraction from M. 
bovis AN5 was subfractionated and the subfractions analysed and tested.  The use of AN5 
for subfractionation was primarily due to biosafety concerns over the cultivation of large 
volumes of AF 2122/97 when a pellicle of AN5 was already available.  Further, analysis of 
the lipids from M. bovis AN5 showed little difference when assessed by MPA (figure 3:1 
and figure 3:3) and ninhydrin stained TLCs (figure 3:2 and figure 3:4). 
 
Despite the similarities when analysed by TLC, it was important to assess the ability of the 
AN5 - derived fraction to mediate similar responses seen to the AF 2122/97 - derived 
lipids.  To this end, both polar lipid fractions were used to stimulate bovine MDDC and 
the effect on expression of MHCII and CD1b was assessed. 
 
As was seen previously (figure 4:4), stimulation of bovine MDDC with both the AF 
2122/97 and AN5 - derived polar lipids generated a significant reduction in the expression 
of MHCII (figure 5:1 A).  Only the AF 2122/97 - derived polar fraction was capable of 
driving a significant reduction in the levels of CD1b (figure 5:1 B), however a clear trend 
for reduced CD1b is evident after stimulation with the AN5 - derived polar fraction.  
Overall both the effector and phenotypic responses to the AN5 - derived polar lipid 
fraction were similar to that seen with the AF 2122/97 - derived lipids and the AN5 - 
derived fraction was used for subfractionation. 
 
115 
Chapter Five   Effect of Lipid Subfractions on Bovine Innate Immune Cells 
Initially subfractionation was attempted using column chromatography.  Silica packed 
columns were run in CHCl3 with increasingly polar eluents, made by the addition of 
increasing proportions of CH3OH.  This method of fractionation, and variations there on, 
have been used in a variety of settings and with much success(334-336), however this 
method failed to separate the AN5 - derived polar lipid fraction.  Despite the lack of any 
polar solvent in the first eluent, the entire fraction was visible in this elute (figure 5:2 A).  
The addition of 2 % CH3OH caused the elution of the rest of the fraction (figure 5:2 B) and 
no further lipid material appeared in any subsequent elutions (figure 5:2 C - H).  The lack 
of separation could be related to the flow rate of the column.  If this was too fast, the 
column would not have fully equilibrated and the lipid fraction would be forced through 
the column.  This could also explain the fact that of the 50 mg of polar fraction loaded 
onto the column, less than 1 mg of material was eluted from the column. 
 
Although large scale column chromatography failed to generate any discriminate 
subfractions and was found to be extremely inefficient, many authors have reported 
successful column chromatographic separation of polar lipids(334-336).  As a refinement, 
silica packed SPE columns were used with smaller starting quantities of AN5 - derived 
polar fraction.  While this method did allow for the elution of PI and DPG in 5 % CH3OH 
(figure 5:3 C) and the PIMs, PI and PE at 50 % (figure 5:3 H) there was no discrimination 
between the subfractions.  Again, other authors have reported successful use of SPE 
columns to separate lipids, including those from M. bovis BCG(337) and M. smegmatis(338), 
however separation of M. bovis BCG lipids required magnesium silicate columns, more 
complex solvent systems and further purification by anion - exchange 
chromatography(338).  The separation of M. smegmatis polar lipids using SPE columns also 
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used a magnesium silicate stationary phase followed by separation by 2D TLC and reverse 
- phase chromatography(337). 
 
Rather than pursue more complex column separation techniques, the separation of lipids 
by TLC and their subsequent removal from the plate was ultimately used for separation.  
A variety of TLC systems have been employed for purification, many with great 
success(339-342).  One dimensional TLC allowed the identification of 6 bands which could be 
individually collected, purified and analysed (figure 5:4).  Subsequent 2D analysis of each 
subfraction demonstrated discrete fractions with minimal carryover of lipid molecules 
between subfractions (figure 5:5). 
 
Having generated 6 individual polar lipid subfractions, these were tested in the same 
innate cell systems described previously.  Measurement of IL - 10 and IL - 12 showed 
increased levels of both cytokines (figure 5:6).  Assessment of the levels of MHCII and 
CD1b after stimulation with the subfractions also showed reductions in the expression of 
both molecules but no differences between the subfractions were observed (figure 5:7). 
 
The use of the subfractions at a single concentration could mask responses as some lipid 
species were present in more than one subfraction, and at different concentrations.  To 
address this, the subfractions were serially diluted and tested again.  Interestingly, 
measurement of IL - 10 production by bovine MDDC showed that after stimulation with 
the 6 serially diluted subfractions, all except band 6 (the solvent front from the 1D TLC 
separations) drove dose dependant increases which returned to the background level as 
the fractions were diluted to 1 µg ml-1 (figure 5:8).  None of the subfractions drove IL - 10 
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production as high as the AN5 polar fraction, suggesting that the response driven by the 
complete fraction may be at least partly synergistic one, requiring components in 
different subfractions (figure 5:8).  No differences in the levels of IL - 10 produced was 
seen between the subfractions suggesting something present in all fractions may be 
responsible for driving the production of IL - 10. 
 
In contrast, differential IL - 12 production was seen after stimulation of bovine MDDC 
with the serially diluted subfractions.  As seen previously, the AN5 - derived polar fraction 
drove increased IL - 12 production as did bands 1, 2 and 4.  Further, the responses seen 
after exposure to these bands were dose dependant and IL - 12 levels returned to the 
background when the subfractions were used at 1 µg ml-1 (figure 5:9).  The highest levels 
of IL - 12 were seen in response to subfractions 1 and 4.  Band 1 consisted of mostly the 
lower mannosylated PIMs and other phospholipids (figure 5:5 A) which are known to 
drive IL - 12 production from DC in vitro(330).  Interestingly, the only identifiable lipid in 
band 4 was PE (figure 5:5 D) and no inflammatory effects have been attributed to this 
molecule. 
 
Although 2 subfractions generated slightly different IL - 12 responses, the lack of 
discrimination between the subfractions based on their ability to drive cytokine 
production was disappointing.  To try to further differentiate the subfractions, the levels 
of MHCII expression were assessed after exposure of bovine MDDC to the serially diluted 
subfractions.  Again, each subfraction drove a reduction in the levels of MHCII present on 
the cells and expression was regained as the subfraction was diluted, but no differences 
in the magnitude of the effect were seen between the subfractions (figure 5:10). 
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Overall, no differences between the subfractions were seen in their ability to mediate the 
responses characterised originally using the crude polar fraction, despite the fact that 
each fraction clearly consisted of different lipid molecules (figure 5:5).  These data 
suggested some other component, or components, present in the subfractions which had 
not been identified.  As lipopeptide had been identified in the crude polar fractions from 
both AF 2122/97 (figure 3:2) and AN5 (figure 3:4) , ninhydrin stained 2D TLCs were 
performed to assess the presence of any remaining lipopeptide in the subfractions (figure 
5:11). 
 
As can be seen in figure 5:11, lipopeptide could be identified in all 6 subfractions, albeit to 
a lesser extent in band 6 (figure 5:11 F).  Interestingly ninhydrin staining residues could be 
seen which were not apparent when the crude fractions had been analysed (indicated 
with red arrows in figure 5:11 A - F).  It is most likely that these molecules were present in 
the crude fraction but not visible due to their lower concentration.  The degree of 
lipopeptide overlap between the subfractions suggests that the lipopeptide molecules 
migrated across the entire 1D TLC plate during the initial separation.  Lipopeptides are 
known to mediate a range of effects on the immune system which may account for the 
apparent lack of lipid specificity seen here.  Despite knowledge of mycobacterial 
lipopeptides, no classification or categorisation has ever been performed, hence there is 
no reference work from which to identify lipopeptides.  The best characterised 
mycobacterial lipopeptide is the 19 kDa lipoprotein, which has been shown to mediate a 
broad range of effects on innate immune cells.  It is known to inhibit antigen processing 
in murine macrophages by decreasing the synthesis and expression of MHCII(301, 313, 343) 
and MHCI(344) as well as increasing IL - 12 production by human macrophages(345).  These 
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are similar to the effects seen when using the crude lipid fractions to stimulate bovine 
MDDC in Chapter Four.  Conversely the same lipoprotein, when cloned into M. 
smegmatis, has been associated with immune suppression by a reduction in the levels of 
IL - 12, IL - 10 and TNFα(346) and lipopeptides from other bacterial genera have been 
shown to stimulate maturation of DC as measured by increasing expression of MHCII, 
CD80 and CD86(347). 
 
The lipopeptides present in these lipid subfractions have not been identified but 
considering the degree of overlap between fractions, and the consistency of the 
biological effects seen, it is not unreasonable to suggest that they may play a significant 
role in the responses seen to the subfractions. 
 
These data demonstrate that selective purification of individual lipid fractions from a 
crude mixture is challenging.  While the lipid content of each subfraction is demonstrably 
different from the others, the biological effects they mediate on bovine MDDC do not 
reflect this and no response can be attributed to any particular lipid.  Lipopeptides, 
surprisingly not removed by modified Bligh and Dyer extraction used to remove the silica 
contamination from the subfractions, can be identified in each fraction.  Further, the high 
degree of lipopeptide carryover between subfractions could explain the similar biological 
responses seen to the subfractions.  In addition, it appears that more lipopeptide is 
present in band 1 and band 4, hinting at a possible cause for the slightly stronger 
responses seen to band 4, whilst less lipopeptide was present in band 6 where responses 
to which were lower in magnitude or non - existent.  That Ac2PIM2 was present in all 
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subfractions apart from band 6 further highlights the difficulty in purifying individual lipid 
molecules and this may also be important in the lack of differential responses. 
 
Also of note is the absence of the higher mannosylated PIMs from these subfractions.  
Two possible explanations the their absence exist: firstly it is possible that the 1D solvent 
system did not allow for their movement from the origin, although this is unlikely as 
almost no lipid remains visible at the origin; or secondly that the high degree of 
mannosylation caused the molecules to locate at the interface of the modified Bligh and 
Dyer extraction during the removal of colloidal silica and the PIMs could have been 
removed with the aqueous phase. 
 
In conclusion, this chapter demonstrates the complexities and challenges associated with 
selective purification of individual lipid species from complex mixtures.  Despite the 
generation of 6 subfractions of differing lipid compositions, probably due to the extensive 
overlap of lipid species across the fractions thus preventing the purification of individual 
lipid species, no differences were seen in the biological responses to the subfractions.  
Further analysis of the subfractions suggested that the presence of Ac2PIM2, lipopeptides 
or both, could explain the consistency of the biological responses.  
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Chapter Summary 
 
• Objective 
To separate the polar lipid fraction into smaller discrete subfractions which 
could be characterised and used to identify which lipid or subset of lipids were 
driving the responses seen previously. 
• Results 
The polar fractions from AF 2122/97 and AN5 were shown to mediate similar 
effects on MHCII and CD1b expression by MDDC and AN5 lipids were used for 
subfractionation.  A variety of methods were trialled but suffered from a lack 
of discrimination and poor efficiency.  Finally, 1D TLC was used to generate 6 
subfractions which were used for testing. 
All subfractions mediated similar effects with no significant differences seen in 
their ability to drive IL - 10 and IL - 12 production or the reduction of MHCII or 
CD1b on MDDC.  This effect was found to be dose dependent. 
Further analysis of the subfractions highlighted the presence of lipopeptide in 
all subfractions. 
• Conclusions 
The selective purification of lipid molecules from complex mixtures is 
challenging.  The presence of lipopeptide in the subfractions, the carryover of 
Ac2PIM2 and the absence of the high mannosylated PIMs confounds the 
biological responses meaning no particular response can be assigned to any 
specific lipid molecule or family. 
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Effect of Lipids on Bovine Acquired Cell - Mediated Immunity 
 
 
Background 
 
Despite the demonstrably different lipid compositions of the lipid subfractions 
and the dose dependant effects they mediated on bovine MDDC in both cytokine 
production and phenotype, no differential effects were seen between the fractions.  
However, a variety of amine containing molecules were identified in all of the 
subfractions which suggested the presence of lipopeptide.  As both lipid and lipopeptide 
molecules have been shown to modulate cell - mediated immunity, the crude fractions 
were assessed for the ability to generate responses in PBMC. 
 
The identification of CD1 proteins as non - polymorphic MHCI - like molecules, and their 
role in the presentation of lipid antigens to T cells(191) has led to much greater 
understanding of the role of lipids in adaptive immunity.  Early work demonstrated the 
role of the Group 1 molecule CD1b in the presentation of mycolic acids(191) however many 
other lipids have since been shown to be presented through CD1b including 
sulphoglycolipids(199, 209) and glycolipids like GMM(202).  CD1b is the most well understood 
member of the Group 1 CD1 family thanks to work in humans but little is known about 
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the other Group 1 molecules due to their genomic deletion in common laboratory 
mice(348).  However there has been recent interest in CD1c since the discovery that 
phosphomycoketide(216) and lipopeptides containing an N - terminal acylation(215) are 
CD1c restricted. 
 
CD1d is the only Group 2 CD1 molecule, and is another well - characterised CD1 protein.  
Ever since the realisation that NKT cells could respond to lipid antigens(191, 205, 349), and the 
subsequent discovery of the CD1d restricted lipid antigen α - Galactosylceramide 
(αGalCer)(226, 350), much research effort has been concentrated on understanding lipid 
antigens.  Although work was initially focussed on invariant NKT cells it has since been 
shown that great diversity exists in the lipid - responsive TCR repertoire(351-353) and that 
these diverse NKT cells contribute to the Th1 / Th2 balance(351, 354).  It has been shown 
that CD1d restricted NKT cells are capable of recognising a variety of lipid antigens 
including phospholipids(227). 
 
Recently, a CD1b restricted subset of T cells has been found(355).  These cells require the 
CD1B gene for their development and have been shown produce proinflammatory 
cytokines in response CD1b expressing DCs(355).  It is clear that NKT cells have a significant 
role to play in lipid mediate responses and the hunt for their antigens has continued(224, 
356, 357). 
 
One of the most important groups of phospholipids are the PIMs.  Interest in PIMs was 
stimulated since it was shown that phosphatidylinositol dimannoside (PIM2) forms the 
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phosphoglycolipid anchor which tethers a large array of glycolipids and lipoglycans, 
including lipomannan and lipoarabinomannan, to the cellular membrane(358). 
 
Previous analysis of the lipid fractions by ninhydrin stained 2D TLC showed the presence 
of lipopeptide in the polar fractions (figure 3:2 and figure 3:4).  These molecules are 
known to modulate adaptive immune responses(275, 277) and have been shown to be 
important targets of the MHC - restricted T cell response to M. tuberculosis(257).  Further, 
many lipids are known to modulate adaptive immunity(202, 203, 216, 355, 359, 360), particularly 
the PIMs(208, 228, 361-363).  Therefore, the polar and apolar fractions were used to assess the 
role of both lipid and lipopeptide in the generation of adaptive immune responses. 
 
This chapter addresses the hypothesis that the crude lipid fractions could be used to 
generated cell - mediated immune responses and thus have potential as subunit vaccine 
candidates.  Further, it was hypothesised that these responses could be characterised 
phenotypically and the potential role of lipid, lipopeptide or a combination of both, could 
be assessed. 
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Results 
 
Lymphocyte Responses to Crude Mycobacterial Lipids 
 
Given that both lipid and lipopeptide are known to affect cell - mediated 
immunity, the crude lipid fractions were screened for their ability to drive adaptive 
immune responses.  The AF 2122/97 - derived polar lipid fraction drove significantly 
increased proliferation (figure 6:1 A) and IFNγ production (figure 6:1 B) when compared 
to the nil control.  Furthermore, polar lipid stimulation drove significantly more 
proliferation and IFNγ production than stimulation with the apolar lipid fraction (figure 
6:1).  The apolar fraction generated no increase in either proliferation or IFNγ production 
(figure 6:1). 
 
 
Figure 6:1 - Effect of stimulation with the AF 2122/97 polar and apolar lipid fractions on bovine PBMC. 
(A) Proliferation measured by 3H - Thy incorporation; (B) IFNγ production measured by Bovigam.  Each point represents 
the mean of triplicate wells; horizontal lines represent the sample median; * p < 0.05, *** p < 0.001 using Friedman 
repeated measures ANOVA with Dunn’s multiple comparisons test.  PWM - Pokeweed Mitogen.  Lipids used at 20 µg 
ml-1 for (A) 5 days or (B) 12 - 16 hours. 
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The polar lipid fraction from M. bovis AF 2122/97 was also compared to the polar fraction 
from M. bovis AN5, as had been done previously for phenotype (figure 5:1) on bovine 
MDDC.  As seen previously, the AF 2122/97 - derived polar fraction drove a significant 
increase in proliferation (figure 6:2 A), whilst the AN5 - derived polar fraction drove an 
even greater increase in proliferation (figure 6:2 A).  A significant increase was also seen 
in IFNγ production after PBMC were exposed to the AF 2122/97 - derived polar lipids or 
the AN5 - derived polar lipids (figure 6:2 B). 
 
 
Figure 6:2 - Effect of stimulation with the AF 2122/97 polar and AN5 polar lipid fractions on bovine PBMC. 
(A) Proliferation measured by 3H - Thy incorporation; (B) IFNγ production measured by Bovigam.  Each point represents 
the mean of triplicate wells; horizontal lines represent the sample median; ** p < 0.01, *** p < 0.001 using Friedman 
repeated measures ANOVA with Dunn’s multiple comparisons test.  PWM - Pokeweed Mitogen.  Lipids used at 20 µg 
ml-1 for (A) 5 days or (B) 12 - 16 hours. 
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Lipopeptide Activity in the Crude Polar Fraction 
 
Having shown that the polar lipid fraction from M. bovis AN5 was capable of 
driving both IFNγ production and cellular proliferation in PBMC from TB infected cattle, 
the effect of lipopeptide in the lipid fraction was assessed by using antibodies to block 
either MHCII or CD1. 
 
As expected, strong proliferative responses were seen to the AN5 polar fraction (figure 
6:3 A, hatched bar).  The addition of an isotype control antibody generated a slight 
reduction in proliferation irrespective of the level of dilution of the antibody (figure 6:3 A, 
grey bars).  Interestingly, the addition of an anti - CD1 antibody did not affect 
proliferation and responses were similar to that seen when the isotype control antibody 
was added (figure 6:3 A, red bars).  Further, the addition of an antibody which blocked 
MHCII molecules generated a dose dependant reduction in proliferation (figure 6:3 A, 
blue bars).  The addition of antibody did not increase the background level of stimulation 
or the ability of the cells to proliferate (data not shown). 
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Figure 6:3 - Effect of blocking CD1 and MHCII on AN5 polar fraction driven cell - mediated responses. 
(A) Proliferation measured by 3H - Thy incorporation and (B) IFNγ production after stimulation with AN5 - derived polar 
lipids in the presence of serial dilutions of anti - CD1 (red bars), anti - MHCII (blue bars) or isotype control (grey bars) 
monoclonal antibodies.  Hatched bars indicate response with no antibody added.  Each bar represents the mean of 
triplicate responses in 3 animals tested with the nil value subtracted (Δ); * p < 0.05, *** p < 0.001 using repeated 
measures ANOVA with Dunnett’s multiple comparison test.  Lipids used at 20 µg ml-1 for (A) 5 days or (B) 12 - 16 hours. 
 
Measurement of the level of IFNγ produced in the same experiment is shown in figure 6:3 
B.  Again, a strong IFNγ response was seen to the AN5 - derived polar fraction in the 
absence of any antibody (figure 6:3 B, hatched bar) and the addition of an isotype control 
or the anti - CD1 monoclonal antibody had no effect on the levels of IFNγ produced 
(figure 6:3 B, grey bars and red bars respectively).  Addition of the anti - MHCII 
monoclonal antibody did cause a small, dose dependant reduction in IFNγ production 
(figure 6:3 B, blue bars).  No antibody - mediated effect was seen with the background 
level of IFNγ production or the ability of the cells to respond to PWM (data not shown). 
 
Although blockade of MHCII appeared to reduce proliferative and cytokine responses it 
was still unclear what sort of molecule might be driving these responses.  To this end, the 
polar lipid fraction was treated with Proteinase K to degrade any lipopeptide present in 
the fraction.  Further, to ensure that the heating required during Proteinase K treatment, 
or the presence of inactivated Proteinase K itself, did not affect the responses, a mock 
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treatment was also performed.  Treatment of the AN5 polar fraction with Proteinase K 
led to reduced proliferation in PBMC (figure 6:4) when compared to the untreated polar 
fraction.  Mock Proteinase K treatment did not alter the ability of the fraction to drive 
strong proliferative responses (figure 6:4).   
 
 
Figure 6:4 - Effect of Proteinase K treatment on proliferative ability of the AN5 polar lipid fraction. 
Proliferation measured by 3H - Thy incorporation after stimulation of PBMC with the AN5 polar lipid fraction.  Each bar 
represents the mean of triplicate responses in 3 animals tested; ** p < 0.01 using Friedman repeated measures ANOVA 
with Dunn’s multiple comparisons test. 
 
Together these data demonstrate a large degree of MHCII restriction within the AN5 - 
derived polar fraction and it is clear that some of the proliferative response driven by this 
fraction can be degraded by treatment with Proteinase K.  However, neither of these 
methods completely abrogate the response suggesting that a lipid factor may be involved 
in driving proliferation. 
 
As the densitometry analysis performed on the AN5 polar fraction (figure 3:6) had 
showed that over half of the total AN5 derived polar lipid fraction consisted of PIMs 
(table 3:2), it was considered a possibility that the non - lipopeptide mediated responses 
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seen could be due to PIM activity.  To address this, 5 highly purified PIMs were obtained 
through a collaborator and used to stimulate bovine PBMC. 
 
Adaptive Immune Responses to Purified PIM Molecules 
 
PBMC from 10 naturally M. bovis infected cattle were cultured for 5 days in the 
presence of each PIM molecule and proliferative responses were measured.  Both the 
frequency and strength of proliferative responses differed depending on the nature of 
the PIM molecule (figure 6:5 A).  PIM2 failed to induce a proliferative response in any of 
the animals studied, while AcPIM2 induced responses in only 3 out of 10 animals.  In 
contrast, Ac2PIM2, AcPIM6 and Ac2PIM6 were more frequently recognised, inducing 
proliferative responses in 6 (Ac2PIM2 and AcPIM6) and 7 (Ac2PIM6) out of 10 animals.  
Overall, significantly greater PBMC proliferation was detected in the Ac2PIM2, AcPIM6 and 
Ac2PIM6 treatment groups compared to nil stimulated controls, with median values 
tending to be greater following AcPIM6 stimulation (figure 6:5 A). 
 
In addition to measuring proliferative responses, the ability of the PIM molecules to 
induce IFNγ responses in the same animals was assessed (figure 6:5 B).  Again, the 
frequency of responding animals differed depending upon the nature of the PIM 
molecule.  AcPIM2 was least recognised, inducing responses in only 2 of the 10 animals.  
PIM2, Ac2PIM2 and Ac2PIM6 were more frequently recognised, with responses detected in 
3 (PIM2) and 4 (Ac2PIM2 and Ac2PIM6) out of 10 animals.  AcPIM6 was most frequently 
recognised, inducing responses in half of the animals studied.  Furthermore, AcPIM6 was 
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the only PIM molecule to induce significantly greater levels (p < 0.01) of IFNγ overall 
when compared to nil stimulated controls (figure 6:5 B). 
 
 
Figure 6:5 - Effect of stimulation with purified PIMs on bovine PBMC. 
(A) Proliferation measured by 3H - Thy incorporation; (B) IFNγ production measured by Bovigam.  Points represent 
triplicate wells for each of 10 animals tested; lines indicate sample median; * p < 0.05, ** p < 0.01, *** p < 0.001 using 
Friedman repeated measures ANOVA with Dunn’s multiple comparisons test. 
 
 
Phenotyping of AcPIM6 Responsive Cells by Flow Cytometry 
 
 As AcPIM6 was the only PIM molecule to generate significantly increased levels of 
IFN-γ (figure 6:5 A) and produced the greatest increase in the median proliferative 
response (figure 6:5 B), this antigen was used to stimulate PBMC from an M. bovis 
infected animal to characterise the proliferating cell populations by flow cytometry. 
 
CellTrace Violet labelled cells were incubated for 5 days with antigen before being 
harvested and labelled for flow cytometric analysis.  After stimulation with either PPD - B 
or AcPIM6, 3 populations of proliferating cells were identified based on cell surface 
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phenotyping: (i) CD4+ T cells (CD3+ CD4+); (ii) CD8+ T cells (CD3+ CD8+); and (iii) NKT like 
cells (CD3+ CD335+). An example of the gating strategy for identifying proliferating NKT 
like cells is highlighted in figure 2:4, which demonstrates a greater level of proliferating 
cells in response to stimulation with AcPIM6 (58.29 %) when compared to the nil antigen 
control (29.87 %). 
 
 
Figure 6:6 - Assessment of proliferating cell phenotype by flow cytometry 
Proliferation of CD3+ CD4+, CD3+ CD8+ or CD3+ CD335+ cells in response to either PPD - B (grey bars) or AcPIM6 (red 
bars).  Each bar represents the percentage of cells proliferating after subtraction of the unstimulated control. 
 
The effect of stimulation with either PPD - B or AcPIM6 on the three different cell 
populations are summarised in figure 6:6.  Stimulation with PPD - B drove antigen specific 
proliferation of approximately 60 % of the CD4+ T cells (CD3+ CD4+).  Similarly, an antigen 
specific proliferative response was seen in approximately 15 % of the CD8+ T cells (CD3+ 
CD8+) to PPD - B.  A slight increase in NKT cell (CD3+ CD335+) proliferative responses 
(approximately 20 %) was also seen to these antigens (figure 6:6). 
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Stimulation with AcPIM6 induced only limited proliferation of CD4+ T cells (approximately 
5 %) and no proliferation of CD8+ T cells above the background (figure 6:6).  In contrast, 
approximately 30 % of the NKT cell population mounted a proliferative response after 
stimulation with AcPIM6 (figure 6:6).  Little or no proliferation above the unstimulated 
negative control was seen in the CD3- CD335+ cells or the CD3+ γδTCR+ populations (data 
not shown). 
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Discussion 
 
 Having tested the lipid subfractions on bovine MDDC and found no differences 
(see Chapter Five), it appeared that both lipid and lipopeptide may have an important 
role to play in the ability to mediate bovine immune responses.  Lipopeptides have been 
shown to be important immune mediators, primarily in the context of adaptive 
immunity(257, 360, 364) and the fact that lipids can generate adaptive immune responses has 
been well documented(199, 202, 205, 209, 215, 216, 226, 342, 350, 352, 353).  However, before assessing 
the potential roles of lipopeptide and lipid on bovine adaptive immune responses,  
the existing lipid fractions had to be screened to see if they were capable of driving such 
responses. 
 
Similarly to the effects seen when screened in MDDC, the polar lipid fraction generated 
significantly greater responses in PBMC than the apolar fraction (figure 6:1) and the 
response driven by the AN5 - derived polar lipids was comparable or stronger (figure 6:2).  
There is no difference in overall lipid content between the fractions when analysed by 
TLC (figure 3:1 and figure 3:3), nor is any difference apparent after staining with ninhydrin 
(figure 3:2 and figure 3:4).  However, analysis of the densitometry of both fractions 
highlighted the largest difference between the two bacterial strains is the proportion of 
the polar fraction made up by PIM which may account for the stronger responses 
generated after exposure to the AN5 - derived lipid fraction. 
 
To assess the role of lipopeptide in the AN5 polar fraction, proliferation and IFNγ were 
measured after either the addition of antibodies to block MHCII or CD1 or after treatment 
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ofthe lipid fractions with Proteinase K.  The blocking of MHCII, but not CD1, reduced 
ability of the AN5 - derived polar fraction to drive proliferation (figure 6:3) as did 
treatment of the fraction with Proteinase K (figure 6:4).  Clearly a proportion of the 
responses measured are restricted through MHCII and degradable by Proteinase K 
treatment, but these treatments do not completely abrogate the responses.  It may be 
that the remaining responses are lipid mediated, however the possibility that some 
lipopeptide remains after Proteinase K treatment or that MHCII blocking is not absolute 
cannot be ignored.  These data are in line with other work showing that Proteinase K 
treatment of chloroform : methanol extracts of M. tuberculosis reduced, but did not 
abrogate, the ability of the fraction to drive IFNγ production from human PBMC(257).  
Interestingly, the authors also treated their fraction with lipase and found similar results, 
suggesting that, in crude extracts at least, lipopeptide plays a role in driving T cell 
responses but is not responsible for all the activity seen.  More recent studies have 
highlighted specific mycobacterial lipopeptides capable of modulating the CD4+ T cell 
response(364) and suggested a recognition mechanism(360). 
 
Many cell populations found within PBMC have been shown to be affected by lipid 
antigens.  Invariant NKT cells, restricted through CD1d, are particularly well 
characterised(356, 357) but conventional CD4+ T cells have been shown to be reactive to 
lipids presented in the context of CD1b(202, 203) and lipid - induced, IL - 17 secreting γδ TCR+ 
T cells have been shown to be important in early granuloma formation(359).  
Unfortunately, the presence of lipopeptide in the crude fractions, as well as the 
subfractions, meant that they were not suitable for further dissection of the bovine 
adaptive immune response to lipids.  To address this, a selection of highly purified PIM 
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molecules was obtained and the ability of these highly purified PIMs to drive immune 
responses was assessed.  
 
The larger and more complex PIM molecules tested (Ac2PIM2, Ac2PIM6 and AcPIM6) drove 
significant levels of proliferation (figure 6:5 A) while only AcPIM6 was able to drive 
significant production of IFNγ (figure 6:5 B).  Interestingly, the same antigens were used 
to stimulate whole blood overnight and the supernatants were assayed for IFNγ but none 
was seen (data not shown). 
 
There are very few studies showing the effect of mycobacterial lipids in short incubation, 
whole blood assays.  Cell - mediated immune responses to lipid antigens are more 
commonly assessed by EliSPOT with incubation times of at least 48 hours required before 
measurable responses become apparent(228, 300).  The discrepancy between the whole 
blood and PBMC IFNγ responses may be due in part to the requirement for antigen 
processing and presentation of PIMs(208).  Another possibility is that the frequency of lipid 
responsive cells is low and an extended incubation allows for expansion of these cells.  
This is supported by the demonstration of strong proliferative responses induced after 
stimulation of PBMC with PIMs (figure 6:5 A).  A recent study has shown that bovine NKT 
cells are present only at low frequencies in peripheral blood (0.1 % - 1.7 %)(365). 
 
Previous work using mice has shown that the ability of PIMs to generate cell - mediated 
responses is dependent on the acyl structures of the molecules.  Early work performed 
using PIM2 and PIM6 demonstrated that the acyl chain was essential for NKT cell 
recruitment while the complexity of the mannose residues did not alter the response(323) 
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however it was subsequently shown that the second acyl chain of PIM4 enhances binding 
to murine CD1d but that the polar mannose head was essential for antigen recognition, 
proliferation and IFNγ production(228).  As well as the number and location of acyl chains, 
their degree of unsaturation and cis, but not trans, stereochemistry is critical in 
determining antigenicity(357, 366). 
 
As the only molecule to drive significant IFNγ responses and one of the most potent 
inducers of proliferation, AcPIM6 was used to characterise the proliferative response.  
Stimulation with AcPIM6 induced higher levels of proliferation in NKT cells than in CD4+ or 
CD8+ T cells (figure 6:6).  However, from these data it is not possible to tell if the 
proliferative CD4+ or CD8+ also co - express CD335 as our flow cytometric labelling panels 
do not allow the discrimination, however this is a distinct possibility. 
 
Although well characterised in humans and mice, the presence of NKT cells in cattle has 
been a controversial issue.  Originally bovine CD1D was identified as a pseudogene(367, 368) 
and it was assumed that cattle lacked an NKT population as CD1D genes are a 
prerequisite for NKT cell development(369, 370).  Nevertheless, further studies have shown 
that despite its unusual structure the bovine CD1D gene is expressed and translated in 
vivo(371).  Furthermore, recent work has identified a subset of cattle lymphocytes that 
express both T cell (CD3) and NK cell (NKp46) markers, suggesting the presence of an NKT 
cell population in bovine peripheral blood(365).  In addition to CD1d restricted invariant 
cells, human CD1b restricted variant NKT cells have been described in transgenic mice(355) 
and, given the presence of functional CD1b in cattle, the existence of a CD1b restricted 
NKT cell population cannot be ruled out.  Furthermore, bovine NKT cells have been 
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shown to express both αβ and γδ TCRs, have a broad TCR repertoire and have fully 
functional NKp46, CD16 and CD3 signalling pathways(365).  Interestingly these cells require 
ligation of their CD3 to produce IFNγ.  While this may initially suggest a CD3 binding 
component may be present in the PIM preparations, it is worth noting that the cytokine 
producing cells have not been identified. 
 
In conclusion, this chapter demonstrates that the crude lipid preparations are capable of 
generating adaptive immune responses.  A significant portion of the proliferative 
response was shown to be restricted through MHCII and treatment of the lipid fraction 
with Proteinase K also reduced its proliferative activity.  The use of highly purified PIM 
molecules enabled phenotypic identification of NKT proliferating in response to PIM 
stimulation.  Given that NKT cells have been shown to be important in the development 
of protective immunity to certain intracellular pathogens including the influenza virus(372) 
and Leishmania major(373), lipid molecules such as AcPIM6 may have a role to play in 
future vaccines either as protective antigens or biological adjuvants. 
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Chapter Summary 
 
• Objective 
Assessment of the lipid fractions ability to generate adaptive immune 
responses and identify if the presence of lipopeptide in the fractions was 
responsible for any stimulation.  Characterisation of responding cell 
populations within PBMC. 
• Results 
Crude polar lipid fractions were capable of generating both proliferative and 
cytokine responses.  Much of the proliferative response was shown to be 
restricted through MHCII and the proliferative activity of the polar fraction 
could also be reduced by treatment with Proteinase K.  Not all proliferative 
response was driven through MHCII or degraded by Proteinase K activity 
suggesting a lipid component existed.  As the most abundant lipid family in the 
polar fraction, highly purified PIMs were used to stimulate PBMC and NKT 
were cells found to be the main proliferative population. 
• Conclusions 
The presence of lipopeptide in lipid preparations is of significance and may be 
responsible for much of the response seen when using crude fractions.  
However, lipid molecules are also capable of driving functional responses from 
cells of the adaptive immune system. 
Bovine NKT cells are capable of recognising, and proliferating in response to 
the highily mannosylated lipid AcPIM6. 
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Concluding Remarks 
 
 
 The primary purpose of this study has been to address the hypothesis that lipids 
from M. bovis constitute a source of molecules that could aid in the development of 
control measures for BTB such as subunit vaccines (as antigens or immunomodulatory 
adjuvants) or diagnostic reagents.  To work towards these goals it is necessary to 
characterise their immunological properties and to identify individual compounds with 
the desired properties.  The data presented here describe bovine immune responses 
directed at lipids extracted from 2 strains of M. bovis. 
The 3 main objectives of the work reported here were laid out at the end of Chapter One 
and each shall be addressed here: 
 
• Develop methods to isolate and characterise lipid moieties from M. bovis: 
While the method used to extract polar and apolar lipid fractions in this study is 
not novel, a full 2D TLC analysis of lipids from M. bovis AF 2122/97 has not been 
published previously.  At this macroscopic level, little difference can be seen 
between AF 2122/97 - derived and AN5 - derived lipid fractions.  However, the 
application of densitometrical analysis allowed for some further refinement to the 
comparisons.  Also shown here, and not previously published, is ninhydrin staining 
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of these lipid fractions which demonstrated the presence of a range of 
unidentified amine residues within the polar fractions.  This work constitutes the 
first published documentation of the polar and apolar lipid fractions from M. bovis 
AF 2122/97. 
Further analysis of the polar fraction was attempted by chemical subfractionation.  
This proved to be technically demanding, partly due the poor efficiency of column 
chromatography methods and subsequently due to the difficulty in removing 
colloidal silica from TLC preparations.  Despite these challenges, lipid subfractions 
were successfully prepared but ninhydrin staining of 2D TLCs demonstrated 
lipopeptide contamination in all subfractions. 
That lipopeptides can mediate immune responses is well known but, despite this, 
no comprehensive lipopeptide screening has been published for any members of 
the M. tuberculosis complex.  The ability to extract and purify lipids using simple 
methods is of limited use without further work to analyse and identify lipopeptide 
contaminants and their role in modulating host immunity. 
 
• Assess the effect of M bovis lipids on bovine APC to identify potential 
immunomodulatory activity which could be exploited in the development of 
novel adjuvants: 
Stimulation of bovine MDDC with the polar and apolar lipid fractions showed that 
components within the polar lipid fraction are capable of mediating effects on the 
host APC.  Significant reduction in important molecules such as MHCII and CD1b 
was seen, as well as increased IL - 10 and IL - 12 secretion, and these responses 
could hamper the hosts ability to mount an appropriate immune response.  
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Despite the presence of lipids known to stimulate Th1 responses, the potentially 
deleterious effect of the polar lipids on APC may constitute a strategy employed 
by the bacilli to increase the chances of successful infection.  Further refinement 
of the polar fraction was attempted to try to identify which moieties might be 
responsible for these effects however, despite the different lipid composition of 
the subfractions, no differences were found in the ability of the subfractions to 
mediate reduction in MHCII expression or increase the secretion of IL - 10.  
Despite the increased levels of IL - 12 measured after stimulation of APC with the 
polar lipids, the elevated levels of IL - 10 and reduction in important antigen 
presentation molecules mediated by the lipid fractions is precisely the opposite of 
an adjuvanting response. 
Clearly further work is required on purification of individual lipids.  More complex 
chemical technologies and more advanced purification methods have been 
applied by others to obtain individual lipid molecules free from contamination 
with lipopeptide and it is these approaches that must be taken to further separate 
and define the lipid fractions from M. bovis. 
 
• Identify the lipid targets of the bovine adaptive immune response which could 
be used as innovative vaccine candidates: 
Initial experiments documented in this thesis demonstrated the ability of the 
crude lipid fractions to drive proliferative and cytokine responses in bovine PBMC.  
Interestingly, stronger responses were seen to the polar fraction, as had been the 
case with innate immune cells.  The finding that much of the proliferative 
response to the polar fraction was restricted through MHCII and could be partially 
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degraded by treatment of the lipid fraction with Proteinase K again highlights the 
potential role of lipopeptide in these lipid preparations.  However, neither 
blockade of MHCII nor enzymatic degradation of lipopeptide completely 
abrogated proliferative responses and the use of purified PIM molecules enabled 
the identification of AcPIM6 as a natural ligand of bovine NKT cells.  The presence 
of these cells in cattle has only recently been shown and the discovery of a ligand 
so soon is a remarkable achievement. 
Whether or not AcPIM6 or other lipid molecules could be used as vaccine 
candidates remains an open question.  The non - polymorphic nature of CD1 
molecules makes them good targets for a vaccine antigens and the ability to 
target a specific cell population with an individual antigen has been demonstrated 
in this thesis.  However, the restriction of the proliferating NKT cells is currently 
unknown but warrants further investigation. 
 
The main achievements of this thesis are the extraction and screening of the M. bovis - 
derived lipid fractions, the documentation of the effects of the lipid fractions on bovine 
APC and the identification of a specific lipid ligand capable of driving proliferation in 
bovine NKT cells.  However, this thesis also highlights the lack of knowledge surrounding 
the lipopeptide content of the mycobacterial cell wall and underlines the requirement for 
cross - discipline collaboration to separate the individual components of these extracts 
and fully understand the interaction at the point of contact between host and pathogen. 
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derived polar and apolar lipid fractions on bovine
innate immune cells
Chris Pirson1*, Gareth J Jones1, Sabine Steinbach1, Gurdyal S Besra2 and H Martin Vordermeier1Abstract
Mycobacterial lipids have long been known to modulate the function of a variety of cells of the innate immune
system. Here, we report the extraction and characterisation of polar and apolar free lipids from Mycobacterium bovis
AF 2122/97 and identify the major lipids present in these fractions. Lipids found included trehalose dimycolate
(TDM) and trehalose monomycolate (TMM), the apolar phthiocerol dimycocersates (PDIMs), triacyl glycerol (TAG),
pentacyl trehalose (PAT), phenolic glycolipid (PGL), and mono-mycolyl glycerol (MMG). Polar lipids identified
included glucose monomycolate (GMM), diphosphatidyl glycerol (DPG), phenylethanolamine (PE) and a range of
mono- and di-acylated phosphatidyl inositol mannosides (PIMs). These lipid fractions are capable of altering the
cytokine profile produced by fresh and cultured bovine monocytes as well as monocyte derived dendritic cells.
Significant increases in the production of IL-10, IL-12, MIP-1β, TNFα and IL-6 were seen after exposure of antigen
presenting cells to the polar lipid fraction. Phenotypic characterisation of the cells was performed by flow
cytometry and significant decreases in the expression of MHCII, CD86 and CD1b were found after exposure to the
polar lipid fraction. Polar lipids also significantly increased the levels of CD40 expressed by monocytes and cultured
monocytes but no effect was seen on the constitutively high expression of CD40 on MDDC or on the levels of
CD80 expressed by any of the cells. Finally, the capacity of polar fraction treated cells to stimulate alloreactive
lymphocytes was assessed. Significant reduction in proliferative activity was seen after stimulation of PBMC by polar
fraction treated cultured monocytes whilst no effect was seen after lipid treatment of MDDC. These data
demonstrate that pathogenic mycobacterial polar lipids may significantly hamper the ability of the host APCs to
induce an appropriate immune response to an invading pathogen.Introduction
Bovine tuberculosis (BTB), caused by Mycobacterium
bovis (M. bovis), is a zoonotic disease of significant eco-
nomic, animal and public health burden. Consumption
of raw or unpasteurised animal products and contact
with infected carcasses plays a large role in zoonotic M.
bovis infection of humans in Africa and South America
[1,2]. Yet this is not a problem solely associated with
poverty and less developed countries as evidenced by a
recent report that up to 45% of all TB infected children
in San Diego were caused by M. bovis [3]. The incidence
of BTB in cattle in Great Britain (GB) has undergone
steady and continual increase since 1998 despite the* Correspondence: chris.pirson@ahvla.gsi.gov.uk
1TB Research Group, Animal Health and Veterinary Laboratories Agency –
Weybridge, New Haw, Surrey, Addlestone KT15 3NB, United Kingdom
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reproduction in any medium, provided the orimplementation of control measures, possibly due to the
presence of a wildlife reservoir [4]. Within GB, BTB has
spread drastically since the Foot & Mouth disease out-
break in 2001 with the annual number of animals
slaughtered rising from a mean of 7116 animals between
1998 and 2001 to an annual mean of 26 277 cases be-
tween 2002 and 2010 inclusive [5].
The first point of contact between M. bovis and its
host is likely to be interaction between receptors of its
sentinel cells of the innate immune system such as
macrophages or dendritic cells (DC) and the surface
expressed molecules of the bacilli, the majority of which
are lipid in nature [6,7]. Recognition of mycobacterial
lipids by macrophages has been demonstrated via the
mannose receptor, complement receptors, scavenger
receptors and CD14 [8-10]. Furthermore, various lipidstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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human macrophages [11]. DC are known to possess and
utilise these same receptors as well as other, structurally
related molecules such as the DC specific C - type lectin
(DC - SIGN) which have also been heavily implicated in
immune recognition of the bacilli [12-14].
Many lipids have been implicated in mycobacterial
virulence which are not found in other bacterial genera.
Lipomannan (LM), lipoarabinomannan (LAM), the
phosphatidylinositol mannosides (PIMs), the cord fac-
tors trehalose mono- and dimycolate (TMM and TDM)
and the phthiocerol dimycocerosates (PDIMs) are all
surface bound mycobacterial lipids capable of modulat-
ing innate immunity [15-17]. Recently, newly identified
lipids, such as monomycolyl glycerol (MMG), have been
shown to modulate host immunity [18] and hyperviru-
lence [19]. However, little data exist which describe the
effect of M. bovis derived lipid on bovine innate cells.
Previously published work usually relies on non - patho-
genic mycobacterial species or makes use of an animal
model rather than the pathogen’s natural host. For ex-
ample, work performed by Hope et al. uses bovine
monocyte-derived DC (MDDC) but these cells are sti-
mulated with a synthetic lipopeptide [20] rather than a
M. bovis-specific lipid antigen. Additionally, although
Reed et al. demonstrated that blockage of synthesis of
the phenolic glycolipid (PGL) correlated with increased
secretion of TNF-α, IL - 6 and IL - 12 by the host, and
removed the “hyperlethal” phenotype displayed by the
bacilli, this was only shown in the murine model [19].
Thus, to assess host immune responses to its natural
pathogen’s lipid constituents, lipids were extracted from
virulent M. bovis AF 2122/97 and used to stimulate vari-
ous bovine innate immune cells isolated from live, TB
free, cattle. Cellular responses were evaluated by measur-
ing cytokine production, alterations in cell surface mole-
cules and induction of T-cell proliferation.
Materials and methods
Preparation of bacterial isolates for lipid extraction
Bacterial isolates were grown in Middlebrooks 7H9
medium as previously described [21].
Briefly, bacterial cells were grown in 100 mL volumes
in rolling culture flasks inoculated with 1 mL of a starting
culture. At mid - log phase, cultures were decanted into
sterile tubes and pelleted before being washed twice in
sterile water. Finally, pellets were resuspended in 5 mL
sterile water and heat killed in a water bath at 80 °C to
90 °C for between 1 and 2 h and finally freeze dried.
Extraction of crude free mycobacterial lipid
The extraction of mycobacterial lipid has been previ-
ously described [22]. Briefly, freeze dried bacterial cells
were suspended in methanolic saline before an equalvolume of petroleum ether was added and the mixture
stirred for 12 to 16 h. Cells were pelleted by centrifuga-
tion (7000 g for 10 min) and the non-aqueous phase
containing the apolar lipids was removed and stored. An
equal amount of petroleum ether was added to the aque-
ous lower phase and the mixture stirred for 2 h before
being centrifuged (7000 g for 10 min) and the non-
aqueous layer removed and pooled with the first. These
non-aqueous petroleum ether extracts were dried using a
rotary evaporator with cold finger condenser and the
lipid transferred to a pre-weighed glass tube in 4 : 1
CHCl3 : CH3OH. Evaporation of the CHCl3 : CH3OH
was achieved using a heating block and N2 gas stream
and the tube weighed to determine the mass of apolar
lipids extracted.
Extraction of polar lipids was performed by adding
CHCl3, CH3OH and 0.3% aqueous NaCl in a 9 : 10 : 3
ratio to the cell pellet. The mixture was stirred for 12 to
16 h before being passed through 2 Whatman # 91 fil-
ters. Once dried, the cells were recovered from the filter
papers and re-extracted twice using a 5 : 10 : 4 mixture
of CHCl3, CH3OH and 0.3% NaCl. After a final filtration
to remove the cells, equal volumes of CHCl3 and 0.3%
NaCl were added and the mixture stirred for one hour,
after which the aqueous phase containing the polar
lipids was removed and dried in a rotary evaporator.
Final polar lipid mass was ascertained as described for
the apolar petroleum ether extracted lipid fraction.
Analysis of lipid fractions by 2D Thin Layer
Chromatography (TLC)
Aluminium backed silica gel 60 F254 TLC plates (Fisher
Scientific, Loughborough, Leics, UK) were cut into ap-
proximately 6 cm squares and 100 μg of lipid extract
was spotted onto the plates using glass micro - capillary
pipettes. Plates were dried thoroughly before being
placed in TLC tanks containing appropriate solvent mix-
tures (systems A - E, Table 1). TLC plates were dried be-
tween each run and before staining to ensure that
residual solvent was removed. Staining was performed
using a 5% solution of molybdophosphoric acid (MPA)
(Sigma Aldrich, Poole, Dorset, UK) in 95% ethanol (Fig-
ure 1). Stains were sprayed onto TLC plates which were
subsequently charred using a hot air gun before being
photographed or scanned. Identification of individual
lipids was performed by comparison with previously
published TLC analysis [23].
Cattle
BTB free cattle between the ages of 6 and 36 months
were obtained from herds within 4 - yearly testing
parishes with no history of a BTB breakdown in the past
4 years. These animals were purchased when around
6 months old and transported to AHVLA. Whilst at
Table 1 Solvent systems for TLC analysis of mycobacterial lipids (adapted from [22]).
Solvent System Run Direction Components Runs Lipids Resolved
A 1 petroleum ether : ethyl acetate (98 : 2) 3 PDIM, TAG, MQ
2 petroleum ether : acetone (98 : 2) 1
B 1 petroleum ether : acetone (92 : 8) 3 AT, FA
2 toluene : acetone (95 : 5) 1
C 1 chloroform : methanol (96 : 4) 1 FA, GLY
2 toluene : acetone (80 : 20) 1
D 1 chloroform : methanol : water (100 : 14 : 0.8) 1 CF, SL, DAT
2 chloroform : acetone : methanol : water (50 : 60: 2.5 : 3) 1
E 1 chloroform : methanol : water (60 : 30 : 6) 1 DPG, PE PI, PIM
2 chloroform : acetic acid : methanol : water (40 : 25 : 3 : 6) 1
Pirson et al. Veterinary Research 2012, 43:54 Page 3 of 11
http://www.veterinaryresearch.org/content/43/1/54AHVLA they tested negative for BTB using both the
Bovigam IFNγ assay (Prionics AG, Schlieren-Zurich,
Switzerland) and the single intradermal comparative cer-
vical tuberculin test (SICCT).
Isolation of bovine PBMC from whole blood
Whole blood was mixed in equal amounts with sterile
HBSS containing 10 U mL-1 heparin. This mixture was
overlaid onto Histopaque 1077 (Sigma Aldrich) and cen-
trifuged at 800 g for 40 min. The PBMC interface was
removed using a pastette and washed twice in HBSS
containing heparin. Live cells were identified via trypan
blue exclusion and enumerated using a haemocytometer.
Isolation of CD14+ monocytes from bovine PBMC
PBMC were suspended in 80 μL of MACS rinsing buffer
per 107 cells before the addition of 10 μL of MACS anti
- CD14 MicroBeads (Miltenyi Biotec, Bisley, Surrey, UK)
per 107 cells. After a 15 min incubation at +4 °C on a ro-
tator, cells were pelleted and resuspended in 500 μL per
108 cells and passed through MACS LS columns as per
the manufacturer’s instructions.
The CD14+ fraction was counted and cells diluted to
1.5 × 106 mL-1 in cell culture medium (RPMI 1640
containing 25 mM HEPES, 10% FCS, 1% NEAA,
5 × 10-5 mM β2 - mercapto-ethanol, 100 U mL-1 penicil-
lin and 100 μg mL-1 streptomycin [Gibco Life Technolo-
gies, Paisley, UK]).
Generation of bovine cultured monocytes and MDDC
CD14+ monocytes were plated in 1 mL volumes at
1.5 × 106 mL-1 in 24 well plates (Nunc Nunclon, Ros-
kilde, Denmark) before adding either 1000 U mL-1
equine GM-CSF (Kingfisher Biotech, St Paul, MN, USA)
(cultured monocytes) or 1000 U mL-1 equine GM-CSF
and 4 ng mL-1 bovine IL-4 (AbD-Serotec, Kidlington,
Oxon, UK ) (MDDC). Cells were cultured at 37 °C+ 5%
CO2 for 3 days [20], following which they were har-
vested, re-plated at 1.5 × 106 mL-1 in fresh cell culturemedium and the appropriate volume of lipid solution
was added. Cells were cultured for a further 12 to 16 h
before supernatants were collected and cells harvested
for subsequent flow cytometric analysis.
Preparation of lipid antigen suspensions
Suspensions of all lipid antigens were prepared in an
aqueous phase for use in cell culture experiments after
first removing any CHCl3 : CH3OH by evaporation using
an N2 gas stream. Cell culture medium was added to the
dried lipid and the mixture subjected to 2 cycles of heat-
ing at 80 °C and then sonication for 5 min. Apolar and
polar lipids were used to stimulate cells in vitro at
20 μg mL-1 for 12 to 16 h. These conditions were shown
to be optimal in previous experiments (data not shown).
Measurement of cytokine production
Culture supernatants were assayed for cytokine levels
using the MSD multiplex platform (Meso Scale Discov-
ery, Gaithersburg, MD, USA) as previously described
[24,25]. Briefly, supernatants were analysed using a cus-
tom multiplex electrochemiluminescent system which
allows simultaneous detection of IL-1β, IL-6, IL-10,
IL-12, MIP-1β and TNF-α (Meso Scale Discovery).
Multiplex 96 well plates were supplied with target cap-
ture antibodies spotted onto 6 separate carbon electro-
des in each well (anti-bovine TNF-α [Endogen,
Rockford, IL, USA]; anti-bovine IL-10 and anti-bovine
IL-12 [AbD-Serotec]; anti-bovine IL-1β, anti-bovine IL-6
and cross-reactive anti-human MIP-1β [Meso Scale Dis-
covery]). Plates were blocked with MSD assay buffer for
30 min at room temperature before the addition of sam-
ples or standards for 1 h at room temperature. Recom-
binant standard controls (Meso Scale Discovery) were
prepared by serial dilution. After incubation, plates were
washed and combined biotinylated secondary detector
antibodies were added for a further hour. Finally, plates
were washed, loaded with MSD read buffer and analysed
using an MSD Sector Imager 6000.
Figure 1 2D TLC analysis of crude, free lipids extracted from M. bovis AF 2122/97 and stained with MPA. A - D: Apolar fraction analysed
with TLC systems A, B, C and D. E and F: Polar fraction analysed with systems D and E. PDIM - phthiocerol dimycocerosate; MQ - menaquinone;
TAG - triacyl glycerol; PAT - pentacyl trehalose; PGL - phenolic glycolipid; MMG - monomycolyl glycerol; TMM - trehalose monomycolate; TDM -
trehalose dimycolate; GMM - glucose monomycolate; DPG - diphosphatidyl glycerol; PE - phosphatidyl ethanolamine; PIM - phosphatidylinositol
mannosides (integers denote number of mannoside or acyl groups); PI - phosphatidyl inositol; P - phospholipid.
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Cultured cells were suspended in PBS and labelled with
the live / dead indicator ViViD (Invitrogen Life Tech-
nologies, Paisley, UK) before being transferred to a 96well plate and washed using 150 μL MACS rinse buffer.
Cells were stained for 15 min using either anti-bovine
CD14 (ccG33; Institute for Animal Health; 1:50 dilu-
tion), anti-equine MHCII (MCA1085; AbD Serotec; 1:50
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AHVLA; 1:10 dilution), anti-bovine CD80 (IL - A159;
cell supernatant; AHVLA; 1:10 dilution), anti-bovine
CD86 (IL-A190; cell supernatant; AHVLA; 1:10 dilu-
tion), anti-bovine CD1b (CC14; AbD Serotec MCA831G;
1:10 dilution) or an IgG1 isotype control (Av20; Institute
for Animal Health; 1:50 dilution). Labelled cells were
washed using 150 μL MACS rinse buffer and secondary
labelling was performed using a 1:400 dilution of anti-
IgG1 conjugated to R-Phycoerythrin (R-PE) (Invitrogen;
P21129) in 50 μL volumes for 10 min. After incubation,
cells were washed by the addition of 150 μL PBS, pel-
leted and resuspended in 100 μL of 2% paraformalde-
hyde (Cytofix; BD Biosciences, Oxford, Oxon, UK) for at
least 30 min at 4 °C before analysis on a CyAn ADP ana-
lyser. For capture and analysis, initial gating was on sin-
gle, ViViDlo (live) cells into a subsequent small cell/
lymphocyte exclusion gate.
One way mixed lymphocyte reaction
Bovine MDDC and cultured monocytes were prepared
from 1 animal as described above. Following 3 days in
culture, cells were pulsed with lipid antigen overnight
before being enumerated, washed to remove any cyto-
kines and lipid from the media and incubated at 107
cells mL-1 in the presence of Mitomycin C at
100 μg mL-1 for 30 min at 37 °C + 5% CO2. Lipid pulsed,
Mitomycin C treated MDDC or cultured monocytes
were cultured in 1 mL at 37 °C + 5% CO2 at 2 × 10
5 with
1 × 105 PBMC isolated from a second, allogeneic animal.
After 5 days, cells were pulsed overnight with 1 μCi
well-1 of 3H-thymidine before being harvested using a
Harvester 96 Mach III (TomTec Inc, Hamden, CT,
USA). Lymphocyte proliferation was assessed by the
increased cellular incorporation of 3H-thymidine which
was measured using a MicroBeta2 2450 (Perkin Elmer,
Waltham, MA, USA).
Data and statistical analysis
All data representation and statistical analysis was per-
formed using GraphPad Prism version 5.04 and Graph-
Pad InStat version 3.06 (GraphPad Software, La Jolla,
CA, USA). Flow cytometric data was analysed using
repeated measures ANOVA with a Bonferroni multiple
comparisons post test. Cytokine profile analysis was per-
formed using a Friedman non-parametric repeated mea-
sures ANOVA with Dunns multiple comparisons test.
Results
Extraction and analysis of lipid from AF 2122/97
In order to identify individual lipid components within
the polar and apolar fractions, lipids extracted from the
M. bovis reference strain (AF 2122/97) were subjected to
2D TLC analysis using solvent systems of increasingpolarity and subsequently stained with MPA. Analysis of
the apolar fraction using the least polar TLC system
(Figure 1a) identified the presence of phthiocerol dimy-
cocerosates (PDIMs), menaquinone (MQ) and triacyl
glycerol (TAG). System B (Figure 1b) revealed that the
apolar fraction also contained pentacyl trehalose (PAT),
phenolic glycolipids (PGL) and monomycolyl glycerol
(MMG). System C (Figure 1c) allowed further resolution
of both MMG and PGL. The most polar system used to
analyse the apolar fraction (system D, Figure 1d) identi-
fied both trehalose monomycolate (TMM) and dimyco-
late (TDM; cord factor) as well as glucose monomycolate
(GMM).
TLC analysis of the polar lipid fraction using system D
showed the presence of TMM and TDM (Figure 1e)
while the most polar solvent system (E, Figure 1f )
enabled identification of the most polar lipids, which
included diphosphatidyl glycerol (DPG), phosphatidyl
ethanolamine (PE), phosphatidylinositol mannosides
(PIMs, integers denote number of mannoside or acyl
groups), phosphatidyl inositol (PI) and an unknown
phospholipid (P).
Cytokine responses to M. bovis - derived lipids
Innate immune cells are known to produce cytokines in
response to appropriate antigenic stimuli. In order to as-
sess the effect of M. bovis - derived lipids on 3 types of
bovine innate cells (freshly isolated monocytes, cultured
monocytes and MDDC), cytokine production was mea-
sured after stimulation with the lipid fractions (Figure 2).
The cytokines investigated included IL-10, IL-12, TNF-α,
MIP-1β, and IL-6.
Significantly increased IL-10 secretion was seen from
all 3 cell types following stimulation with the polar lipid
fraction (Figure 2a). Strong IL-10 responses were seen
for 3 animals, while only modest increases were noted
for the remaining cattle (Figure 2a). In contrast, little or
no significant increase in IL-10 production was seen fol-
lowing stimulation with the apolar lipid fraction, al-
though apolar lipids induced some IL-10 production by
cultured monocytes and MDDC from 3 animals. All
responses to apolar lipids were by far lower than those
induced by the polar lipid fraction.
IL-12 levels in the culture supernatants were measured
simultaneously and the results are shown in Figure 2b.
Stimulation with the polar lipid fraction induced a large
increase in IL-12 production by MDDC, while lower
responses were also observed from monocyte and cul-
tured monocyte populations. In contrast to the polar
lipids, stimulation with the apolar lipid fraction resulted
in minimal increases in IL-12 production by monocytes,
cultured monocytes or MDDC.
Levels of MIP-1β were also found to be significantly
increased after exposure to the polar lipid fraction with
Figure 2 IL - 10 (A), IL - 12 (B), MIP - 1β (C), TNFα (D) & IL - 6 (E) production by monocytes and cultured cells in response to
stimulation with crude lipid fractions. Points represent mean responses from duplicate wells for each of 7 animals tested. Lines indicate that
cells were derived from the same animal; * 0< 0.05; ** p< 0.01; *** p< 0.001.
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(Figure 2c). Both cultured monocytes and MDDC pro-
duced noticeably more MIP-1β than fresh monocytes,
with MDDC from 6, and cultured monocytes from 3, of
the 7 animals responding strongly (Figure 2c).
Significant increases in TNFα production were also
seen, again in response to the polar lipid fraction
(Figure 2d). While polar lipid treated cultured mono-
cytes from all 7 cattle produced significant levels ofTNFα, considerably more TNFα was produced by
MDDC (Figure 2d). Further, the level of TNFα produc-
tion was similar between fresh and cultured monocytes
(Figure 2d).
The production of IL-6 (Figure 2e) followed a broadly
similar pattern to that of TNFα (Figure 2d) although
statistical significance was not achieved. Fresh mono-
cytes from 2 cattle produced more IL-6 after exposure
to the polar lipids, which also drove increased IL-6
Figure 3 Surface expression of MHCII (A), CD86 (B), CD1b (C) and CD40 (D) on cultured cells and fresh monocytes after exposure to
crude polar and apolar lipid fractions. A single point represents the median fluorescence intensity of the specific stain after subtraction of an
isotype control (ΔMFI) for each of 7 animals tested; ** p< 0.01; *** p< 0.001.
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(Figure 2e). Polar lipid driven IL-6 production by MDDC
was noted in 5 of the 7 animals screened, with one of
these animals producing more IL-6 to the apolar lipid
fraction than the polar. While statistical significance was
not achieved, the levels of IL-6 produced by MDDC are
notably higher than from fresh or cultured monocytes
(Figure 2e).
These data clearly demonstrate that the polar lipid
fraction drives the production of significant amounts of
IL-10, IL-12, MIP-1β and TNFα from all cell types. Fur-
thermore, it is clear that MDDC produced more IL-12,
TNFα and IL-6 than fresh or cultured monocytes and
MIP-1β production is greater from both cultured mono-
cytes and MDDC than in fresh monocytes.
Phenotypic responses to M. bovis - derived lipids
Exposure of bovine antigen presenting cells to the polar
lipid fraction lead to significant increases in the produc-
tion of a variety of cytokines (Figure 2a-e), all of which
can play important roles in directing the subsequent cell
mediated response. In order to further assess the effect
of M. bovis - derived lipids and the local cytokine milieu
on these cells, analysis of the expression of key antigen
presentation related molecules was assessed by flow
cytometry (Figure 3).Stimulation with the polar lipid fraction resulted in a
significant reduction in the cell surface expression of
MHCII on all three cell types (Figure 3a). Furthermore,
MHCII expression was also lower on MDDC following
stimulation with apolar lipids, although this did not
achieve statistical significance (Figure 3a). CD86 expres-
sion was also significantly reduced on all three cell types
following stimulation with the polar lipid fraction
(Figure 3b). While there was a trend for lower CD86 ex-
pression on all three cell types following stimulation
with the apolar lipid fraction, this again did not achieve
statistical significance (Figure 3b). Interestingly, the
lipid-specific antigen presentation molecule CD1b,
which was constitutively expressed on MDDC, was not
present on monocytes or cultured monocytes nor could
it’s expression be modulated in these cell types by myco-
bacterial lipids (Figure 3c). By contrast, MDDC
expressed CD1b constitutively and incubation with the
polar lipid fraction resulted in a significant reduction in
CD1b surface expression (Figure 3c).
Not all cell surface molecules were down-regulated
following treatment with lipids. CD40 expression on
both monocytes and cultured monocytes increased sig-
nificantly following stimulation with the polar lipid frac-
tion (Figure 3d), although no effect was seen on MDDC.
Finally, no significant difference was seen in CD80 levels
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lipid fractions (data not shown).
In summary, these data demonstrate that M. bovis -
derived lipids, and in particular the polar fraction,
downregulate the expression of several key cell surface
molecules involved in antigen presentation.
Consequence of exposure to M. bovis - derived lipids
To identify and assess any functional consequence of the
lipid induced reduction in molecules related to antigen
presentation the ability of lipid treated innate cell types
to stimulate an alloreactive response was assessed. Co-
culture of the responder PBMC population with either
untreated MDDC or cultured monocytes resulted in a 5
- fold increase in their proliferation (Figure 4). No prolif-
eration was noted for either MDDC or cultured mono-
cytes in the absence of responder cells (data not shown).
Polar lipid treated MDDC retained their ability to induce
proliferation in the responder population despite the
downregulation of important costimulatory molecules.
In contrast, allo - stimulation of the responder popula-
tion by polar lipid treated cultured monocytes resulted
in significantly reduced proliferative responses to levels
comparable with the unstimulated responder control
cells (Figure 4).
Discussion
Mycobacterial lipids have long been implicated in the
interaction between the pathogen and its host. Here we
describe the consequence of exposure to lipids derived
from a virulent M. bovis on the innate immune cells of
cattle.Figure 4 Proliferative responses (in counts per minute [CPM]) of 1 × 1
bars) or polar lipid treated (red bars) MDDC or cultured monocytes. B
*** p< 0.001.Extraction of mycobacterial lipids and their subse-
quent analysis by 2D TLC has been previously described
[22], but little data exists on total lipid profiling of M.
bovis. Previous work by Dandapat et al. [26] attempted
to characterise M. bovis based on the expression of PGL
and PDIMs, but only as a tool for identification of the
organism. In Figure 1, we have applied a complete range
of TLC analyses to polar and apolar lipid extracts which
has allowed the identification of a broad range of charac-
teristic mycobacterial lipids including PDIMS
(Figure 1a), the M. bovis characteristic PGL [27] (figure 1
B-C), TDM (Figure 1d-e) and PIMs (Figure 1f ). As
expected, no sulphoglycolipid was found (Figure 1d).
Interestingly, TDM was found in both the polar and
apolar extracts (Figure 1d-e). This may be related to it’s
particularly amphipathic nature [28] and variable acyl-
ation states which are known to alter both immunogen-
icity and hydrophobicity [29,30] and may cause the
molecule to split differentially across the biphase inter-
face during lipid extraction.
To discover if the lipid fractions were capable of medi-
ating responses of bovine innate immune cells, stimula-
tion experiments were performed and the level of a
range of cytokines was analysed. Significant increases in
the production of various cytokines were measured only
after cells were exposed to the polar lipid fraction. Per-
haps most striking is the significant increase in the pro-
duction of the Th-1 polarising IL-12 and the anti-
inflammatory cytokine IL-10 (Figure 2a-b). While this
may seem contradictory, it is important to note that the
fractions used are complex mixtures of a variety of lipids
some of which are known to induce potent05 PBMC after allotypic stimulation with either untreated (grey
ars represent the mean of triplicate wells ± standard error of the mean;
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[18] and others, such as glycerol monomycolate
(GroMM) are known Th2 polarisers [31].
Little evidence exists on cytokine production by anti-
gen presenting cells after treatment with lipids, however
many lipids have been assessed in the context of both
CD4+ and CD8+ T cells. For example, TDM, which is
present in the polar and apolar fractions (Figure 1d-e),
has been shown to induce both Th1 and Th2 cytokines.
The induction of IFNγ and IL-12 and the depletion of
IL-4 producing NK cells has been attributed to TDM
[32,33] as well as a role, along with IL-6 and TNFα, in
stable granuloma formation [34]. Yet TDM is also impli-
cated in the production of IL-5 and IL-10 in a CD1
dependent manner [35]. Furthermore, GroMM has been
implicated in the induction of Th2 polarising responses
[31] where as the closely related GMM has been shown
to induce Th1 cytokine responses in T cells [36]. Anti-
inflammatory effects have also been attributed to PIM2
and PIM6 where, upon lipid treatment of LPS activated
macrophages, Doz et al. measured downregulation of
TLR4, TNFα, IL-12p40, IL-6, KC and IL-10 as well as
MyD88 mediated NO release [37].
Given the significant increase in IL-10 production by
all innate cell types assessed, and the important role
these cells play in generating and directing the im-
mune response, we analysed the expression of antigen
presentation associated cell surface molecules after
lipid exposure. Lipid treatment of APCs leads to a sig-
nificant decrease in the levels of costimulatory mole-
cules associated with antigen presentation including
MHCII and CD86 on all cell types studied and CD1b
on MDDC (Figure 3a-c). Negative regulation of these
molecules by a variety of lipid components has been
noted previously, especially MHCII in human and
murine systems. Similar to the data presented here, the
19-kDa lipoprotein is capable of downregulating
MHCII expression on human THP-1 macrophages by
inhibiting activation of the IFNγ - induced CIITA
[38,39]. Downregulation of MHCII, as well as TLR2
and TLR4, has also been reported on human MDDC
after lipid exposure [40] and a further study also found
impaired expression of CD1a, MHCII, CD80 and CD83
on human MDDC [41].
Downregulation of CD1 molecules has also been
shown through the discovery that MDDC generated
from BCG treated monocytes did not express CD1 and
showed reduced MHCII, CD40 and CD80 [42] and this
has since been shown to be due to cell wall associated
carbohydrate α-glucan [43] and mediated through the
p38 MAPK pathway [44]. However these experiments
have all been performed in human or murine systems
and with specific lipids, often from avirulent bacterial
isolates.Interestingly, treatment of fresh and cultured mono-
cytes with the polar lipid fraction significantly increased
the level of CD40 expression (Figure 3d) and this effect
is not seen on MDDC. This finding seems contradictory
to the published literature [42,45] however these studies
used BCG or TDM alone, rather than the complex and
more biologically representative lipid preparations
derived from virulent mycobacteria used here, as well as
being performed in human or murine macrophage mod-
els. Bovine MDDC expression of CD40 does not alter
after stimulation with either polar or apolar lipids which
may be due to its constitutively higher levels of expres-
sion than on fresh or cultured monocytes.
Finally, no difference was seen in the expression of
CD80 after lipid treatment, although this has also been
reported in other systems using virulent M. tuberculosis
or avirulent BCG derived lipids [41,42,45].
The significant loss of MHCII, CD86 and CD1b is
consistent with the phenotype of an impaired antigen
presenting cell [46]. Given the effect of the polar lipids
on the expression of these molecules and the concurrent
increase in IL-10 production, we hypothesised that the
polar lipid fraction, or one of its components, hampers
the ability of the cells to successfully present antigen to
T cells and may be able to suppress the induction of a
Th1 response during infection. To assess any functional
deficit in these cells, especially due to the loss in MHCII,
lipid treated and untreated cells were used to drive allo-
typic proliferative responses.
Cultured monocytes drove proliferation of allogeneic
PBMC (Figure 4) and treatment of cultured monocytes
with the polar lipid fraction significantly abrogated
these responses as suggested by the downregulation of
MHCII and other costimulatory molecules. Proliferative
responses were also seen when allogeneic PBMC were
combined with untreated MDDC (Figure 4) however no
difference in proliferation was seen using lipid treated
MDDC despite flow cytometric analysis revealing charac-
teristic reduction in the level of MHCII on the MDDC
(data not shown). While these results seem at odds with
each other, it is possible that the loss of MHCII may be
overcome by the high level of CD40 expressed by MDDC
(Figure 3d) or the constitutively higher levels of IL-12
produced by these cells which further increases signifi-
cantly after lipid stimulation (Figure 2b). Also, some evi-
dence exists that the presence of CD80 is enough to
stimulate allogeneic T cells in the absence of CD86 sig-
nalling [47]. Given the significant reduction in CD86 ex-
pression on MDDC, the maintenance of CD80 may play
a role. Finally, it is possible that, due to constitutively
higher levels of MHCII and CD40 present on MDDC, as
well as their expression of CD1b, the levels of MHCII
and CD86 on these cells remains sufficient to drive an
allotypic reaction.
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fractions are capable of stimulating responses in bovine
innate cells and that these different cell types respond in
distinct ways.
Interestingly, the alteration in cell surface phenotype
of both cultured monocytes and MDDC seen after polar
lipid stimulation is also evident after exposure to the
apolar lipid fraction, albeit to a lesser, not statistically
significant, extent. This may be due to specific lipid
components present in both the polar fraction and the
apolar preparation, such as TDM. However, it may also
be due to the insolubility of less polar lipids in the aque-
ous environment an in vitro culture system which may
limit lipid bioavailability.
In conclusion, we present here the first data to dem-
onstrate the regulatory effects of M. bovis - derived
lipids on bovine innate cells. These lipids, especially
those contained within the polar fraction are capable of
interacting with the host’s innate immune cell’s such that
the cells ability to initiate an adequate T cell response
may be compromised, although this effect could only be
demonstrated for cultured monocytes and not MDDC.
The lipid fractions used in this study contain the total
free extractable lipid from M. bovis AF 2122/97, hence
we were not able to attribute these effects to any specific
lipid entities. However work is currently being under-
taken in our laboratory to further define these responses
and identity the lipids which are responsible for mediat-
ing the effects we have shown. Nevertheless, the effects
mediated by these lipids may play a pivotal role in the
outcome of infection and aid further identification of in-
dividual lipid components responsible for the immuno-
modulatory effects as well as new targets for attenuation
and novel vaccine candidates and adjuvant preparations.
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Highly Purified Mycobacterial Phosphatidylinositol Mannosides Drive
Cell-Mediated Responses and Activate NKT Cells in Cattle
Chris Pirson,a Regina Engel,b Gareth J. Jones,a Thomas Holder,a Otto Holst,b H. Martin Vordermeiera
TB Research Group, Animal Health and Veterinary Laboratories Agency, New Haw, Addlestone, Surrey, United Kingdoma; Division of Structural Biochemistry, Research
Centre Borstel, Leibniz-Centre for Medicine and Biosciences, Borstel, Germanyb
Mycobacterial lipids play an important role in the modulation of the immune response upon contact with the host. Using novel
methods, we have isolated highly purified phosphatidylinositol mannoside (PIM)molecules (phosphatidylinositol dimannoside
[PIM2], acylphosphatidylinositol dimannoside [AcPIM2], diacyl-phosphatidylinositol dimannoside [Ac2PIM2], acylphosphati-
dylinositol hexamannoside [AcPIM6], and diacylphosphatidylinositol hexamannoside [Ac2PIM6]) from virulentMycobacterium
tuberculosis to assess their potential to stimulate peripheral blood mononuclear cell (PBMC) responses inMycobacterium bovis-
infected cattle. Of these molecules, one (AcPIM6) induced significant levels of gamma interferon (IFN-) in bovine PBMCs.
Three PIMmolecules (AcPIM6, Ac2PIM2, and Ac2PIM6) were shown to drive significant proliferation in bovine PBMCs. AcPIM6
was subsequently used to phenotype the proliferating cells by flow cytometry. This analysis demonstrated that AcPIM6 was pre-
dominantly recognized by CD3 CD335NKT cells. In conclusion, we have identified PIM lipid molecules that interact with
bovine lymphocyte populations, and these lipids may be useful as future subunit vaccines or diagnostic reagents. Further, these
data demonstrate, for the first time, lipid-specific NKT activation in cattle.
Members of the mycobacterial genus are renowned for theirwaxy, lipid-rich outer envelope. Under physiological condi-
tions, this outer layer is likely to be the first point of contact be-
tween the bacterial cell and the host’s immune system, and the
outcome of this interaction is pivotal in the establishment of in-
fection. One of the most important groups of membrane bound
lipids consists of the phosphatidylinositol mannosides (PIMs).
Interest in PIMs was stimulated since it was shown that phospha-
tidylinositol dimannoside (PIM2) forms the phosphoglycolipid
anchor which tethers a large array of glycolipids and lipoglycans,
including lipomannan (LM) and lipoarabinomannan (LAM), to
the cellularmembrane (1). PIMs have been shown to interact with
a variety of immune components and mediate significant effects
on the host. Ever since the realization that NKT cells could re-
spond to lipid antigens (2–4) and the subsequent discovery of the
CD1d-restricted lipid antigen -galactosylceramide (-GalCer)
(5, 6),much research effort has been concentrated on understand-
ing lipid antigens. Although work was initially focused on invari-
ant NKT cells, it has since been shown that great diversity exists in
the lipid-responsive T cell receptor (TCR) repertoire (7–9) and
that these diverse NKT cells contribute to the Th1/Th2 balance (7,
10). It has been shown that CD1d-restricted NKT cells are capable
of recognizing a variety of lipid antigens, including phospholipids
(11). More recently, a CD1b-restricted subset of T cells has been
found (12). Similarly to CD1d-restricted invariant NKT (iNKT)
cells, the CD1b-restricted variant cells require CD1B for their de-
velopment and produce proinflammatory cytokines in response
to CD1b-expressing dendritic cells (DCs) (12). It is clear that
NKT-like cells have a significant role to play in lipid-mediated
responses, and the hunt for their antigens has continued (13–15).
Given the ability of lipid molecules to generate responses in
peripheral bloodmononuclear cells (PBMC), we decided to assess
the ability of individual, highly purified natural PIMs to activate
bovine lymphocytes. In this study, we developed a novel extrac-
tion method which allowed us to extract and highly purify a vari-
ety of PIM molecules from virulent Mycobacterium tuberculosis
H37Rv. The ability of these molecules to induce lymphocyte re-
sponses inMycobacterium bovis-infected cattle was investigated by
measuring lymphocyte proliferation and gamma interferon
(IFN-) production. Furthermore, flow cytometry techniques
were utilized to characterize responding cell populations.
MATERIALS AND METHODS
Extraction of PIMs. Using the novel methodology outlined below,
highly pure phosphatidylinositol dimannoside (PIM2), acylphosphati-
dylinositol dimannoside (AcPIM2), diacyl-phosphatidylinositol diman-
noside (Ac2PIM2), acylphosphatidylinositol hexamannoside (AcPIM6),
and diacylphosphatidylinositol hexamannoside (Ac2PIM6) were success-
fully isolated. Individual PIM molecules were analyzed by electrospray
ionization mass spectrometry (ESI-MS) to confirm identity and purity as
shown in Fig. 1. Up to 1 g of dry bacterial mass of Mycobacterium tuber-
culosisH37Rvwas suspended in 20 to 30ml ofH2O and ruptured utilizing
a French press at a minimum of 20,000 kPa. This procedure was per-
formed five times, and the combined sample was lyophilized.
Up to 0.5 g of this lyophilized material was extracted three times ac-
cording to the method of Bligh and Dyer (16). The dry mass was sus-
pended in 4 ml of H2O and washed twice in an additional 2 ml of H2O
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before being transferred into a 100-ml Erlenmeyer flask. To this sample
was added 30 ml of CHCl3·CH3OH (1:2, vol/vol), and the sample was
sonicated (Branson Sonifier 250; output 2, 40%duty cycle, 20min). Then,
10 ml of CHCl3 was added, and the sample was sonicated for a further 5
min. Subsequently, an additional 10ml ofH2Owas added, and the sample
was sonicated for a final 5 min. The sample was decanted evenly into
between two and four 50-ml Nalgene Teflon tubes and centrifuged for 30
min at 10,000 g to generate three phases (a water phase, a CHCl3 phase,
and an interphase). The water phases (containing LAM and LM) were
removed, combined, and lyophilized, while the CHCl3 phases were trans-
ferred into a single 100-ml pear-shaped flask. The total yield of material
after three extractions was about 11% of the bacterial dry mass.
Since the remaining interphases contained a lot of AcPIM6, they were
suspended in 8 ml of H2O and combined into 30-ml Kimble high-speed
glass tubes before being lyophilized. These phases were then extracted
overnight with 30 ml of CHCl3·MeOH (1:2, vol/vol) using a shaker. The
sample was then centrifuged for 30 min at 10,000  g, and the
CHCl3·MeOH phase was removed. This phase was dried under an N2 gas
stream before being resuspended in equal parts of CHCl3·MeOH, filtered
through a 0.2-m-pore-size polytetrafluoroethylene (PTFE) filter, and
dried under N2. This extraction was repeated two times until no PIMs
could be identified (total yield of about 2% of the bacterial drymass). The
obtained PIMs were further purified with silica gel 60 chromatography
(see below), as were the CHCl3 phases of the Bligh and Dyer extraction.
Purification of PIMs. All samples were separated on a column (7 by 1
cm) of silica gel 60 (0.04 to 0.063 mm) which was successively eluted with
(i) 80 ml of CHCl3·MeOH (8:2, vol/vol), (ii) 60 ml of CHCl3·MeOH (1:1,
vol/vol), and finally (iii) 40 ml of CHCl3·MeOH·H2O (10:10:3, vol/vol/
vol). Coextracted cardiolipin and other lipids eluted in the first mobile
phase, most PIMs eluted in the second, and the rest of the PIMs eluted in
the third. Fractions ii and iii were dried under N2, resuspended in 10ml of
CHCl3·MeOH (8:2, vol/vol), and passed through a 0.2-m-pore-size
PTFE filter before being analyzed by high-performance thin-layer chro-
matography (HPTLC). HPTLC was performed using glass-backed 10- by
10-cm silica gel 60 plates (Merck KGAA, Darmstadt, Germany) run in
CHCl3·MeOH·H2O (10:8:2, vol/vol/vol) and stained with Hanessian’s
stain (0.5 g of ceric sulfate and 25 g of ammoniummolybdate in 470ml of
water supplemented with 30 ml of sulfuric acid with stirring) and visual-
ized at 150°C.
Fractions ii and iii from both of the CHCl3 phases of the Bligh and
Dyer extraction and the PIMs extracted from the interphase were then
further separated by high-performance liquid chromatography (HPLC)
using 5-mKromasil 100C18 columns (250 by 20mm) elutedwith eluent
A (CHCl3·MeOH·H2O [240:1,140:620, vol/vol/vol] containing 10 mM
NH4CH3CO2) and eluent B (CHCl3·MeOH [1,400:600, vol/vol] contain-
ing 50 mM NH4CH3CO2). The initial eluent B gradient was 15% for 60
min, followed by 20% for 140 min, 40% for 80 min, and finally 100% for
60min at 4mlmin1. Sampleswere detected by a light-scattering detector
(Sedex; nitrogen pressure, 2  105 Pa; temperature, 50°C; split, 1:70).
Samples were applied in 200 l of CHCl3·MeOH (8:2, vol/vol). For ana-
lytical runs, 10 g of sample was injected while 10 mg was injected for
preparative separations.
Since PIM2 and AcPIM6 coeluted on the C18 column, they were sepa-
rated byHPLC on 5-mProntosil 200-5-C30 reverse-phase columns (250
by 4.6 mm) using the same elution reagents. The initial eluent B gradient
was 5% for 5min, followed by 10% for 15min, 15% for 50min, and finally
100% for 10 min at 0.8 ml min1. Samples were injected as a mixture of
0.6mg in 80l of CHCl3·CH3OH·H2O (10:10:3, vol/vol/vol) and detected
by the light-scattering detector described above.
FIG 1 Mass spectrometric proof of purity of isolated PIMs. Identified molecular masses of PIM2 (calculated molecular mass, 1176.6784 u) (A), AcPIM2
(calculated molecular mass, 1442.9394 u) (B), Ac2PIM2 (calculated molecular mass, 1653.1378 u) (C), AcPIM6 (calculated molecular mass, 20147.0881 u) (D),
and Ac2PIM6 (calculated molecular mass, 2301.3491 u) (E). Letters in parentheses identify the peaks.
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Cattle.Blood samples were obtained from 10 naturally infected, single
intradermal comparative cervical tuberculin test-positive reactors (be-
tween 6 and 36 months of age). Animals were sourced from herds with
confirmed bovine tuberculosis breakdowns in Devon, Herefordshire, or
Worcestershire and were housed at the Animal Health and Veterinary
Laboratories Agency (AHVLA) at the time of blood sampling. Infection
was confirmed by necropsy andM. bovis culture in all animals. All proce-
dures involving animals were carried out under a project license granted
by the Home Office of Great Britain under the Animals (Scientific Proce-
dures) Act 1986. This project was approved by the local VLA Animal
Ethics Committee prior to submission to the Home Office.
Isolation of bovine PBMC from whole blood. Whole blood was
mixed in equal parts with sterile Hanks balanced salt solution (HBSS)
containing 10 U ml1 heparin. This mixture was overlaid onto His-
topaque 1077 (Sigma-Aldrich) and centrifuged at 800 g for 40min. The
PBMC interface was removed using a pastette and washed twice in HBSS
containing heparin. Live cells were identified via trypan blue exclusion
and enumerated using a hemocytometer.
Preparation of lipid antigen suspensions. Briefly, lipids were sus-
pended in an aqueous phase for use in cell culture experiments after re-
moval of CHCl3·CH3OH by evaporation using an N2 gas stream. Cell
culture medium was added to the dried lipid, and the mixture was sub-
jected to two cycles of heating at 80°C and then sonication for 5 min.
Lipids were used to stimulate cells in vitro at 20 g ml1 in all assays.
Lymphocyte proliferation assay. Bovine PBMC were prepared from
all 10 animals as described above and were cultured in complete cell cul-
ture medium (RPMI 1640 medium containing 25 mMHEPES, 10% fetal
calf serum [FCS], 1% nonessential amino acids [NEAA], 5  105 mM
2-mercaptoethanol, 100Uml1 penicillin, and 100gml1 streptomy-
cin [Gibco Life Technologies, Paisley, United Kingdom]) at 37°C in 5%
CO2 for 5 days in the presence of antigen at 2 10
5 cells well1. After 5
days, cells were pulsed with 1 Ci well1 of [3H]thymidine overnight,
before being harvested using a Harvester 96 Mach III (TomTec, Inc.,
Hamden, CT, USA). Lymphocyte proliferation was assessed by the in-
creased cellular incorporation of [3H]thymidine (cpm), which was mea-
sured using a MicroBeta2 2450 plate counter (PerkinElmer, Waltham,
MA, USA). Responses to individual PIMs were considered positive if the
cpm exceeded the mean plus 2 times standard deviation of cpm for non-
antigen-stimulated cultures from all 10 animals.
Measurement of IFN- by Bovigam ELISA. Levels of IFN- in 5-day
supernatants from the proliferation assay were determined using a Bo-
vigam enzyme-linked immunosorbent assay (ELISA) kit (Prionics AG,
Switzerland). Responses to individual PIMs were considered positive if
the optical density at 450 nm (OD450) exceeded the mean plus 2 times the
standard deviation of the OD450 for non-antigen-stimulated cultures
from all 10 animals.
Measurement of proliferation and phenotyping by flow cytometry.
Bovine PBMCwere isolated as described above and labeledwithCellTrace
violet (Invitrogen Molecular Probes, Paisley, United Kingdom) in accor-
dance with the manufacturer’s instructions. Briefly, PBMC were sus-
pended at 1  107 cells ml1 in prewarmed phosphate-buffered saline
(PBS), and 5 mM CellTrace violet was added to a final working concen-
tration of 1M. Cells were incubated at 37°C for 20 min before unbound
dye was quenched with five times the labeling volume of complete cell
culture medium at 37°C for 5 min. Finally, cells were pelleted and washed
in prewarmed complete cell culture medium, plated at 2  105 cells
well1, and incubated at 37°C in 5% CO2 for 5 days in the presence of
antigen.
Cultured cells were harvested and resuspended in flow cytometry buf-
fer (PBS containing 2%FCS and 0.05%NaN3) and labeled for 15minwith
the Near-IR live/dead indicator NIRViD (Invitrogen Life Technologies,
Paisley, United Kingdom) and mouse anti-bovine CD335, also known as
NKp46 (AKS1; AbD Serotec, Oxfordshire, United Kingdom). Cells were
washed in flow cytometry buffer, and secondary labeling of anti-CD335
was performed using a 1:400 dilution of rat anti-mouse IgG2a conjugated
to allophycocyanin for a further 15 min. After a subsequent wash, cells
were further labeled with combinations of R-phycoerythrin (R-PE)-Ze-
non-labeled (Invitrogen Life Technologies, Paisley, United Kingdom)
mouse anti-bovine CD3 (MM1A; WSU Monoclonal Antibody Centre,
Pullman, Washington, USA), mouse anti-bovine CD4 conjugated to Al-
exa Fluor 647 (CC30; AbD Serotec, Oxfordshire, United Kingdom),
mouse anti-bovine CD8 conjugated to Alexa Fluor 647 (CC63; AbD Se-
rotec, Oxfordshire, United Kingdom), and Alexa Fluor 488-Zenon-la-
beled (Invitrogen Life Technologies, Paisley, United Kingdom) mouse
anti-bovine -TCR1 (GB21a; WSUMonoclonal Antibody Centre, Pull-
man,Washington,USA). Finally, labeled cells werewashed in flow cytom-
etry buffer and resuspended in 150 l of 2% paraformaldehyde (Cytofix;
BD Biosciences, Oxfordshire, United Kingdom) for at least 30 min at 4°C
before analysis on a CyAn ADP analyzer. For capture and analysis, initial
gating was on single, NIRViDlo (live) cells into a subsequent lymphocyte
gate before gating on CellTrace violetlo cells.
Data and statistical analysis. All data representation and statistical
analysis were performed usingGraphPad Prism, version 5.04, andGraph-
Pad InStat, version 3.06 (GraphPad Software, La Jolla, CA, USA). Statis-
tical analysis of IFN- and lymphocyte proliferation data was performed
using a nonparametric repeated-measures analysis of variance (ANOVA;
Friedman test) with a Dunn’s multiple comparisons posttest.
RESULTS
Highly purified PIM molecules can be isolated from virulent
mycobacteria. PIMmolecules differing in the number of acyl and
mannose residues were highly purified from M. tuberculosis. Five
distinct PIM molecules were isolated: PIM2, AcPIM2, Ac2PIM2,
AcPIM6, and Ac2PIM6. In total, these lipids constituted 3% of the
bacterial dry mass after silica gel 60 separation. The ability of the
purificationmethod to isolate highly pure PIMs is shown in Fig. 1,
in which the structures and purity of the different PIMmolecules
were confirmed by ESI-MS. In addition, bands corresponding to
AcPIM2 molecules (that differed only in the number of carbon
atoms in the acyl chains) were clearly resolved by thin-layer chro-
matography (TLC) analysis (see Fig. S1 in the supplemental ma-
terial).
Purified PIMmolecules activate lymphocytes fromM. bovis-
infected cattle. In order to assess the ability of purified PIMs to
induce in vitro immune responses in cattle, PBMC from 10 natu-
rally M. bovis-infected cattle were cultured for 5 days in the pres-
ence of each PIM molecule, and the level of IFN- was measured
by ELISA (Fig. 2A). Both the frequency and strength of IFN-
responses differed depending on the nature of the PIMmolecule.
AcPIM2 was least recognized, inducing responses in only 2 of the
10 animals. PIM2, Ac2PIM2, and Ac2PIM6 were more frequently
recognized, with responses detected in 3 (PIM2) and 4 (Ac2PIM2
and Ac2PIM6) out of 10 animals. AcPIM6 was most frequently
recognized, inducing responses in half of the animals studied. Fur-
thermore, AcPIM6 was the only PIM molecule to induce signifi-
cantly greater levels (P 	 0.01) of IFN- overall than nonstimu-
lated controls.
In addition to measuring IFN- production, we also investi-
gated the ability of the PIM molecules to induce PBMC prolifer-
ative responses in the same animals. Again, the frequency of re-
sponding animals differed depending upon the nature of the PIM
molecule (Fig. 2B). PIM2 failed to induce a proliferative response
in any of the animals studied, while AcPIM2 induced responses in
only 3 out of 10 animals. In contrast, Ac2PIM2, AcPIM6, and
Ac2PIM6 were more frequently recognized, inducing proliferative
responses in 6 (Ac2PIM2 and AcPIM6) and 7 (Ac2PIM6) out of 10
animals. Overall, significantly greater PBMCproliferationwas de-
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tected in the Ac2PIM2, AcPIM6, and Ac2PIM6 treatment groups
than in nonstimulated controls, with median values tending to be
greater following AcPIM6 stimulation.
Phenotyping of AcPIM6-responsive proliferating cells by
flow cytometry. As AcPIM6 was the only PIMmolecule to gener-
ate significantly increased levels of IFN- (Fig. 2A) and produced
the greatest increase in the median proliferative response (Fig.
2B), we used this antigen to stimulate PBMC from an M. bovis-
infected animal to characterize the proliferating cell populations
by flow cytometry. Purified protein derivative from M. bovis
(PPD-B) was used as a control antigen. CellTrace violet-labeled
cells were incubated for 5 dayswith antigen before being harvested
and labeled for flow cytometric analysis. After stimulation with
either PPD-B or AcPIM6, three populations of proliferating cells
were identified based on cell surface phenotyping: (i) CD4
T cells
(CD3
 CD4
), (ii) CD8
 T cells (CD3
 CD8
), and (iii) NKT-
like cells (CD3
 CD335
). An example of the gating strategy for
identifying proliferatingNKT cells is highlighted in Fig. 3A, which
demonstrates a greater level of proliferating cells in response to
stimulationwith AcPIM6 (58.29%) than in the non-antigen-stim-
ulated control (29.87%).
The effects of stimulation with either PPD-B or AcPIM6 on the
three different cell populations are summarized in Fig. 3B. Stim-
ulation with PPD-B drove antigen-specific proliferation of ap-
proximately 60%of the CD4
T cells (CD3
CD4
). Similarly, an
antigen-specific proliferative response was seen in approximately
15% of the CD8
 T cells (CD3
 CD8
) to PPD-B. A slight in-
crease in NKT cell (CD3
 CD335
) proliferative responses (ap-
proximately 20%) was also seen to these antigens (Fig. 3B).
StimulationwithAcPIM6 induced only limited proliferation of
CD4
T cells (approximately 5%) and no proliferation of CD8
T
cells above the background (Fig. 3B). In contrast, approximately
30% of the NKT cell populationmounted a proliferative response
after stimulation with AcPIM6 (Fig. 3B). Little or no proliferation
above the unstimulated negative control was seen in the CD3
CD335
 cells or in the CD3
 -TCR
 populations (data not
shown).
DISCUSSION
Mycobacterial lipids have long been implicated in the induction of
responses in both the innate and adaptive cell-mediated immune
responses (17–21). Although one strategy has been published
which allows the isolation of PIMs from the avirulent M. bovis
BCG strain (18, 22–24) and M. tuberculosis H37Rv (22) and cer-
tain synthetic molecules (17, 19, 21), in this study we successfully
developed a novel method for extracting and subsequently highly
purifying and characterizing individual PIM species from the po-
lar fraction of virulentM. tuberculosisH37Rv. The method devel-
oped here improves upon the previously published protocols pri-
marily by using a French press to disrupt the bacterial cells,
thereby increasing PIM yield. Other refinements include the re-
moval of the hot acetone incubation and the use of different re-
verse-phase conditions for PIMpurification. Our strategy allowed
us to isolate a greater yield of more highly purified PIMs, as con-
firmed by ESI-MS, that could be subsequently assayed for their
ability to generate responses in lymphocytes.
To assess the ability of these highly purified PIMs to drive im-
mune responses, the individual molecules were used to stimulate
peripheral lymphocytes isolated from M. bovis-infected cattle.
Only AcPIM6 drove significant levels of IFN- from PBMC (Fig.
2A). Interestingly, whenwhole blood taken from the same animals
was stimulated overnight with the PIM molecules as previously
described (25-27), no IFN- could be measured, and this was not
due to a lack of viability as stimulation with pokeweed mitogen
(PWM) generated high levels of IFN- (data not shown). Al-
though no IFN- production was seen from the whole-blood as-
say, AcPIM6 was able to drive significant production of IFN-
from PBMC incubated for 5 days (Fig. 2A).
There are very few studies showing the effect of mycobacterial
lipids in short-incubation, whole-blood assays. Cell-mediated im-
mune responses to lipid antigens are more commonly assessed by
enzyme-linked immunosorbent spot (ELISpot) assay, with incu-
bation times of at least 48 h required before measurable responses
become apparent (24, 28). Further, the requirement for antigen
processing and presentation of specific PIMs has been demon-
strated previously (20); perhaps the most likely explanation for
the discrepancy between whole-blood and PBMC IFN- re-
sponses is that the frequencies of lipid-responsive cells are low and
that an extended incubation allows for expansion of these cells.
This is supported by our demonstration of strong proliferative
responses induced after stimulation of PBMCwith PIMs (Fig. 2B).
FIG 2 (A) PIM-driven IFN- production as measured by Bovigam ELISA. PBMC were incubated with PIMs at 20 g ml1 for 5 days. Points represent mean
responses from triplicate wells for each of the 10 animals tested; lines represent the samplemedian. ***, P	 0.001. (B) PIM-driven proliferation of bovine PBMC
as measured by [3H]Thy incorporation. Bovine PBMC were stimulated for 5 days with individual PIMs at 20 g ml1. Points represent mean responses from
triplicate wells for each of the 10 animals tested; lines represent the sample median. *, P	 0.05; **, P	 0.01. Nil, nonstimulated controls.
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A recent study has shown that bovineNKT cells are present only at
low frequencies (0.1% to 1.7%) (29).
Previous work usingmice has shown that the ability of PIMs to
generate cell-mediated responses is dependent on the acyl struc-
tures of the molecules. Early work performed using PIM2 and
PIM6 demonstrated that the acyl chain was essential for NKT cell
recruitment while the complexity of themannose residues did not
alter the response (23); however, it was subsequently shown that
the second acyl chain of PIM4 enhances binding to murine CD1d
but that the polar mannose head was essential for antigen recog-
nition, proliferation, and IFN- production (28). As well as the
number and location of acyl chains, their degree of unsaturation
FIG 3 Assessment of proliferating cell phenotype by flow cytometry. (A) Flow cytometric gating strategy. Single, live CD3
CD335
 lymphocytes were assessed
for CellTrace violet labeling, and cells expressing low levels of CellTrace violet were gated for phenotyping. Numbers represent the percentages of proliferating
cells in response to each antigen. FS Lin, forward scatter (linear). (B) Proliferation of CD3
 CD4
, CD3
 CD8
, or CD3
 CD335
 cells in response to either
PPD-B or AcPIM6. Each bar represents the percentage of cells proliferating after subtraction of the unstimulated control.
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and cis, but not trans, stereochemistry are critical in determining
antigenicity (14, 30).
The larger and more complex PIM molecules tested here
(Ac2PIM2, Ac2PIM6, and AcPIM6) drove significant levels of pro-
liferation. AcPIM2 also drove proliferation in 3 animals while
PIM2 generated no positive responses.
As AcPIM6 was the only molecule to drive significant IFN-
responses in our study (Fig. 2A) and one of the most potent in-
ducers of proliferation (Fig. 2B), we decided to use AcPIM6 to
characterize the proliferative response. Stimulation with AcPIM6
induced higher levels of proliferation in NKT cells than in CD4

or CD8
 T cells (Fig. 3). However, from these data it is not possi-
ble to tell if the proliferative CD4
 or CD8
 cells also coexpress
CD335 as our flow cytometric labeling panels do not allow the
discrimination; however, this is a distinct possibility.
Although well characterized in humans andmice, the presence
of NKT cells in cattle has been a controversial issue (31–34). Nev-
ertheless, studies have shown that the bovine CD1D gene is ex-
pressed and translated in vivo (35), and recent work has identified
a subset of cattle lymphocytes that express both T cell (CD3) and
NK cell (NKp46) markers, suggesting the presence of an NKT cell
population in bovine peripheral blood (29). Furthermore, bovine
NKT cells have been shown to express both - and -TCRs, to
have a broad TCR repertoire, and to have fully functional NKp46,
CD16, and CD3 signaling pathways (29). Interestingly, these cells
require ligation of their CD3 molecules to produce IFN-. While
this may initially suggest that a CD3 binding component may be
present in our PIM preparations, it is worth noting that we have
not identified the cytokine-producing cells.
The identification of AcPIM6 as a potent immunostimulatory
molecule is of great interest both as a potential vaccine candidate
(21), an adjuvant formulation (36), or a target for attenuation in
the development of novel live vaccines (37). PIMs have also been
used previously as diagnostic reagents for both tuberculosis and
leprosy, although with limited success (38).
In conclusion, we present here the ability to extract and selec-
tively purify PIMs to a high level of purity. These molecules could
be used to stimulate significant IFN- production and drive sig-
nificant proliferation in PBMC fromcattle.Wehave also been able
to identify the proliferative population and, for the first time, we
have shown antigen-specific NKT activation in cattle.
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Figure 1:
A - D: Apolar fraction analysed
With standard TLC systems A, B, C 
and D
E and F: Polar fraction analysed with 
stadard TLC systems D and E
PDIM - phthiocerol dimycocerosate
MQ - menaquinone
TAG - triacyl glycerol
PAT - pentacyl trehalose
PGL - phenolic glycolipid
MMG - monomycolyl glycerol
TMM - trehalose monomycolate
TDM - trehalose dimycolate
GMM - glucose monomycolate
DPG - diphosphatidyl glycerol
PE - phosphatidyl ethanolamine
PI - phosphatidyl inositol
P - phospholipid
PIM - phosphatidyl inositol
mannosides
Cytokine 
responses to
M. bovis lipids
Monocytes were extracted 
from bovine whole blood and 
cultured with GM-CSF and 
IL-4 (MDDC) or GM-CSF 
alone (CM) for 3 days before 
being washed and stimulated 
overnight with lipid at 20 μg 
ml-1 .
Supernatants were analysed 
by MSD multiplex 
chemiluminescent ELISA for 
the levels of IL-10, IL-12, 
MIP-1β, TNFα and IL-6 (figure 
2).
Polar, but not apolar, lipids 
caused significant increases 
in production of IL-10, IL-12, 
MIP-1β and TNFα in all cells.  
DC produced more IL-12 and 
TNFα than other cells, while 
DC and CM produced more 
MIP-1β than monocytes.
Phenotypic responses to M. bovis lipids
Analysis of antigen presentation associated molecules was performed by flow 
cytometry (figure 3).
The polar lipid fraction caused a significant reduction in expression of MHCII and 
CD86 on all cell types, as well as significant reduction in CD1b expression on MDDC.
CD40 levels increased significantly after polar lipid stimulation of cells where 
expression was not constitutively high.
Figure 3:
Surface expression of MHCII (A), CD86 (B), CD1b (C) and CD40 (D) on cultured cells and fresh monocytes after 
exposure to lipid fractions.  ** p<0.01; *** p<0.001; Repeated Measures ANOVA w. Bonferroni Multiple Comparisons Test
Functional consequence of lipid exposure
An MLR was performed to assess the consequence of reduction in expression of 
MHCII.  Cultured cells were Mitomycin C treated before being mixed with pre-
screened alloreactive PBMC from a different animal. Polar lipid treatment of CM 
led to statistically significant 
abrogation of proliferative 
responses.  However, exposure 
of MDDC to lipids had no effect 
upon their ability to drive 
alloreactive proliferation.  This 
may be due to constitutively 
high levels of CD40 found on 
MDDC or the significantly higher 
levels of IL-12 produced by 
these cells (figure 4).
Figure 4:
PBMC proliferative responses after allotypic stimulation with untreated (light grey bars) or polar lipid treated (dark 
grey bars) cultured cells. Bars represent the mean of triplicate wells ± standard error of the mean. 
*** p<0.001; One Way ANOVA w. Bonferroni Multiple Comparison Test
Conclusions
We present here the first data to fully categorise the lipids of M. bovis and 
demonstrate their regulatory effects of on bovine innate immune cells.  Polar lipids 
induced significant levels of IL-10, IL-12, MIP-1β and TNFα production by innate 
immune cells.  Polar lipids also caused a significant reduction in expression of MHCII, 
CD86 and CD1b.  Finally, polar lipid treated cultured monocytes were shown to be 
compromised in the induction of T cell proliferation. Hence, polar lipids may play a 
pivotal role in the outcome of infection.
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Introduction
The first point of contact between M. bovis and its host is likely to be an interaction 
between the innate immune system and surface expressed molecules of the bacilli.  
The mycobacterial cell surface contains large numbers of diverse and complex lipids 
which are known to interact with innate cell receptors.
Little data exist describing the effect of pathogen derived lipids on innate immune 
cells from the appropriate host. Thus, to assess the immune response of the host to 
the lipids of its natural pathogen, lipids were extracted from virulent M. bovis AF 
2122/97 and used to stimulate various bovine innate immune cells isolated from 
live, TB free, cattle.
M. bovis AF 2122/97 derived lipids
Lipids were extracted from freeze dried M. bovis AF 2122/97 in 2 fractions; apolar
lipids were extracted in petroleum ether and polar lipids in chloroform and 
methanol.  Lipids were analysed using standard 2D TLC systems and individual lipid 
species were identified (figure 1).
Figure 2:
IL-10 (A), IL-12 (B), MIP-1β (C), 
TNFα (D) & IL-6 (E) production 
by monocytes and cultured 
cells in response to stimulation 
with lipid fractions.
* 0<0.05; ** p<0.01; *** p<0.001
Kruskal-Wallis w. Dunn’s Multiple 
Comparisons Test
